Radiation-Induced Bowel Injury (RIBI): Exploring potential predictive and prognostic factors and strategies to improve the management of women treated with Pelvic Radiation for Cervical and Endometrial Cancers: Cancer Survivorship: Improving Quality of Life after Treatment for Gynaecological Cancers by Kuku, SY
  
 
Radiation-Induced Bowel Injury (RIBI): Exploring 
potential predictive and prognostic factors and 
strategies to improve the management of women 
treated with Pelvic Radiation for Cervical and 
Endometrial Cancers. 
Cancer Survivorship: Improving Quality of Life after Treatment 
for Gynaecological Cancers 
 
 
 
STEPHANIE Y KUKU MBCHB MRCOG 
Thesis submitted for the Degree of Doctor of Medicine (MD) 
University College London (UCL) 2015 
  2 
 
DECLARATION 
 
Statement of Originality. 
 
All work presented in this thesis was undertaken by myself unless otherwise stated. 
  3 
Abstract 
 
Introduction: The true incidence of radiation toxicity to the bowel remains unknown; in 
the UK, it has been reported that about 90% of patients who receive pelvic radiotherapy 
will have some change in their bowel function, and in up to 50% this affects their quality 
of life significantly (Andreyev, 2007). It is unclear why some cancer survivors develop 
significant symptoms that arise as a result of multiple functional, structural and 
physiological deficiencies related to radiation injury.  Aims: There is a need to identify 
tissue specific biomarkers of normal tissue injury and identify those patients who might 
be at risk of severe injury to the bowel. In this thesis, I sought to investigate the true 
incidence and presentation of RIBI in a London Cancer Centre.  I then developed a 
template for a scoring model to explore how reporting of symptoms in the clinical setting 
might be improved.  After investigating the use of cell-cycle markers as a marker of 
(chemo)-radiosensitivity, I then utilised these markers in colonic crypt cells to attempt to 
link the proliferative status after exposure to radiation to symptom presentation and 
severity.  Methods and Results: A retrospective cohort study revealed 152 women 
treated for cervical and endometrial cancer with symptoms of RIBI, which were clustered 
into 3 groups using factor analysis.  Exploratory and Confirmatory Factor Analysis was 
used to test a novel scoring model template.  Immunostaining in 35 cervical tumour 
samples with the cell-cycle markers Mcm2, Geminin, and Ki67 did not find expression of 
these markers were linked to (chemo)-radiosensitivity and tumour response.  These 
markers were used to assess proliferation in colo-rectal crypt cells and showed decreased 
expression in all layers suggesting a loss of proliferative capacity after radiation.  
Conclusions:  Young patients with cervical cancer are more likely to develop significant 
symptoms of RIBI.  Our simple scoring tool validated on a prospective cohort could 
provide invaluable data to improve management of women with bowel symptoms after 
radiation.  Further work exploring proliferation in colonic crypt cells after radiation 
exposure could identify women at greater risk of radiation injury. 
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Part I   Radiation Induced Bowel Injury 
 
Chapter One  Introduction 
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1.1    History of Radiation use in Cancer 
In 1895, the discovery of ionising radiation by Wilhelm Roentgen changed modern 
medicine.  By 1896, Emil Grubbe, recognised as the world’s first Radiation Oncologist 
had made the first attempt to treat breast cancer with radiation therapy and soon after in 
1897, the first patients with radiation-induced bowel toxicity symptoms were described 
(Walsh, 1897).  Claude Regaud, a Professor at the Radium institute of Paris, recognised 
quickly that treatment was better tolerated and more effective if delivered slowly with 
modest doses per day over several weeks.  This technique, still known today as 
fractionation still remains the main principle behind radiation delivery in Radiation 
Oncology. 
Early X-ray machines had numerous limitations and were unable to produce high energy, 
deeply penetrating beams, thus making it difficult to treat deep-seated tumours 
(especially in the pelvis) without excessive skin reactions.  Early advocates of radiation 
therapy began to rely on the placement of radioactive sources in close proximity or even 
within the tumour, a technique still known today as Brachytherapy.   In many pelvic 
tumours, most notably cervical and endometrial cancers in women, brachytherapy 
became the mainstay of curative treatment regimes (and mostly remains so in the 21st 
century).  The Radium Institute of London opened in 1911, and intracavity treatment 
began on a large scale.  By the early 1920s, the combination of both external beam deep 
x-ray treatment and brachytherapy had become the standard with a reported 5-year 
survival of 45% (Phillips, 1944).  Improvements in treatment delivery have occurred, first 
with the introduction of supervoltage radiotherapy in the 1940s and then subsequently 
with the linear accelerator in the 1960s.  Attempts at radio-sensitisaton using agents such 
as hyperbaric oxygen in the 1970s and early 1980s were disappointing.  
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1.2 Early Retrospective Study – History of Radiation Toxicity 
The early 20th century brought advances mainly in optimising treatment doses and 
delivery, as well as in planning treatment, through advances in radiation physics and 
oncology.  A retrospective review  (DeCosse et al, 1969) of radiation-induced toxicity at 
University Hospitals Cleveland of 100 patients treated for pelvic malignancies between 
1922 and 1968 was published in 1969.  Gastrointestinal complications following 
radiation for cervical cancer was reported in 11.6% of patients.  In this cohort bowel 
injuries were multiple and defined as; ‘proctitis’: n=44; ‘rectal ulcer’: n=10; ‘stricture’: 
n=19; ‘rectovaginal fistula’: n=29; ‘colitits’: n=17; ‘ileitis’ or ‘jejunitis’: n=25; rectal 
‘polyps’: n=1; ‘radiation-induced rectal carcinoma’: n=1.   The majority (95%) of 
patients in this early study were women (carcinoma of cervix: n=75; carcinoma of uterus: 
n=9; bladder carcinoma: n=2; vagina: n=5; prostate: n=1).   The average age of patients 
was 52 years range (1-77).  Previous ‘supra-cervical’ hysterectomy had been performed 
in 14 women, adnexal surgery in 12, and appendicectomy in 12.  Over 50% of patients 
(57/100) had a significant medical history; hypertension in 39, arteriosclerotic heart 
disease in 15, diabetes in 9, ‘intestinal’ disease in 6, previous cancer in 3, ‘rectal disease’ 
in 3, previous tuberculosis infection in 2, and syphilis in 2.  Ten (10) women had suffered 
previous pelvic inflammatory disease (PID).  In 78% of patients treatment was delivered 
with curative intent.  External beam radiation alone was administered in 17, radium alone 
in 6, and the remaining patients had a combination of both.  Sixteen percent (16/100) of 
the patients had surgery combined with radiotherapy.  In this study death was attributed 
to radiation-induced bowel injury in 22/100 (22%) patients (mean follow-up 7 years); 
28/100 patients died of cancer-related causes.   
 
1.2.1 Early experience of Radiation Toxicity after treatment for Cervical Cancer 
The cervical cancer patients with reported symptoms of toxicity in this study (DeCosse et 
al, 1969) were compared to 227 cervical cancer patients treated during the same period 
with no gastrointestinal symptoms.  It is unlikely that a true comparison could have been 
made between these two groups given the study was conducted over a 40 year period.  It 
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is also important to note that treatment doses and delivery varied significantly over this 
period.  Nevertheless, the group found a significant relationship between having a history 
of hypertension and reporting radiation-induced bowel symptoms (p<0.025).  Pre-
radiation supra-cervial hysterectomy was also found to be significantly associated with 
bowel toxicity (p<0.025).  Of the 75 patients with cervical cancer, 67 were treated with 
external pelvic radiation (EBRT).   
External beam therapy was considered ‘high-dose’ if the dose to the mid-plane of the 
pelvis was >9,000 rads.  Intra-cavity radium was employed in 67/75 (89%) women with 
cervical cancer.  Seven patients, (29.1%) with non-rigid radium applications, and 8 
(18.6%), with Ernst radium application were considered to have high radium dosage.  
Thus, 20.0% of all patients with cervical carcinoma received radium applications in 
excess of 7,000 rads for one application, or 9,000 rads for two applications.  
 
1.2.2 Radiation-Induced Bowel Injury as reported in 1969 
Patients with rectal injury in this study (DeCosse et al, 1969) were classified into two 
groups for analysis.  The first group of patients (n=52) presented with proctitis, rectal 
ulcer and stenosis, mostly within the first year after radiation therapy; 14 patients 
presented two or more years after completion of treatment.  Symptoms of diarrhoea, 
bleeding and tenesmus were not found to correlate well with the extent of rectal 
pathology on histology.  The presence of crampy abdominal pain was unusual in pure 
rectal injury and generally could be related to more distal bowel injury.  Radiation-
induced rectal ulcers were usually reported between 4 and 12 months after start of 
treatment and were usually single, less than 4cm in diameter and seen on the anterior 
rectal wall at the level of the cervix.  The second group of patients described consisted of 
29 patients with confirmed recto-vaginal fistulas.  The average interval from completion 
of radiation therapy to presentation was 22 months (range: 3 months -12 years).  
Interestingly, it was reported that prior to developing fistulas these patients had reported 
symptoms similar to the first group but generally more severe in nature.   
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In this series, 34 patients were reported to have non-rectal bowel injury: small bowel in 
17, colon in 9, and to both small and large bowel in 8.  Twenty-five (n= 25) of these 
patients were classified as having ileitis/jejunitis.  In 21 of these 25 patients the diagnosis 
was confirmed with a histopathological examination of operative biopsy samples or 
autopsy findings.  In the remaining 4 patients, barium examination of the small bowel 
(indicated by presenting symptoms) demonstrated radiation injury.  Thirteen (13/34) 
patients also had rectal injury and 15 had associated urinary tract injury.  Patients with 
small bowel injury were reported to have presented with ‘ileitis’ or symptoms of partial 
to complete (small bowel), intestinal ischaemia or necrosis, and less commonly, with an 
enteric fistula.   
The presenting findings of colon injury were reported as ‘colitis’, stenosis or obstruction, 
(usually sigmoid), necrosis and a sigmoid vaginal fistula.  In the small bowel injury 
group, in patients presenting with symptoms of acute bowel obstruction or perforation, 
the interval from radiation to presentation was on average 6.5 years (range 1 month – 31 
years).  Sixteen patients in this study required surgery for intestinal resection due to 
complications from radiation-induced injury; bowel perforation, bowel obstruction and 
vesico-vaginal fistula in one patient.  Of the patients who required surgical intervention, 2 
patients died during the first 30 days after bowel resection, whilst 3 others died within the 
2 years following surgical management of the radiation-induced bowel injury.   
This early study, although retrospective, highlighted the multiple and complex ways in 
which radiation damage to the gastrointestinal tract can present, and the high morbidity 
related to treatment.  The overall toxicity rate was reported at 11.6%, comparable to 
another study (Powel-Smith, 1965) published in the same decade. 
 
1.3 Radiation in the Modern Era 
Since DeCosse and his group published the above study in 1969, with similar results the 
use of advanced, highly effective radiotherapy techniques and more targeted treatment 
has evolved.  Despite these advances in treatment delivery techniques, radiation toxicity 
to surrounding healthy normal tissue remains a barrier to achieving better cancer cure 
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rates (Andreyev, 2007a,b). The number of cancer survivors has increased since the 60s 
and so too has the number of patients reporting and presenting with symptoms related to 
radiation injury of bowel, bladder and other tissues.  
Much of the technological progress in recent decades has been due to computer and 
imaging advances, in particular axial-imaging methods and three-dimensional treatment 
planning.  The standard for radiation oncology centres is now to perform computed 
tomography (CT) - based imaging for treatment planning, with treatment delivery 
advances combining computer algorithms and software packages, which optimise the 
number, shapes and intensities of beams.  Known as three-dimensional (3D) conformal 
radiotherapy, this technique allows far more effective coverage of tumours whilst better 
protecting normal adjacent organs.  Modern developments in cellular and molecular 
biology continue to attempt to find new designs for targeted delivery.  A discovery 
known as the ‘bystander’ effect, an intercellular signalling pathway described by several 
authors (Mothersill et al, 2001; Turesson et al, 2003) describes the intercellular signalling 
pathways whereby irradiated cells exert effects on neighbouring cells.  It emphasizes the 
need to consider the entire tumour microenvironment within modern studies of radiation 
effects.   
 
 
1.4 Incidence of Cervical and Endometrial Cancer 
Cervical Cancer remains a leading cause of deaths worldwide, and remains the 3rd most 
common cancer in women and the 12th in the UK, accounting for about 2% of all new 
cases of cancer in women (Cancer Research UK, 2010).  Most women present with 
locally advanced disease and radiotherapy remains an integral part of standard treatment.  
Concomitant Chemo-radiation (CRT) - radical radiotherapy (external beam radiotherapy 
(EBRT) plus intra-cavity brachytherapy (ICB)) together with weekly chemotherapy has 
improved survival rates (Vale et al, 2010), however toxicity still remains a major issue 
affecting survivorship and uncomplicated cure rates. 
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Endometrial cancer remains the most common gynaecological malignancy in the western 
world, and the 4th most common cancer in women.  In 2005-2009, 77.3% of women in 
the UK survived for 5 years or more (Cancer Research UK, 2010).  Endometrial cancer, 
locally advanced, with high-risk prognostic features, is usually treated with primary 
surgery (total abdominal hysterectomy (TAH) and bilateral salping-oophorectomy 
(BSO)) followed by sequential combined adjuvant chemotherapy followed by external 
beam radiotherapy and vaginal vault brachytherapy (VVB).  Patients with ‘high-risk’ 
prognostic indicators for locally advanced disease and loco-regional (pelvic) recurrence 
are usually offered radiotherapy alone without chemotherapy. 
 
1.5 Radiation doses and delivery in Cervical and Endometrial Cancer 
Radiation toxicity has been reported in doses as low as 5-12 (Gray) Gy but usually occurs 
in patients exposed to higher doses (Theis et al, 2010).  Pelvic radiotherapy for cervical 
and endometrial cancer is delivered according to national guidelines.  Various dosimetric 
studies (Leschert, 1995; Roeske et al, 1997) over the last few decades have investigated 
the effects of radiation on tumour control whilst measuring for toxicity.  Roeske et al, 
(1997) investigated the correlation between treatment and dosimetric factors with the risk 
of late rectal sequealae in 183 patients treated with radiation therapy for cervical 
carcinoma.  All patients received a combination of EBRT and ICB. The median EBRT 
dose was 45Gy, delivered in daily doses of 1.6-2.0Gy per fraction.  Higher doses were 
given to patients with locally advanced disease, ranging from 75-85Gy to 80-90Gy in 
patients with larger lesions.  Additional parametrial and para-aortic radiation boosts were 
also given to patients with advanced disease.   
Twenty-eight (15.3%) patients developed late rectal sequelae (n=12; Grade 3 toxicity).  
Patients with diabetes (p=0.03), and those who received conventional EBRT doses 
>50Gy (p=0.03) were found to be significantly associated with the risk of rectal toxicity 
symptoms on multivariate analysis.  A defined threshold above which rectal sequelae 
were more common was identified over the ranges of doses evaluated, using a linear-
quadratic model.  This threshold was 87% at a total rectal dose of 60Gy and decreased to 
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60% at a rectal dose of 80Gy.  Figure 1.1 shows the dose-response curve of complication 
probability, with a clear increase in toxicity over 60Gys. 
 
 
 
Figure 1.1 Dose (D)-Response curve analysis (Roeske et al, 1997).  Plot of the probability of developing 
rectal sequelae as a function of total rectal dose (maxCRD).  Data points represent probabilities determined 
from index study).  The smooth curve represents the maximum likelihood estimate of the logistic function 
p(D) =1/[1 + (TD50/D)k; where k=6.6 and TD50 = 105 Grays  
 
The current standard for radical treatment of endometrial cancer is a total dose of 45Gy in 
25 daily fractions over 5 weeks in a single phase.  Radiotherapy is delivered after 3-
dimensional planning with data from computerised tomography (CT) scans.  Tolerance 
dose limits for rectum is limited to <70Gy, whilst the bladder dose limit for the entire 
course is set at <60Gy.  All patients also receive High-Dose Rate (HDR) vaginal vault 
brachytherapy (VVB) with full insertion of a vaginal applicator; 12Gy in 2 fractions to 
0.5cm from the surface of the applicator. 
Conventional “box” technique delivers external beam radiotherapy by using bony 
landmarks to define the target volume for pelvic radiotherapy.  Treatment is delivered 
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differences are accounted for in the biological model, vol- 
umetric differences are not. Thus, to evaluate the impact 
of the volumetric difference on the complication dose- 
response relationship, the percentage of rectal dose deliv- 
ered by the EBRT was used as a surrogate. This percent- 
age was plotted against the maxCRD and maxBRD for 
each patient. Threshold percentage levels for each total 
rectal dose were determined above which complications 
were more common. 
Statistical analysis 
All statistical analyses were performed using a com- 
mercial software package (Stata Corporation, College Sta- 
tion, TX). Individual patient and dosimetric factors were 
dichotomized (e.g., energy < 6 vs. 2 6 MV) in the uni- 
variate analysis. Comparison of proportions was per- 
formed using the Pearson chi-square test or Fisher exact 
test whenever appropriate. Logistic regression analysis 
(multivariate) was performed with all significant factors. 
Doses entered into the multivariate model were analyzed 
as continuous variables. Local control (LC), relapse-free 
(RFS), and cause-specific survival (CSS) analyses were 
plotted according to the method of Kaplan-Meier. LC is 
defined as the absence of a central recurrence. 
RESULTS 
The 5-year actuarial LC, DFS, and CSS of the entire 
group were 94.2%, 83.0%, and 86.9%, respectively. The 
corresponding lo-year results were 94.2%, 73.2%, and 
74.3%, respectively. The excellent outcome of these pa- 
tients reflects our exclusion of patients with <2 years of 
follow-up and those who recurred within this time period. 
Incidence of late rectal sequelae 
Twenty-eight patients (15.3%) developed late rectal se- 
quelae. This includes 13 patients (7.1%) with Grade 1, 3 
patients (1.6%) with Grade 2, and 12 patients (6.6%) with 
Grade 3 late rectal sequelae. The incidence of Grade 2 and 
3 rectal sequelae was thus 8.2%. 
Factors aflecting risk of late rectal sequelae 
Four patient-specific factors (age, diabetes, hyperten- 
sion, and stage) obtained statistical significance in terms 
of late rectal sequelae in the univariate analysis. Patient 
age > 55 years was associated with a higher incidence of 
rectal sequelae than age zz 55 years (12.5 vs. 4.2%) (p = 
0.04). The risk of late rectal sequelae was higher in pa- 
tients with a history of diabetes (18.5 vs. 5.7%) (p = 0.04) 
and hypertension (13.1 vs. 4.7%) (p = 0.05) than in pa- 
tients without these conditions. Finally, locally advanced 
patients (Stage IIB-III) had a higher incidence of late rec- 
tal sequelae than patients with early-stage disease (12.6 
vs. 4.2%) (p = 0.04). Patient weight and history of pelvic 
surgery did not reach statistical significance in the uni- 
variate analysis. In addition, no difference was seen in the 
incidence of late rectal sequelae in patients who developed 
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a recurrence either centrally or outside the pelvis com- 
pared to patients who remained free of disease. 
Four treatment-related factors (beam energy, conven- 
tional and biological EBRT dose, and Point A dose) were 
also found to be significant in terms of late rectal sequelae 
in the univariate analysis. Patients treated with low-energy 
photon beams (16 MV) had a higher incidence of rectal 
sequelae than patients treated with higher-energy beams 
(~6 MV) (11.5 vs. 0%) (p = 0.01). The use of conven- 
tional EBRT doses 2 50 Gy resulted in a higher rate of 
sequelae than treating with <50 Gy (17.7 vs. 6.4%) (p = 
0.03). Similarly, biological EBRT doses > 105 BED were 
associated with a higher risk of late sequelae than bio- 
logical doses I 105 BED (27.3 vs. 7.3%) (p = 0.05). 
Finally, patients treated with Point A doses > 86 Gy ex- 
perienced a higher rate of sequelae than did patients 
treated with lower doses (18.0 vs. 5.0%) (p = 0.01). Con- 
ventional rectal dose (maxCRD) reached borderline sig- 
nificance with doses above 80 Gy dose, resulting in a 
higher incidence of complications than lower doses (25.0 
vs. 5.5%) (p = 0.11). The remaining treatment-associated 
factors did not reach statistical significance in the univar- 
iate analysis. 
Multivariate (logistic regression) analysis was per- 
formed on the significant factors from the univariate anal- 
ysis. Only one patient and two treatment factors remained 
significant: diabetes (p = 0.03), Point A dose (p = O-04), 
and the conventional EBRT dose (p = 0.03). The remain- 
ing patient and treatment factors (patient age, hyperten- 
sion, stage, beam energy, maxCRD, and biological EBRT 
dose) failed to reach statistical significance. 
Dose-response curve analysis 
Rectal complication dose-response curves are shown in 
Figs. 1 and 2 based on the maxCRD and maxBRD, re- 
1.0- 
0.8 - 
0.6 - 
Complication Probability vs. 
Conventional Rectal Dose 
:: 
40 50 60 70 80 90 
Dose (Gy) 
Fig. 1. Plot of the probability of developing rectal sequelae as 
a function of the total rectal dose (maxCRD). Data points rep- 
resent probabilities determin d from this study. The smooth 
curve represents the maximum likelihood estimate of the logistic 
function (Eq. 5). The associated parameters are k = 6.6, TDso 
= 104 Gy. 
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either with anterior and posterior fields or with a 4-field box technique, which reduces the 
volume of the small bowel in the treated volume (Gallagher et al, 1986).  Studies 
assessing coverage of the uterus and cervix have reported that a field border placed in the 
middle of the symphysis pubis is inadequate for 50-60% of the patients (Bonin et al, 
1996), however conventional radiotherapy continues to be used worldwide. In a 
retrospective review of endometrial cancer (Greven et al, 1991), the incidence of late 
complications using a 4-field box technique was reduced from 23% to 4% with the use of 
conformal radiotherapy.   
Radiotherapy planning has been improved in the 21st century by the integration of 
computed tomographic (CT) imaging, allowing the dose of radiation to match or conform 
to the outline of the target.  This shaping of the radiation fields is known as Conformal 
Radiotherapy and would now be considered best practice in pelvic radiotherapy 
treatment.  Though the fields for conformal radiotherapy are usually larger than those 
used for the conventional box technique, the individualised shaping of the fields allows 
more shielding of the organs at risk.  Conformal radiotherapy can reduce the mean 
volume receiving at least 90% of the prescribed dose (V90) by 23%, 4%, 18%, and 11% 
for the bladder, the rectum, the small bowel, and the large bowel respectively. 
In cervical cancer, the outcome of radiotherapy-related treatment changed significantly in 
1999 with the National Cancer Institute recommendation (NCI, 1999) based on 5 studies, 
recommending the use of chemotherapy with radiotherapy.  This changed the standard of 
care overnight.  Radical radiotherapy for cervical cancer involves delivery of a total dose 
of 50.4Gy in 28 daily fractions over 5.5 weeks delivered in a single phase with 
concomitant weekly chemotherapy (Cisplatin 40mg/m2) weekly for a maximum of 6 
weeks during radiotherapy. 
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1.6 Incidence of Radiation-Induced Injury after treatment of Cervical and 
Endometrial Cancer; the extent of the clinical problem. 
The true incidence of radiation toxicity to the bowel remains unknown; symptoms are 
generally under-reported, whilst studies in the published literature are mostly 
incomparable.  In the UK, it has been reported that about 90% (Andreyev, 2007a) of 
patients who receive radiotherapy will have some change in their bowel function, and in 
up to 50% this affects their quality of life significantly (Andreyev, 2007b).  Regardless of 
modern radiotherapy techniques, the incidence of severe toxicity after (chemo)-radiation 
for cervical cancer remains about 10% (Vale et al, 2010).   A significant proportion of 
these patients is young and though cured of cancer, are burdened with symptoms of 
radiation-induced bowel injury (RIBI) which adversely affects their activities of daily 
living and adds increasing costs to healthcare (Andreyev, 2005). 
(Denton et al, 2002) published the results of audit of the prevalence of late severe 
complications at 5 years following radiotherapy for cervical carcinoma using 
retrospectively collected morbidity data as an indicator of quality of care.  Only severe 
toxicity  (grade 3 and 4) according to the Franco-Italian Glossary (Sinistrero et al, 1993) 
was recorded.  Data was reported from 1558 cases of cervical cancer treated with radical 
intent in 1993 drawn from 53 of 55 UK treatment centres.  In all the centres but one, 
morbidity was graded retrospectively at the time of the audit.  Surgery was combined 
with radiotherapy in 30.4%, and 6.7% of patients received chemotherapy as part of 
primary treatment.  The 5-year survival of the entire cohort was 47%, and 40% for the 
subset selected to have radiotherapy alone.  The prevalence of late severe morbidity was 
6.1%. Variations in treatment technique and administration was observed between 62% 
of the centres. 
 “The absence of defined diagnostic criteria for late radiation complications and the 
multitude of grading systems complicate retrospective reporting although the grade of 
measurable tissue damage may or may not translate into a corresponding score from the 
patients perspective.  All these discrepancies also need to be recorded if we are to 
concentrate on measuring the effects that actually matter to patients”. 
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Numerous authors in both retrospective and prospective studies have documented the 
range in reported incidence of late complications in patients treated with radiation therapy 
for cervical and endometrial cancers (Andreyev, 2007).  Eifel et al, (1995) reported major 
complication rates at 3 and 5 years of 7.7% and 9.3%, in a retrospective study of 1784 
patients with FIGO stage 1B cervical cancer treated with initial radiation between 1960 
and 1989.  Complication rates were calculated actuarially; at 5 years there was a small 
but continuous risk of approximately 0.34% a year, with an overall actuarial risk of 
having had a major complication of 14.4% at 20 years. A recent national survey (Henson 
et al, 2012) of practice and opinions of clinical oncologists in the UK revealed most 
oncologists estimate up to 24% of patients at 1 year have bowel symptoms following 
pelvic radiotherapy.  Clinical oncologists continue to recognise late-onset bowel 
dysfunction after pelvic radiotherapy as a significant problem. 
 
 
1.7 Radiation Injury to the Bowel -Natural History and Mechanism  
 
1.7.1 Biological Effect of Radiation  
The lethal cellular effects of radiotherapy are mediated by DNA damage within tumour 
cells.  Cells undergo a critical period after irradiation that determines their fate: cell 
death, repaired damage, or continued growth and division without complete repair.  On a 
molecular level, radiation damage initiates very complex signalling cascades that results 
in a variety of responses including cell cycle arrest, induction of stress response genes, 
DNA repair, and apoptosis (Connell et al, 2007).  The signalling proteins ATM and ATR 
have a central role in these responses (Fig. 1.2).  
Radiation causes cell death through free radicals, which subsequently stimulate single or 
double-stranded DNA breaks.  Electromagnetic waves produce biologic effects on tissues 
by the production of electrons after their interaction with normal tissues.  These electrons 
induce the formation of hydroxyl and other free radicals.  Cellular radiosensitivity is 
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dependent on the cell cycle.  Cells are most vulnerable to the killing effect of radiation 
during the G2-M phases of the cell-cycle (M- Mitosis). Rapidly proliferating tissues such 
as intestinal crypt cells are therefore particularly sensitive to radiation.  Stem cells within 
the crypts are particularly at risk and damage to and death of these epithelial cells leads to 
reduction in differentiated epithelial cells and consequently, a loss of mucosal integrity 
(Bismar et al, 2002; McGovern, 2005; MacNaughton, 2000).     
 
 
Figure 1.2. A simplified overview of some of the cellular pathways involved in response to ionizing 
radiation (Connell et al, 2009) 
 
1.7.2 Normal tissue responses to radiotherapy 
 
Radiotherapeutic injury to ‘normal’ tissue that is included in the radiation field is a 
complex process that involves multiple responses as a result of repetitive injury during a 
course of treatment involving a repetitive series of exposure to radiation.  Whilst the first 
response to injury involves ‘wound healing’, the second set of responses perpetuates a 
cascade of cellular and extracellular responses that includes endothelial cell change and 
reduce radiation-associated chromosome abnormalities (61), and
reduce some radiation toxicities clinically (62).
Cells undergo a critical period after irradiation, which determines
their fate: death, repaired damage, or continued growth and division
without complete repair. On the molecular level, radiation damage
initiates very complex signaling cascades that result in a variety of
responses including cell cycle arrest, induction of stress response
genes, DNA repair, and apoptosis. The signaling/surveillance
proteins ATM and ATR have central roles in these responses (Fig.
3). They act via phosphorylation of several downstream targets
including the chromatin protein histone H2AX (63). Over the last
decade, we have witnessed a mas ive growth in knowledge
regarding the molecular bases of these response/repair pathways,
as detailed in our prior publications (64).
Although DNA damage is generally regarded to be the primary
event leading to radiation-induced cell lethality, numerous non-
DNA related mechanisms have recently been implicated in cellular
responses to radiation. Two examples of this are radiation-induced
ceramide production from plasma membrane–derived sphingo-
myelin and the activation of intracellular signaling pathways (65).
Radiation-induced signaling of epidermal growth factor receptor
(EGFR), for example, can have a prosurvival effect. Pharmacologic
inhibition of this effect can potentially be achieved with anti-EGFR
antibodies (66) or chemical inhibitors of EGFR tyrosin kinase
activity ( for example, gefitinib, and erlotinib).
Another important recent discovery is the bystander effect, an
intercellular signaling pathway described by several authors
whereby irradiated cells exert effects on neighboring untreated
cells (67, 68). These responses in neighboring cells consist of broad
cellular changes including gene activation, induction of genomic
instability, differentiation, and changes in apoptotic potential. This
occurs even when bystander cells are physically separated from the
irradiated cells; therefore it seems to be mediated, at least in part,
by diffusible substances (69). The bystander effect emphasizes the
need to consider the entire tumor microenvironment with modern
studies of radiation effects, rather than concentrating on individual
cells. This notion has become particularly crucial, given that host
stromal components within tumors are now known to contribute
to radiation responsiveness also. Experiments in mice have
implicated host-derived blood vessels as a target of radiotherapy,
in terms of both tumor control (70) and complications in normal
tissues (71).
Many of these advances in our understanding of radiation effects
are now leading to newer thinking in the design of targeted
therapeutics (72, 73). Inhibitors of angiogenesis are also being
considered as potential radiation modulators (74, 75), after the
initial discoveries of angiostatin and endostatin by Folkman’s
laboratory (76, 77). Although advances such as these are
encouraging, truly tumor-selective radiosensitizing c mpounds
remain somewhat elusive (78).
Figure 3. A simplified overview of some of the cellular pathways involved in response to ionizing radiation (modified from ref. 64).
Cancer Research
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activation of the coagulation system, inflammation, epithelial regeneration, granulation 
tissue formation, tissue restitution and remodelling.  Figure 1.3 shows the sequence of 
events involving both the immune system and the microvascular endothelium in acute 
phase with ongoing responses that are presumed to be responsible for progression of 
injury over a long period of time (Denham et al, 2002).  Healthy tissue toxicity remains 
the single most important radiation-dose-limiting factor and obstacle to improving cancer 
cure rates.  During radiotherapy of pelvic tumours, parts of the small and large bowel 
(and bladder) are included in the treatment field and thus the bowel remains at risk, 
regardless of improvements in treatment delivery techniques. 
 
 
Figure 1.3.  Phases of normal wound healing progressing to radiation-induced fibrosis over time 
(Bentzen MS 2006).  Timeline illustrating normal ‘wound’ healing after radiation trauma.  This response to 
tissue injury is precisely orchestrated and it is probable that continued interference with the normal control 
of wound healing that leads to excessive deposition of extracellular matrix (ECM) and collagen that is 
characteristic of radiation fibrosis.  ROS, reactive oxygen species; RNS, reactive nitrogen species; TGF-β, 
transforming growth factor- β. 
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solid tissues. TGFβ can usefully be classified as a cytokine 
a d a growth factor. It has attracted much interest in 
fibrosis research, and there is a large and rapidly grow-
ing body of knowledge on this protein and its biological 
action. TGFβ belongs to a superfamily comprising over 
60 proteins in multicellular organisms, with at least 
29 of these encoded by the human genome and more 
than a dozen related molecules in invertebrates38. These 
proteins regulate a wide range of processes, including 
embryonic development, homeostasis, cell-cycle control 
and wound healing31. Dysfunction of the TGFβ system 
seems to be involved in various severe human diseases, 
including immunodeficiency, cancer, defective wound 
healing and a long list of fibrotic diseases in the kidney, 
liver and lung, as well as arteriosclerosis, rheumatoid 
arthritis and scleroderma. Interestingly, in the present 
context, TGFβ has a dual role in tumour suppression 
and tumour promotion39,40. TGFβ is a potent inhibitor of 
endothelial cell proliferation, in the mammary gland for 
example41. It has been proposed that during malignant 
progression breast cancer cells might become refractory 
to the growth-inhibitory effect of TGFβ, and that TGFβ, 
through its effect on the extracellular matrix, might pro-
mote invasion and metastasis in patients with advanced 
disease41–43.
TGFβ exists in three isoforms (TGFβ1–3), and these 
show a high degree of homology between various species. 
Similar molecules are found in commonly used biological
models such as Caenorhabditis elegans and Drosophila 
melanogaster31. TGFβ is secreted in latent form and is 
unable to bind to the receptor unless it is activated in the 
extracellular space by dissociation of the active mature 
TGFβ from the latency associated peptide (LAP)44. This 
means that a large extracellular pool of latent TGFβ can 
be rapidly mobilized after a triggering event. Ionizing 
radiation is one of the few exogenous factors that have 
been shown to induce TGFβ activation, and this happens 
within an hour or less of giving doses as low as 0.1 Gy45,46. 
The active TGFβ binds to pairs of two distinct transmem-
brane receptors (FIG. 2), TGFβR1 and TGFβR2, and it has 
been shown that TGFβR1 is unable to bind TGFβ in the 
absence of TGFβR2, and conversely, that the binding of 
TGFβ to TGFβR2 does not activate the signalling pathway 
in the absence of TGFβR147. The biological advantage of 
this relatively complex — compared with other similar 
ligand–receptor systems — activation of the signalling 
pathway is not clear, but it probably contributes to the 
versatility of the transcriptional response to TGFβ. The 
signalling pathway itself is rather simple: the only estab-
lished intracellular signalling effectors are the Smad pro-
teins, of which there are five R-Smads (receptor-regulated
Smads; SMAD1, 2, 3, 5 and 8) that are directly phospho-
rylated by the type I receptor, a co-Smad (SMAD4) that 
forms heteromeric complexes with the R-Smads and 
two inhibitory Smads (SMAD6 and 7) that antagonize 
TGFβ signalling48. The final transcriptional response 
Figure 1 | Phases of normal wound healing and radiation-induced fibrosis over time. Normal wound healing (above 
the timeline) is a precisely orchestrated response to tissue injury, from the initial platelet response immediately after the 
trauma to the final remodelling of the scar tissue more than a year later. Radiation activates the whole wound-healing 
machinery (see also FIG. 2), but in addition to these processes the unique nature of radiation damage initiates a series of 
processes (below the timeline) that are distinct from those involved in normal wound healing. These processes span the 
whole timescale of normal wound healing, and it is probable that it is this continued interference with the normal control 
of wound healing that leads to the excessive deposition of extracellular matrix (ECM) and collagen that is characteristic of 
radiation fibrosis. ROS, reactive oxygen species; RNS, reactive nitrogen species; TGFβ, transforming growth factor-β.
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1.7.3 Molecular Biology of Radiation Effect on Intestines  
Under normal physiological conditions, both small intestinal and colonic epithelium have 
a low rate of spontaneous apoptosis.  In the colon, the apoptotic rate is very low because 
of the presence of bcl-2, which protects the cells from programmed cell death.  In animal 
experiments, a rapid increase in the rate of apoptosis of the intestinal crypts was seen 
when the animals were exposed to low-dose radiation 1-5 centigrays (cGy).  The rate of 
apopotosis was dose dependent and reached a plateau at 1 Gray (Gy).  Apopotosis 
(programmed cell death) induced by radiation is dependent on the presence of p53 in the 
stem cell (Clarke et al, 1994).  Small intestinal cells were most sensitive to radiation 
compared with stem cells in the colon and rectum because of the presence of bcl-2 in the 
latter.  The 5% risk of complications at 5 years was estimated at a dose level of 45-50Gy 
for the small intestines and 60-65Gy for the colorectal mucosa (Cohen and Creditor, 
1983).  
Ionizing radiation also activates the translation of the gene coding for transforming 
growth factor β (TGF-β). TGF-β is a multifunctional peptide growth factor, classed as a 
cytokine and growth factor, with a wide range of effects on growth, differentiation, 
extracellular matrix deposition, and immune response.  It is ubiquitous and exists in 
multiple tissues.  There are 3 known isoforms -1, -2, -3.  TGF-β-1 is implicated mainly in 
the pathogenesis of fibrosis by stimulating the expression of collagen and fibronectin 
genes and the chemostaxis of fibroblasts. 
Allgood et al (1996), in a study investigating the influence of timing of concomitant daily 
boost on the development of intestinal radiation injury in a rat model, observed that 
radiation injury was significantly more severe when early concomitant (second daily) 
boosts alone were received earlier (first 6 days) of a 12 week course compared to late 
boosts (last 6 days).  Both the incidence of complications and the degree of 
histopathologic injury were reduced in the early boost group.  Relative collagen content 
of irradiated intestine was significantly increased in the early boost group compared to 
the late boost group at 2 weeks and 26 weeks following irradiation.  Irradiated intestine in 
the early boost group exhibited decreased labelling index at 2 weeks whereas irradiated 
intestine in the late boost group had normal labelling index and increased total crypt 
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cellularity at 2 weeks.  This study, amongst others explains the basis to the evidence for 
concomitant boosts to be given towards the end of the radiation schedule to minimize the 
risk of subsequent complications.  Normal ‘healthy’ tissue radiated at the end of a course 
of treatment differs in repair status at the beginning of the course (Denham et al, 2002). 
 
Cell cycle checkpoints contribute to survival after exposure to ionizing radiation by 
arresting the cell cycle and permitting repair after an interval.  This  ‘compensatory 
proliferation’ occurs later in a course of radiotherapy than at the start.  Radiation leads to 
a dose-dependent loss of functional cells through their mitotic death, both immediately 
after exposure and during the subsequent compensatory phase, resulting in accelerated 
proliferation as an expression of radiation damage. Consequently, the more severe 
damage following larger doses of radiation is seen earlier during a course of radiation 
treatment, than the comparatively milder damage produced with smaller doses of 
radiation.   
 
 
1.7.4 Acute Radiation Injury 
 
Acute Radiation Toxicity 
Acute or ‘early’ radiation toxicity is injury which manifests within days of commencing a 
course of radiotherapy usually occurring within 3 months of radiation therapy and 
affecting quality of life at the time of treatment.   Early intestinal injury is a direct result 
of cell death in the rapidly proliferating crypt epithelium and an acute inflammatory 
reaction in the lamina propria.  Insufficient replacement of the villus epithelium and 
breakdown of the mucosal barrier subsequently manifests as symptoms following crypt 
cell death.  Symptoms of acute bowel toxicity include nausea, abdominal pain and 
cramps, diarrhoea and fatigue.  Approximately 60-80% of patients will experience 
symptoms of acute toxicity (Andreyev, 2007b).  Nausea usually occurs almost 
immediately, while diarrhoea and abdominal pain manifest 2-3 weeks into treatment.  
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Acute symptoms will usually resolve within 1-3 months of completing treatment 
(Andreyev et al, 2011). 
A prospective study (Hovdenak et al, 2000) examined the sequential development and 
associations of clinical, endoscopic, and histopathological rectal toxicity during ongoing 
radiation therapy.  Thirty-three (33) patients with pelvic carcinomas (prostate, bladder, 
and endometrium (n=2)) were assessed before radiation, after 2 weeks of treatment, and 
towards the end of the treatment course (6 weeks).  Rigid sigmoidscopy was performed, 
and 2-3 forceps biopsies were obtained from the posterior rectal wall, 10cm from the anal 
verge.  Symptoms of acute toxicity were recorded, and endoscopic changes graded.  
Histological changes in the surface epithelium, glandular layer, and lamina propris were 
assessed using an ad hoc scoring system, macrophage accumulation was evaluated in 
anti-CD68 stained sections.   
The prevalence of symptoms of acute toxicity increased from baseline to 2 weeks and 
from 2 to 6 weeks (p<0.001).  Sixty-one (61%) and 86% of patients had symptoms 
recorded on questionnaire at 2 and 6 weeks respectively. Pre-treatment endoscopy and 
biopsies were found to be unremarkable.  In contrast, endoscopic changes were maximal 
at 2 weeks. Biopsies obtained during treatment demonstrated: atrophy of the surface 
epithelium, acute cryptits, crypt abscesses, crypt distortion and atrophy and stromal 
inflammation.  Histological changes particularly those within the surface epithelium were 
consistently more pronounced at 2 weeks than they were at 6 weeks; no association was 
found between endoscopic pathology and individual clinical symptoms at 6 weeks.  
 
 
1.7.5 Chronic Radiation Injury 
 
Radiation-Induced Bowel Injury (RIBI) is classified as delayed or chronic ‘enteropathy’ 
when it occurs over 3 months after radiotherapy.  Pelvic Radiation Disease (PRD), 
delayed ‘radiation enteropathy’ or chronic RIBI is usually progressive and has major 
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implications for cancer survivors and can lead to substantial long term morbidity and 
mortality if not managed appropriately.  The incidence of severe late toxicity (Radiation 
Therapy Oncology Group – RTOG Grade 3 – 4) has decreased in the last few decades 
due to improvements in treatment delivery techniques.  Regardless, studies suggest that 
up to half of patients will still suffer symptoms of chronic RIBI (Hauer-Jensen et al, 
2014).  The incidence of severe toxicity after (chemo)-radiotherapy of cervical cancer 
remains around 10% (Vale et al, 2010). 
The prevalence of chronic radiation enteropathy following radiotherapy for cervical and 
endometrial cancer and its impact on quality of life was reported in 117 women 
(Abayomi et al, 2009) who were asked to complete a validated questionnaire exploring 
bowel problems and quality of life.  Responses were scored and compared to scores for 
women with known faecal incontinence (Bugg et al, 2001) with a condition-specific 
health-related questionnaire for the assessment of women with anal incontinence.  Forty-
seven percent (47%) of women gained scores indicative of ‘CRE’- chronic radiation 
enteritis.  Younger women (p<0.001) and women with cervical cancer (p<0.05) were 
more likely to score for CRE. No significant relationship was observed between score 
and either radiotherapy dose or stage of cancer.   
 
 
1.8 Clinical Features and Diagnosis 
 
The main clinical features of chronic RIBI can develop before acute symptoms subside 
are known to be related to multiple factors including altered intestinal transit, nutrient 
malabsorption, and gut dysmotility (Husebye et al, 1994; Andreyev, 2007b).   As the 
injury to bowel may be in multiple sites, the range of symptoms patients can present with 
is vast, ranging from abdominal pain, vomiting, diarrhoea and faecal urgency, to rectal 
bleeding, per-rectal mucus and flatulence (Andreyev, 2007b).  It is well recognised that 
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symptom aetiology within any one patient can be multi-factorial, with more than half of 
patients having more than one cause for their symptoms (Andreyev et al, 2005).   
Chronic diarrhoea may be secondary to malabsorption syndromes (bile salts, 
carbohydrates), small bowel bacterial overgrowth, new colonic neoplasia, or new 
inflammatory bowel disease.  Complications of chronic progressive injury such as entero-
enteric fistula can also contribute to diarrhoea and increase in bowel frequency.  
Abdominal pain and vomiting can occur as part of acute or sub-acute bowel obstruction 
or may be related to radiation-induced small (or large) bowel fistulas.  Weight-loss, and 
non-specific symptoms like fatigue and lethargy can also occur (Theis et al, 2010). 
Denham et al, (1999) investigated the significance of the various late rectal symptoms 
that appear after radical prostatic irradiation.  Patients with prostate cancer treated 
between 1987 and 1994 were recalled for examination and asked to complete a detailed 
questionnaire concerning late radiation-induced symptoms and the effects on their normal 
daily life.  The incidence of acute ‘proctitis’ symptoms occurring during therapy and the 
late symptoms recorded were assessed, as well the relationship between late symptoms 
and late EORTC/RTOG score and impact on normal daily life. The presence of 
symptoms of acute proctitis was the only factor to predict the presence of late symptoms 
and late EORTC/RTOG score in this series (odds ratio (OR): 1.7-2.57, p=0.009-0.0007).   
Cluster analysis revealed the presence of five subgroups of patients with varying 
permutations of different late rectal symptoms, including one group with minimal 
symptoms (p<0.0001).  While bleeding and rectal discharge were the major contributors 
to late EORTC/RTOG score (p<0.0001 and 0.04), faecal urgency, and bleeding were 
found to be the most important factors to impact on normal life (p<0.0001 and p<0.0003).  
A relatively low concordance was found between late EORTC/RTOG score and the 
patients’ self-assessment of the effect of their symptoms on their normal daily lives. 
Some late symptoms including bleeding and rectal discharge become less prevalent after 
3 years of follow-up with a resulting improvement in EORTC/RTOG score.  Other 
studies have shown faecal urgency to be at the ‘core’ of symptoms in patients with 
significant symptoms of RIBI (Routledge et al, 2003; Putta and Andreyev, 2005; Capp et 
al, 2009). 
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In one of the earliest prospective studies in the published literature (Yeoh et al, 1993), the 
authors evaluated both the short and long-term effects of radiation therapy on 
gastrointestinal function in 27 patients with potentially curable disease (female: 23; male: 
4) before commencement of radiation, during, and 6-8 weeks, 12-16 weeks and 1-2 years 
after completion of radiotherapy.  Seventeen (17) patients received pelvic radiation alone 
and 10 received both abdominal and pelvic radiation; cervical (n=13), Endometrial (n=5), 
synchronous endometrial and ovarian (n=1), and 3 ovarian cancers in the women. Eleven 
(11) patients had radiation followed gynaecological surgery (TAH with or without 
BSO/Omentectomy).  Gastrointestinal symptoms, absorption of bile acids, vitamin B12, 
lactose and lipid levels were measured.  Other endpoints analyses included gastric 
emptying, small-intestinal and whole-gut transit, stool weight and intestinal permeability.   
Results were compared with those from 18 normal volunteers.  All 27 patients completed 
at least 2 series of measurements and 18 completed all 5.  Increased stool frequency 
during radiation treatment was associated with decreased bile acid absorption and vitamin 
B12 absorption, increased faecal fat excretion, increased presence of lactose 
malabsorption and faster whole gut transit.  The investigators reported an improvement of 
most of the changes with time, however at 1 year after the completion of irradiation, the 
frequency of bowel actions was greater, bile acid absorption was less, and small-intestinal 
transit was more rapid when compared with those at baseline and normal subjects.   
Symptoms of delayed radiation-induced bowel injury may be due to mucosal atrophy 
dysfunction, or intestinal dysmotility leading to (small bowel) bacterial overgrowth.  The 
manifestations of each feature can vary between patients and thus investigating clinical 
signs and symptoms can be difficult and should be individualised.  Table 1.1 below 
demonstrates the patho-physiological features with possible signs and symptoms 
associated with these. 
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Table 1.1. Patho-physiological features (and Diagnostic Evaluation) of Delayed Radiation 
Enteropathy (Taken from Hauer-Jensen et al, 2003). 
 
 
1.8.1 Endoscopic diagnostic features of Radiation-Induced Bowel Injury 
 
The role of endoscopy in evaluating patients who present with symptoms of radiation-
induced bowel toxicity (RIBI) is limited.  No systematic and objective scoring for 
mucosal damage and findings at endoscopy specific to RIBI exists to date.  A recent 
study (Kim et al, 2011) described chronic rectal mucosal damage after pelvic 
radiotherapy (RT) for cervical cancer in 32 women.  The median follow-up for the cohort 
was 35 months after EBRT and ICB.  The Vienna Rectal Score (VRS) was used to 
describe the endoscopic findings and was compared to the European Organization for 
Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group 
(RTOG) morbidity score and the dosimetric parameters of radiotherapy. 
The ratio of rectal dose calculated at the rectal point [RP] was compared to the prescribed 
dose, the biologically effective dose [BED] at the RP during radiotherapy planning.  
Rectal symptoms were noted in 28/32 patients (rectal bleeding, n=21; bowel habit, n=6;  
per-rectal mucus, n=1).  Four (4/32) patients had no symptoms.  Endoscopic findings 
included telangectasia (n=18), congested mucosa (n=20), ulceration (n=50 and a stricture 
(n=1).  The RP ratio and BEDs were found to be significantly associated with the 
studies,31-33 and animal studies using modifiers of
acute injury34,35 have shown that acute injury
often contributes to development of chronic
changes (ie, consequential injury or indirect in-
jury). The clinical significance of these observa-
tions is that modifiers that ameliorate acute tox-
icity may also reduce the incidence or severity of
chronic radiation enteropathy.
Clinical Diagnosis and Management of
Bowel Injury
Acute Radiation Enteropathy
Acute intestinal radiation toxicity seldom oses
diagnostic dilemmas, and diagnostic tests are
usually not indicated. Management is symptom-
atic and follows general guidelines for treating
similar symptoms in other situations. Hence, con-
ventional antidiarrheal, antiemetic, spasmolytic,
and defoaming agents are mainstays in the man-
gement of acute bowel toxicity. P tients with
severe diarrhea that does not respond to first-line
antidiarrheal drugs may benefit from treatment
with a synthetic somatostatin analog. In patients
in whom the effect of conventional antiemetics is
unsatisfactory, serotonin antagonists may relieve
symptoms. Complications requiring surgical in-
tervention (severe bleeding or perforation) are
exceedingly rare in the acute setting.
A plethora of pharmacological and nutritional
compounds and diets, ranging from vitamins and
amino acids to cytokines and enzymes have been
subject to investigation as intestinal radiation
response modifiers in preclinical and, to a lesser
extent, clinical studies. Although many of these
interventions have produced promising results,
none is of yet in general use in the prophylaxis or
therapy of acute intestinal radiation toxicity.
These agents are discussed later.
Delayed Radiation Enteropathy
Delayed radiation enteropathy, uncomplicated by
intestinal obstruction, perforation, or fistula for-
mation, is usually managed conservatively. How-
ever, in contrast to acute intestinal radiation tox-
icity, the diagnosis and therapy of delayed
radiation enteropathy is less straightforward.
This is mainly because of the multifaceted n ure
of the disorder and variations among patients in
terms of the dominant pathophysiological pro-
cess(es). A pathophysiology-based approach is
clearly preferable to an empiric (trial and error–
based) approach.
Radiation-induced intestinal dysfunction may
be a result of (1) mucosal dysfunction (because f
atrophy, reduced activity of brush border mem-
brane enzymes, reduced mucosal blood flow,
and/or impaired lymph drainage) and/or (2) in-
testinal dysmotility with bacterial overgrowth
and digestive dysfunction (because of stricture
formation and neuromuscular dysfunction). The
relative significance of these processes varies
from patient to patient and, thus, it is important
to individualize the diagnostic and therapeutic
approach. The pathophysiological features of de-
layed radiation enteropathy, their corresponding
symptoms, and strategies for diagnostic evalua-
tion are summarized in Table 1.
Table 1. Pathophysiological Features and Diagnostic Evaluation of Patients With Delayed Radiation
Enteropathy
Pathophysiological Feature Clinical Sign or Symptom Diagnostic Evaluation
Mucosal dysfunction Lactose intolerance Lactose absorption test
Vitamin B12 deficiency Schilling test
Steatorrhea Fecal fat excretion test
mucosal permeability tests
Stricture or stagnant loop syndrome
with bacterial overgrowth
Diarrhea Diagnostic imaging
Breath tests
Endoscopic sampling
Intestinal dysmotility Bloating Intestinal manometry
Constipation Functional imaging
Diarrhea Intestinal transit tests
Abnormal bile acid recirculation Cholerrheic diarrhea Specific breath tests to assess bile
acid absorption and deconjugation
Bowel Injury 359
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EORTC/RTOG score and thus severity of symptoms.  Other earlier studies also suggest 
telengiectasia and congested mucosa to be the most prevalent endoscopic findings in 
radiation enteropathy/proctopathy (Hasleton et al, 1985; den Hartog Jager et al, 1985).   
Endoscopic follow-up studies also suggest that late (rectal) mucosal changes improve 
over time with a peak at 12 months after treatment (Hovdenak et al, 2000; O’Brien et al, 
2004).  A high incidence of rectal damage however, is usually found when endoscopy is 
done to evaluate symptoms of severe rectal bleeding (Figures 1.5 and 1.6). 
 
1.9 Histopathological Diagnostic Features 
 
Radiation enteropathy is characterised by diffuse collagen deposition and progressive 
occlusive vasculitis.  The vasculitis and fibrosis progress over time, resulting in 
narrowing of the intestinal lumen with dilatation of the bowel proximal to the stricture.  
The affected segments of the intestine and serosa become thickened.  Ulceration, 
necrosis, and occasional perforation of the intestinal wall may occur (Hasleton et al, 
1985).  The increased expression of TGF-β is particularly enhanced in areas with 
histopathological changes consistent with radiation injury: mucosal ulceration, mucosal 
and serosal thickening, inflammatory cell infiltrates, and vascular sclerosis.  Pathological 
examination of bowel specimens from patients who underwent surgery for radiation 
enteropathy showed an increased immunoreactivity of TGF-β in areas with vascular 
sclerosis and fibrotic areas of serosa and muscularis propia compared with patients who 
underwent surgery for other reasons (Richter et al, 1996).  Figure 1.4 shows cellular 
changes seen in early and late effects of radiation. 
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Figure 1.4. Cellular changes in Early and Late Effects of Radiation.  Taken from Andreyev et al, 
2011. (a) and b) Early effects.  There is marked distortion of the mucosa.  There are withered crypts lined 
by epithelial cells that have lost mucin and show toxic damage with abundant pale eiosinophilic cytoplasm.  
The crypts contain cellular debris.  The nuclei contain prominent nucleoli.  The lamina propria contains 
scattered plasma cells and eiosinophils.  Endothelial cells are enlarged with large nuclei containing 
prominent nucleoli. (c) Late Effect.  Large bowel mucosa shows fine fibrosis of lamina propria with dilated 
and small capillaries.  Some crypts show mucin depletion.  (d) Late Effect. There is crypt distortion and 
branching with fibrosis in the lamina propria that is slightly condensed around the crypts.  An eosinophil is 
seen in the lamina propria.  
 
1.10 Risk Factors for Radiation-Induced Bowel Injury 
 
Inter-patient variability in normal tissue response to radiotherapy is well recognised.  All 
tissue will express some level of response to radiotherapy at molecular, histological and 
clinical level, yet not all patients will develop injury significant enough to manifest as 
clinical symptoms.  The incidence and severity of radiation-induced bowel injury is 
dependent on a number of patient and treatment factors (Table 1.1).   
Patient factors such as low body mass index (BMI), presence of other co-morbidities; 
diabetes, hypertension, collagen disorders, and pre-existing inflammatory bowel disease 
(IBD) have been implicated with a higher risk of developing symptoms of RIBI (Chon 
injury which manifests itself either quickly or after a
long period. These processes can be revealed clini-
cally as:
(1) damage to speciﬁc neurological, enzyme based
and muscular functions (and probably also local
hormonal regulation) of the gastrointestinal tract
(2) acute inﬂammatory processes and chronic cyto-
kine activation
(3) development of chronic ischemia within the
gastrointestinal wall, surrounding stroma and
mesenteries
(4) progressive pro-ﬁbrotic processes within the
gastrointestinal wall, surrounding stroma and
mesenteries
(5) changes in preexisting conditions or the
development of new conditions unrelated to
radiotherapy, which also cause symptoms indis-
tinguishable from those arising as a result of
radiotherapy.
Histological consequences of radiation on
normal tissues in the gastrointestinal tract
During the 5 or 6 weeks of radical external beam
radiotherapy, an acute inﬂammatory reaction is seen
in those parts of the gastrointestinal tract, which are
exposed to radiotherapy. Radiation travels in a
straight line, with only minor scatter, so it does not
respect normal anatomical planes. Five small studies
have characterized the developing changes in the
human rectum in the acute setting but changes in
the small bowel during radiotherapy have not been
examined in humans. Data from small bowel changes
in animal models are available but some caution needs
to be exercised in extrapolating these data to the
human. First, animals in these studies have often
not been treated with fractionated regimens analo-
gous to those used in humans. Second, direct appli-
cability of the information from the animal model to
the human is sometimes unclear in that there are a
variety of responses to the same radiation dose in
different animal models [46]. Certainly, different
animal models are required to investigate different
phases of radiation damage.
In humans (Figure 1a–d), the rectal acute response
following radiotherapy is an inﬂammatory process
characterized by acute cryptitis, crypt abscesses, crypt
distortion and atrophy with invasion of the epithelium
by neutrophils and eosinophilic granulocytes followed
by loss of lamina propria lymphocytes. By 2–4 weeks,
eosinophilic micro-abscesses or inﬁltrates extending
c
a b
d
Figure 1. (a and b) Early effects. There is marked distortion of the mucosa. There are withered crypts lined by epithelial cells that have lost
mucin and show toxic damage with abundant pale eosinophilic cytoplasm. The crypts contain cellular debris. The nuclei contain prominent
nucleoli. The lamina propria contains scattered plasma cells and eosinophils. Endothelial cells are enlarged with large nuclei containing
prominent nucleoli. (c) Late effect. Large bowel mucosa shows ﬁne ﬁbrosis of the lamina propria with dilated and congested small capillaries.
Some crypts show mucin depletion. (d) Late effect. There is crypt distortion and branching with ﬁbrosis in the lamina propria that is slightly
condensed around the crypts. An occasional eosinophil i seen in th lamina propria.
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and Loeffler, 2002).  A history of previous abdominal surgery predisposes to RIBI due to 
anatomical changes caused by bowel adhesions, leading to fixation of small bowel loops 
in the radiation field (Forbes, 2001; Letschert et al, 1990; Hauer-Jensen et al, 2014).   
As discussed earlier, the total radiation dose and the volume of irradiated bowel 
(determined by the planning fields) remain the most important factors predisposing to the 
risk of RIBI.  Evidence shows severe enteropathy and bowel injury is relatively rare with 
doses <50 Gy. The total dose at which 5% of patients are expected to experience 
enteropathy from RIBI at 5 years (TD5/5) is 50Gy for a third of the volume of the small 
bowel and 40Gy for the whole volume.  The dose at which 50% of patients will develop 
enteropathy at 5 years (TD50/5) is 60Gy for a third of the volume and 55Gy for the 
whole volume.  The tolerance for large bowel is slightly higher than for small bowel; 
TD5/5 of 55Gy for a third of the volume and 45Gy for the whole volume, with a TD50/5 
of 65Gy for a third of the volume and 60Gy for the whole volume of the colon (Emami et 
al, 1991. 
There is considerable evidence to show that extended field techniques and using anterior-
posterior opposing fields can cause significantly more bowel toxicity than 3-4 field 
treatment (Letschert et al, 1990; Mak et al, 1994) and the more modern conformal CT 
planning techniques (Greven et al, 1991). 
The addition of chemotherapy has also been shown to increase the rates of radiation -
induced bowel injury however a systematic review of trials comparing concomitant 
chemo-radiation to radiation alone for the treatment of locally advanced cervical cancer 
concluded that, although concomitant chemo-radiation resulted in a two-fold increase in 
acute bowel toxicity, this was not found to be associated with late adverse effects 
(Kirwan et al, 2003). 
From my review of the literature, I have compiled the evidence for risk factors as shown 
in table 1.2 below. 
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Treatment-Related Factors References 
Radiation Dose Emami B et al, 1991 
Roeske et al, 1997 
Volume/length of Irradiated bowel Emami et al, 1991 
Time-dose fractionation Dahlberg M et al, 1998 
Bujko K et al, 2006 
Hovdenak et al, 2000 
Concomitant Chemotherapy Ooi et al, 1999 
Letschert et al, 1990 
Kirwan et al, 2003 
Patient-related Factors  
BMI (LOW) Eifel PJ et al, 2002; 
Wedlake LJ et al 2010 
Previous Abdominal Surgery Forbes, 2001  
Letschert et al, 1990 
Previous Bowel Disorders  (IBD*) Willett CJ et al, 2000 
Medical Co-morbidities – Diabetes, Vascular Disorders, 
Collagen disorders 
Herold D et al, 1999; Potish RA et al, 
1983; Ross JG et al, 1993; Lin A et al, 
2008 
Smoking Eifel PJ et al, 2002 
Chon and Loeffler, 2002 
Genetic Predisposition? West CM et al, 2011 
Table 1.2.  Risk Factors for Radiation-induced Bowel Injury (Evidence from the Literature). IBD* - 
Inflammatory Bowel Disease (Ulcerative Colitis, Crohn’s Disease) 
 
1.11 Investigating symptoms of Radiation injury to the Bowel 
 
In 2012 a practice guidance was designed and published by the Royal Marsden ‘Pelvic 
Radiation Disease’ Group (Andreyev et al, 2012) on behalf of the British Society of 
Gastroenterology, to facilitate clinical practice and improve management of patients with 
symptoms of RIBI in accordance with the goals set out by the National Cancer 
Survivorship Initiative (NCI Vision, 2010).  Table 1.3 below summaries the suggested 
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algorithmic approach used by the Royal Marsden Hospital, UK for investigating 
symptoms of RIBI. 
 
 
Table 1.3 Algorithm depicting simplified principles of work-up and common approaches for 
managing patients with delayed gastrointestinal symptoms after radiotherapy at the Royal Marsden 
London.  Abbreviations; BAM, bile-acid malabsorption; FFA, free fatty acid; GI, Gastrointestinal; 
QOL, quality of life; SIBO, small intestinal bacterial overgrowth (Taken from Hauer-Jensen et al, 
2014). 
 
Current symptom questionnaires and scoring tools, such as LENT/SOMA (Late-Effects 
Normal Tissue taskforce – Subjective, Objective, Management, Analytical) and Radiation 
Therapy Oncology Group (RTOG) questionnaire have limited use in the clinical setting 
in assessing and evaluating patients symptoms; they are still mostly unable to direct 
diagnosis of underlying pathologies related to RIBI (Andreyev, 2007a,b).   
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The second, fundamentally different approach consists 
of agents that modulate various pathophysiological, cel-
lular or molecular responses that occur down ream from 
radiation. These interventions seek to increase radiation 
tolerance, ameliorate secondary normal tissue injury or 
enhance repair capacity. Such approaches include, for 
example, various immune-modulating drugs,40,88 entero-
trophic agents,89–96 compounds that modulate intra-
luminal contents,97,98 and a variety of other strategies.99–104 
Interventions that target downstream radiation effects 
might be generally more appealing in the cancer treat-
ment situation because they do not interfere directly with 
the mechanism of radiation. Therefore, tumour protection 
is often, albeit by no means always, less of a concern than 
it is with free radical scavengers and antioxidants. A com-
prehensive, up-to-date discussion of the various strategies 
that have been and are under investigation is beyond the 
scope of this Review, but has been covered elsewhere.25
Screening for compounds
Many compounds have demonstrated fairly robust radio-
protective effects in animal studies. However, few have 
advanced to clinical testing and most of those that do fail, 
either because of clinical toxicities, a lacklustre protective 
effect or concerns about tumour protection. Moreover, 
substantial barriers need to be overcome in the drug 
development process. First, there is a false perception that 
the prevalence of radiation enteropathy is lower than it 
really is (again, the prevalence of radiation enteropathy is 
actually higher than that of IBD). Second, there is a lack of 
general public appeal for radiation enteropathy and also 
a lack of interest from clinicians and institutions (some-
times motivated by financial or medico-legal considera-
tions). Third, radiation enteropathy is a complex disorder 
that requires multidisciplinary expertise often not readily 
available in the cancer treatment environment. Fourth, 
many clinicians feel that any treatment of delayed radia-
tion enteropathy is unlikely to be successful. Finally, the 
pharmaceutical and biotechnology industry has devoted 
little attention to radiation enteropathy research from.
The interest in finding so-called medical counter-
measures against radiation (drugs for use in the radio-
logical and nuclear emergency situation, in which 
radiation injury to the bone marrow and intestine is the 
main determinant of survival) has spawned a resurgence 
in activities to find compounds to protect the intestine 
against radiation. Such drugs can potentially also benefit 
the cancer patient who undergoes radiation therapy—so 
called dual benefit drugs. The recommended steps in the 
development process of such drugs have been reviewed 
by Movsas and co-workers.105 First, for a candidate drug 
to be selected, there needs to be evidence of general or 
organ-specific healthy tissue protection and lack of 
tumour protection. Drug candidates that fulfil these cri-
teria undergo testing to determine the maximal-tolerated 
dose, pharmacokinetics, pharmacodynamics and toxicity. 
Refer appropriately e.g.:
■ Gynaecology
■ Urology
■ Psychological support
■ Pain team
■ Rheumatology
■ Lymphoedema services
■ Physiotherapy
Non-GI unmet needs identi!ed Holistic assessment GI symptoms
Recurrence unlikely Possible recurrence
New GI
Symptoms following 
cancer treatment
Longstanding GI
symptoms pre-dating 
cancer treatment
Re-stage 
■ Cross-sectional imaging
■ Tumour markers
■ Appropriate endoscopy
Bleeding from 
radiation-induced 
telangiectasia
GI symptoms 
affecting QOL
Minimal symptoms
Not affecting QOL
No alarm features
Investigate and
manage as with any
 non-cancer GI patient
Positive
Refer to oncologistReassure
■ Flexible endoscopy assessment
■ Optimize bowel function
■ Bleeding not affecting QOL:
 reassure; no treatment needed
■ Bleeding affecting QOL; stop/reduce  
 anticoagulants if possible; if severe  
 start sucralfate enemas 
■ Discuss de!nitive treatment options:
 ■ hyperbaric oxygen therapy (may   
 improve other symptoms but time-  
 consuming)
 ■ argon plasma coagulation (easily  
 available but high risk of serious
 complications) 
 ■ formalin therapy (simple to perform   
 but long-term outcomes unknown)
Are there lifestyle/ 
medication/ 
dietary/ endocrine/ 
psychological/ 
other non-GI
causes for 
the symptoms?
Intermittent or constant 
steatorrhea or diarrhoea 
Exclude: SIBO/BAM/
pancreatic insuf!ciency/ 
FFA malabsorption/
lactose intolerance/
 endocrine causes
Nocturnal 
defecation/
obstructive 
episodes
 indicate
organic
disease
Urgency/faecal incontinence
If no organic disease:
■ Assess !bre intake
■ Pelvic "oor and toileting  
 exercises
■ Stool bulking agent
■ Anti-diarrhoeals
■ Tricyclic antidepressants
■ Biofeedback 
Figure 7 | Algorithm depicting simplified principles of work-up and common approaches for managing patients with delayed 
gastrointestinal symptoms after radiation therapy used at the Royal Marsden Hospital, London, UK. Abbreviations: BAM, bile 
acid malabsorption; FFA, free fatty acid; GI, gastrointestinal; QOL, quality of life; SIBO, small intestinal bacterial overgrowth.
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Useful Initial investigations include: 
 Vitamin B12 levels 
 Thyroid function tests 
 Coeliac Screen  
 Selenium Homocholic acid taurine (SeCHAT) Test 
 Glucose hydrogen/methane breath test 
 Upper GI endoscopy + duodenal aspirate 
 Flexible Sigmoidoscopy +/- Biopsy 
 Computed Tomography (CT) Scan 
 Magnetic Resonance Imaging (MRI) Abdomen and Pelvis  
 
Initial laboratory tests are useful to exclude malabsorption and anaemia.  As multiple 
sites of injury may contribute to symptoms, the choice of investigations are guided by 
symptoms; patients with rectal bleeding will have blood tests to exclude anaemia and will 
be referred to endoscopy to exclude new neoplasia.  Investigation of symptoms of RIBI 
may show pathological changes in multiple areas of small and large bowel, which may 
not be related to presenting symptoms.   
The role of imaging in investigating patients with gastrointestinal symptoms after 
radiotherapy has long been established and CT and MRI scans are part of initial 
investigations in patients presenting with symptoms of acute or sub-acute bowel 
obstruction to exclude radiation-induced strictures and fibrosis in both small and large 
bowel.  An algorithmic approach to investigating symptoms should enable the structured 
evaluation of symptoms of RIBI. 
 
1.12 Severe complications arising from Radiation-Injury to the Bowel 
 
Patients can present with severe symptoms affecting quality of life after radiotherapy 
(Andreyev, 2007 & 2010) including:  
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 Transfusion-dependent rectal bleeding requiring intervention (Figures 1.5 and 1.6) 
 Acute or sub-acute bowel obstruction requiring surgery and enteral feeding 
 Intestinal Fistulas 
 Bowel Perforation 
 
 
 
 
 
 
 
Figure 1.5 Transfusion-dependent Rectal Bleeding requiring endoscopic treatment.  Case 1. This 
patient was part of our follow-up in our cohort study (chapter 2) and presented with recurrent significant 
rectal bleeding affecting her quality of life.  She required Argon Beam Diathermy (APC) (2 separate 
treatments) to control symptoms 
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Figure 1.6. Case 2. Argon 
Beam Diathermy for moderate 
to severe radiation proctitis in a 
cervical cancer patient presenting 
with rectal bleeding. 
 
 
 
 
1.13 Non-Surgical Interventions in the Management of Radiation-Induced Bowel 
Injury 
 
Acute radiation enteropathy and the manifestations of late radiation injury to the bowel; 
‘pelvic radiation disease’ – haemorrhages, fistulas, obstruction, abscesses, bowel 
perforations, strictures account for a large amount of morbidity in patients, affecting their 
quality of life, distrupting cancer survivorship with an increasing cost to healthcare. 
Acute RIBI is mostly self-limiting and usually requires only conservative management.  
In most cases, only a small proportion of women require admission and inpatient 
management of dehydration with acute colitis or enteritis.  Chronic RIBI (radiation 
enteropathy/colopathy/proctopathy) however is poorly predictable and a progressive 
disease manifesting in severe cases as a consequence of irreversible injury to the bowel.  
The management of chronic radiation injury to the bowel remains challenging, with 
surgery indicated only in severe cases with complications such as small/large bowel 
strictures with fibrosis, partial/complete obstruction, perforation and fistulas.   
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Despite the high prevalence of radiation-induced bowel injury, the evidence for effective 
treatments stil remain limited.  Therapeutic options are available and wide-ranging and 
can be tailored to the clinical presentation and the underlying aetiology once identified.  
Denton et al, (2002) published a systematic review for non-surgical interventions for the 
management of late radiation proctitis.  This study highlighted the lack of randomised 
controlled trials in proving the efficacy of most therapeutic options.   
Diarrhoea in chronic enteropathy can be managed with anti-motility agents such as 
loperamide or codeine phosphate.  Probiotics and Prebiotics alter the intestinal microbial 
environment and may prevent radiation enteropathy (Seal et al, 2007) and current trials 
are underway to support this. Bacterial overgrowth has been shown to respond to 
antibiotics (Danielsson et al, 1991; Meyers et al, 2001; Gasbarrini et al, 2007). 
Cholestyramine is used to treat bile-acid malabsorption, which has been shown to 
account for 35-72% of symptoms in patients suffering from bowel symptoms following 
radiotherapy (Andreyev et al, 2005; Danielsson et al, 1991; Ludgate and Merrick, 1985).  
Rectal RIBI (radiation proctopathy) with bleeding can be managed with sulcrafate 
enemas (Kochhar et al, 1991; Sanguinetti et al, 2003).  Rectal bleeding can be controlled 
with Argon beam therapy (endoscopic) or hyperbaric oxygen (Hauer-Jensen et al, 2014; 
Clarke et al, 2008).      
The recent ORBIT trial (Andreyev et al, 2013) showed that patients’ symptoms can be 
helped significantly if a systematic algorithmic approach is used to elicit symptoms.  This 
trial also showed that a nurse trained to manage symptoms can be as effective as a senior 
gastroenterologist, especially with limited resources and long waiting times for referrals 
to gastroenterologists by oncologists. 
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1.14 Surgical Management of Radiation-Induced Bowel Injury 
 
The incidence of severe RIBI requiring surgical intervention remains significant and has 
been stated as being up to one-third of all patients receiving curatve doses of pelvic 
radiation (Andreyev, 2007).  In one cohort study, (Lefevre et al, 2011) approximately 
one-third of patients with chronic radiation enteropathy required surgery, which was 
associated with a high morbidity rate and a high risk of re-operation.  The aim of this 
study was to report outcome after surgery for radiation enteropathy.  The cohort consisted 
of 107 patients; (94 women; 87.8%).  The main indication for surgery was symptomatic 
stricture (76.6%).  Forty-nine (49) ileo-caecal resections (45.8%) were performed.  
Overall and surgical morbidity rates were 74.8% (80 patients) and 28% (20) respectively.  
Fourteen (14) patients (13.1%) underwent re-operation for complications after the initial 
surgery.  Re-operation rates at 1 and 3 years of follow-up were 37 and 54% respectively.  
Risk factors for reoperation or recurrent enteropathy were: emergency surgery (OR 2.72, 
95% CI 1.57-4.86), anastomotic leakage (OR 2.53, 95% CI 1.54-4.42) and male sex (OR 
3.57 95% CI 1.87-7.29).  The only protective factor for re-operation was ileo-caecal 
resection (compared to intestinal bypass surgery or adhesiolysis) during the first surgical 
operation (OR 4.48 95% CI 2.52-8.31). 
Regimbeau et al (2001) reported 109 patients (62% with gynaecological cancer) with 
chronic radiation enteropathy (mean radiation dose 55Gy +/- 17Gy (range 10 to 105Gy) 
between 1984 and 1994 were operated on with a mean follow-up of 40 months (range 1 -
293). Five (5) patients died in the post-operative period.  Operative mortality was 
significantly higher in the resection group (5% vs 0%).  Thirty-three (33; 30%) of 
patients experienced post-operative complications including anastomotic leak in 11.  At 
the end of follow-up, parenteral nutrition (TPN) remain mandatory for 18 (32%) patients 
from the resection group versus 14 (38%) in the conservative group.  The difference was 
not significant.  Twenty-one patients (21; 19%) at follow-up were diagnosed with short 
bowel syndrome (<1m) associated with diarrhoea.   
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Gavazzi et al, (2006) compared the long term outcome of patients with radiation-induced 
intestinal obstruction treated either surgically or with intestinal rest and home parenteral 
nutrition (HTPN), 17 patients underwent surgery and 13 were supported by HTPN.  Fifty 
percent (50%) of these patients had been treated for gynaecological cancers.  Long term 
nutritional autonomy and survival seemed to be better in patients initially treated with 
intestinal rest and HTPN; 46% required surgery after a mean period of 12.7 months of 
nutritional support because of persistence of symptoms supported by radiological 
evidence indicating surgical intervention.  
 
1.15 Preventing and Reducing Normal tissue effects from Pelvic Radiation 
 
Interventions to reduce the incidence of RIBI and protect healthy tissue from radiation 
effects, whilst maintaining optimal tumour control remain largely unavailable.  Previous 
and ongoing studies have explored various strategies.  As radiation-specific injury is 
initiated by reactive oxygen species, antioxidant, free radical scavengers and various 
cyto-protectors have been subjects of study for decades.  Amifostine, a potent scavenger 
of free radicals has been investigated for the prevention of RIBI (Ben-Josef et al, 2002).  
Superoxide dismutase has also been explored as a potential for radio-protection 
(Salvemini et al, 2002).   
Other interventions to prevent toxicity involve exploring the modulators of the patho-
physiological or cellular responses to radiation by seeking agents that can increase 
radiation tolerance, ameliorate secondary normal tissue injury, or enhance repair capacity 
(Hauer-Jensen et al, 2014).   
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1.16 Advances in Radiobiology: Optimising Planning and Delivery techniques 
 
Intensity Modulated Radiotherapy (IMRT) 
For most pelvic tumours radiotherapy remains a mainstay of treatment, and in 
gynaecological cancers especially for locally advanced cervical cancers.  Newer 
techniques such as IMRT, which allows a higher degree of conformity to tumour, 
provides the opportunity, to further reduce radiation related toxicity whilst also 
potentially improving local control by increasing tumour dose.  By varying the intensity 
of the radiation beam, IMRT allows more shaping of radiation fields even around 
concavities.  The dose distribution of IMRT fits more precisely to the target volume, 
producing a concave shape at the posterior aspect of the PTV, reducing the dose to the 
rectum, and also anteriorly, curving around the lateral lymph node target volume while 
sparing more of the central bladder and bowel (Powell, 2010). 
Mundt et al, (2001) have sown a reduction in Grade 2 gastrointestinal toxicity from 91% 
to 60% in a cohort of 40 patients (70% post-operative, 40% primary radiotherapy).  Late 
toxicity was reduced from 50% to 11%.  Portelance et al (2001) showed in a dosimetric 
study that IMRT reduces small bowel, rectum and bladder doses in patients with cervical 
cancer receiving pelvic and para-aortic irradiation.  CT scans studies of 10 patients with 
cervical cancer were used as anatomic references for planning.  Upon completion of 
target and critical structure delineation, the imaging and contour data were transferred to 
both an IMRT planning system (Corvus, Nomos) and a three-dimensional planning 
system (Focus, CMS) on which IMRT as well as conventional planning with two- and 
four-field techniques were derived.   
Treatment planning was done on these two systems with uniform prescription, 45Gy in 
25 fractions to the uterus, cervix and the pelvic and para-aortic lymph nodes.  
Normalisation was done to all IMRT plans to obtain a full coverage of the cervix with the 
95% isodose curve.  Dose-volume histograms were obtained for all the plans. The 
volume of small bowel receiving the prescribed dose (45Gy) with IMRT technique were: 
four fields, 11.01 +/- 5.67%; seven fields, 15.05 +/- 6.76% and nine fields, 13.56 +/- 
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5.30%.  These were all significantly better than with two-field (35.58 +/- 13.84%) and 
four-field (34.24 +/- 17.82%) conventional techniques (p<0.05).  The fraction of rectal 
volume receiving a dose greater than described was as follows; four fields, 8.55 +/- 
4.64%; seven fields, 6.37 +/-5.19%, nine fields, 3.34 +/- 3.0%; in contrast to 84.01 +/- 
18.37% with two–field and 46.37 +/- 24.97% with four-field conventional technique 
(p<0.001). This study demonstrated that with similar target coverage, normal tissue-
sparing is superior with IMRT compared to convention radiotherapy in cervical cancer 
treatment. 
 
1.17 Improving uncomplicated cancer cure rates and the Cancer Survivorship 
Initiative 
 
There is a need to identify tissue specific biomarkers of normal tissue injury and identify 
those patients who might be at risk of severe injury to the bowel.  Patients with cervical 
cancer especially are usually young and fit with symptoms that significantly affect their 
quality of life. 
Prospective trials and research into the better understanding of the patho-physiology of 
RIBI continue to be difficult given the complex relationship between symptom 
presentations these patients and the nature of the toxicity and RIBI.  
In this thesis I will attempt to answer the following questions and explore the following: 
1. True incidence and presentation of RIBI in a London Cancer Centre. 
2. How scoring and reporting of symptoms might be improved. 
3. Can Cell-cycle markers of radiotherapy be used as a marker of (chemo)-
radiosensitivity? 
4. Whether cell-cycle markers in colonic crypt cells can shed more light on the 
proliferative status after exposure to radiation and if this linked to severity of 
RIBI, grade of histopathological features and other endpoints. 
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Chapter Two  A Retrospective-Prospective Cohort Study  
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Chapter Two  A Retrospective Cohort Study  
Radiation-Induced Bowel Injury: The Impact of Radiotherapy after 
treatment for Gynaecological Cancers 
 
2.1 Introduction   
 
The true prevalence of late bowel toxicity in the UK remains unknown due to the paucity 
of prospective studies in patients who following completion of radiotherapy.  Many 
patients are discharged from oncology centres follow-up after 2-5 years, and some are 
investigated and treated for bowel symptoms and complications in other units/hospitals.  
The reporting of late toxicity remains poor; patients rarely report mild chronic symptoms 
of loose stools and diarrhoea, or those symptoms not considered to be related to 
treatment, or ‘embarrassing’ symptoms like flatulence and faecal incontinence/leaking.  
Although the majority of women who receive pelvic radiation will present with 
symptoms of acute radiation-induced bowel injury (‘Radiation 
Enteritis/Proctitis/Proctopathy’), which may be present during and up to 3 months after 
treatment, some of these women report symptoms settle and a return to normal function 
(Andreyev 2007a).  It remains unclear why only a proportion of women (5-50%, 
depending on study) (DeCosse et al, 1969; Galland and Spencer, 1985; Theis VS et al, 
2010) never settle or indeed some go on to represent months or years after pelvic 
radiotherapy with symptoms of radiation-induced bowel injury or ‘Pelvic Radiation 
Disease’.  
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2.2 Materials and Methods 
 
2.2.1 Study Cohort 
The records of 541 patients diagnosed between February 2003 and June 2010 within the 
North London Cancer Gynaecological Cancer Network who required radiation as part of 
their treatment were reviewed; 219 patients with histologically confirmed Cervical 
Cancer- International Federation of Gynaecology and Obstetrics (FIGO) stages IB2-IVA 
and 322 women with Endometrial Cancer FIGO stages IB-IV treated with radiotherapy 
with or without surgery and/or chemotherapy.  Inclusion criteria included patients with 
both cancer types who had received a ‘treatment’ dose of radiation according to standard 
protocols at our centre who then reported symptoms of bowel toxicity requiring 
investigation or referral to a gastroenterologist.  Patients who presented with symptoms 
after 3 months from completion of radiotherapy were included in the study as well as 
those who reported ‘chronic’ symptoms that had not subsided or improved since the end 
of treatment.  Exclusion criteria included patients who received a ‘palliative’ dose (20-
30Gy) of radiation for recurrence or advanced disease, and patients who reported mild 
symptoms immediately after completion of radiotherapy that had settled by the next 
subsequent follow-up.  
 
2.2.2 Data Collection 
 
Oncology and radiotherapy databases were searched to identify all patients who had 
received radiotherapy with curative intent.  The gastroenterology database was also 
searched to include all patients referred from oncology for investigations of bowel 
symptoms following radiotherapy. Clinical data on cancer demographics, treatment 
received, outcome and follow-up was obtained from hospital records.  Original pathology 
reports were reviewed for histological type, FIGO stage, and tumour grade.  I extracted 
data on: date of diagnosis, past medical and smoking history, date and type of primary 
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surgery, stage of disease, type and dose of radiotherapy, and date of completion of 
radiotherapy, chemotherapy received, disease recurrence or progression; date of 
presentation with bowel symptoms, nature of symptoms and degree to which symptoms 
affected quality of life (QoL), investigations and treatment of chronic radiation-related 
bowel symptoms, as well as status at last oncology and gastroenterology  follow-up were 
all also obtained from individual patient records, clinic letters, and review of imaging 
reports and other investigation results.   
Patients were followed up in the multidisciplinary oncology clinics every 3 months for 2 
years, then 6 monthly for 2 (early stage endometrial), and annually to 10 years 
(locally/(advanced) stage cervical) depending on cancer type and stage.  Clinical 
examination and routine screening bowel and bladder toxicity screen were undertaken 
and documented.  Patients were referred to gastroenterologists if bowel symptoms were 
moderate and deemed to be affecting the patients’ quality of life or if they had symptoms 
that required investigations (for example rectal bleeding).  Computerized Tomography 
(CT) or Magnetic Resonance Imaging (MRI) was undertaken if clinically indicated. 
Patients referred from neighboring cancer units initially were followed up at the centre 
for 2 years and were then referred back to the regional units if there were found to be free 
of disease after 2 or more years.   
 
Treatment Received 
 
Cervical Cancer; 
Chemotherapy 
Majority of patients FIGO (IB-IVA) received concomitant chemo-radiation with weekly 
Cisplatin 40mg/m2.   
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Radiotherapy 
Radiotherapy was given according to our defined cancer centre’s protocol - concurrently 
with weekly Cisplatin; almost all patients received primary radiotherapy stages (IB - IV): 
external beam radiation (EBRT) to the pelvis (50.4Gy in 28 fractions over 5.5 weeks 
using 8-15mV photons) and intracavity brachytherapy (ICB) using an intrauterine ovoid 
system (15Gy in 2 fractions/HDR/point A).  Extended fields were used to treat para-
aortic lymph nodes (PALN) using an AP/PA field to a dose of 45Gy in 25 fractions over 
5 weeks.  Where parametrial invasion or pelvic side wall extension was evident, a further 
5.04Gy in 3 fractions was delivered to the pelvic side wall (n=27, 38%). 
 
Surgery 
Patients were selected based on risk determined by clinical staging for laparoscopic para-
aortic node dissection.  Primary surgery was not indicated for locally advanced stage 
disease in the majority of patients.  
 
Endometrial Cancer; 
 
Surgery 
Primary treatment for all patients involved a total hysterectomy with bilateral salpingo-
oophorectomy (TAH/BSO) with peritoneal washings.   
Chemotherapy 
When adjuvant chemotherapy was given, patients received 6 cycles of carboplatin AUC 5 
and paclitaxel 175mg/min2 every 3 weeks.  This was usually within 4 weeks after 
primary surgery. 
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Radiotherapy  
Radiotherapy to the pelvis was delivered using external beam radiotherapy at a dose of 
45Gy in 25 fractions over 5 weeks with an additional 12Gy in 2 fractions to the vaginal 
vault.  Radiation treatment started immediately after recovery from surgery or 
chemotherapy if received, and was usually within 2-4 weeks of completion of 
chemotherapy.   
 
Radiotherapy Planning 
Until 2006, radiotherapy was planned using orthogonal films, and delivered using four 
orthogonal fields.  From 2007, radiotherapy was delivered using 3-D conformal 
radiotherapy, planned using a dedicated CT planning scan, and with IV contrast unless 
contra-indicated.  The planning target volume (PTV) was defined as the clinical target 
volume (CTV) (obtained form pre-treatment MRI and EUA) with a 10mm expansion.  
The external beam radiation to the pelvis was delivered using a four-field (AP/PA and 
two lateral fields) arrangement.   
The conventional pelvic field extended from the top of L5 to the bottom of the obturator 
foramen or 2cm below the lowest level of disease and laterally 1.5cm beyond the bony 
pelvis.  The lateral fields extended from the anterior border of the symphysis pubis to the 
S2/3 interspace posteriorly. 
 
2.2.3 Data Analysis 
 
Comparison between patient and treatment groups was done using Chi-squared analysis 
for discrete variables.  Student’s t-test was used to compare means.  Risk 
factors/predictors for severe late bowel injury were assessed using univariate and 
multivariate ordinal logistic regression.  Survival data were analysed using log-rank test 
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and Kaplan-Meier method was used to show time course and chronicity of late bowel 
symptoms related to survival.   
Factor analysis was used to assess associations between the multiple presenting 
symptoms and correlate this with our data set outcomes.  Survival was defined from date 
of completion of cancer therapy to date of last follow-up or death.  Status of bowel injury 
symptoms/disease was defined as the interval from first documented presentation with 
bowel symptoms to date last seen by gastroenterologists or late toxicity status recorded 
by oncologists.  A p value <0.05 was considered significant.  Statistical analyses were 
performed with SPSS version 19.0. 
 
2.2.4 Factor Analysis 
 
As majority of patients presented with multiple signs and symptoms, we sought to find 
correlation between symptoms in different subsets or ‘clusters’.  Factor analysis tells us 
what variables in a set of data ‘group’ or ‘go together’ (Schmitt, 2011).  This method of 
analysis explores the underlying variance structure of a set of correlation coefficients.  If 
the analysis is designed to account for only the variance in the correlation coefficients 
and ignore the error variance (i.e., the variance not accounted for by the correlation 
coefficients), it is called a ‘Factor Analysis’ (Stapleton, 1997).  If the analysis is designed 
to account for all the variance including that found in the correlation coefficients and 
error variance, it is called a Principal Components Analysis.  The idea behind the choice 
of this method was to take into account all presenting symptoms within each group of 
symptoms patients reported, as well as the pattern of variable ‘groupings’ in the entire 
cohort.  In both types of analyses, the factors that underlie the correlations involved in all 
‘groupings’ are calculated. 
Factor analyses study the construct validity of a model.  In convergent validity similar 
tests/items load together, whilst in divergent validity unrelated tests load separately.  Both 
are used to reduce errors in the model.  The factor loadings calculated is the correlation 
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of each of the items/variables within each factor or ‘cluster’.  The communalities 
represent the total proportion of variance that the analysis accounts for in each item. 
Oblimin rotation reduces the cross-loadings between the factors.  The Kayser-Myer-
Olkin (KMO) statistic and Bartlett’s test of Sphericity were also calculated to determine 
the factorability of the data.   
 
Eigen Values 
 
Determining the number of factors (i.e. clusters) to extract is traditionally based on Eigen 
values greater than 1 (Gaskin and Happell, 2014) and visual inspection of the scree plot. 
Eigen values fit into the overall picture as they decide the number of ‘factors’ to use in 
such an analysis.  They represent the amount of ‘information’ captured by each factor.   
A Scree Plot shows Eigen values on y-axis and the number of possible factors on the x-
axis.  It always displays a downward curve.  The point where the slope of the curve 
levels, the ‘elbow’, indicates the number of factors that should be generated by the 
analysis.   
 
2.3 Results 
 
2.3.1 Patients 
The clinico-pathologic variables and characteristics of patients are summarised in Table 
2.1.  Documented evidence was available for 152 women treated for gynaecological 
cancers (cervix; n=77, endometrial; n=75) at our oncology department who subsequently 
reported symptoms suggestive of radiation-induced bowel injury.  Almost half of patients 
with cervical cancer were treated for stage IIB disease (35/77; 45.5%) with moderately 
differentiated tumours; grade 2 (47/77, 62%).  Majority were squamous cell carcinomas – 
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57/77; 74%).  Thirty-two (41.6%) women with cervical cancer were smokers.  Twelve 
(16%) patients had a previous diagnosis of hypertension and 2 patients with type II 
diabetes, whilst 4 patients had been previously diagnosed with irritable bowel syndrome 
(IBS).   
Seventy-five (75) patients treated for primary endometrial tumours were found to have 
reported new gastrointestinal symptoms after completion of radiotherapy, presumed to be 
radiation-induced.  Over 50% of women had stage I/II disease: IC (26/75) and IIB 
(21/75) endometrial cancers; grade 2 tumours (46/75, 61%) and adenocarcinomas (61%).  
Only 5 of the women reported as smokers. Four (4) patients also had IBS and 5 had a 
previous history of diverticular disease (none in the cervical cancer group).  One of these 
women had had a previous bowel perforation related to diverticular disease (and one of 
only 5 women in the endometrial cancer group who subsequently required surgery for 
resection of radiation-induced small bowel stricture).  Median age was 52 years in the 
cervical cancer group and 63 years in the endometrial cancer group.  
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Primary Cancer Endometrial Cervical 
Total no of patients reviewed 322 219 
Patients presenting with significant symptoms of 
chronic treatment-related bowel injury (% of 
total) 
75 (23%) 77 (35%) 
 Frequency (%) 
Median age (range) 63 (40 -80) 52 (27-81) 
Stage 
I 32 11 
II 23 51 
III 18 10 
IV 0 4 
Recurrence 3 1 
Grade 
1 3 3 
2 40 40 
3 25 25 
Unknown 5 10 
Histology 
Squamous Cell 0 57 
Adenocarcinoma 61 17 
Adenosquamous 0 1 
Uterine Serous Papillary 3 0 
Mixed* 6 0 
Small Cell 0 1 
Clear Cell 1 1 
MMMT 7 0 
Smoking** 
Yes 5 32 
No 63 36 
Ex (>5yrs) 5 6 
Past Medical History 
Bowel - IBS  4 4 
Bowel - Diverticular disease 5 0 
Hypertension 2 12 
Diabetes (type II) 4 2 
Interval to Presentation (months) 
Median (range) 10 (1 - 61) 8 (1 – 106) 
Table 2.1. Patient Characteristics and Cancer Demographics. 
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Treatment – Cervical Cancer 
 
Chemotherapy:  Over 96% patients received 5 cycles of Cisplatin or more.  Sixteen 
(21%) patients also received neo-adjuvant chemotherapy with 6 weeks of weekly 
Carboplatin and Paclitaxel within a clinical trial (McCormack et al, 2013). Two patients 
received Carboplatin and Etoposide for small cell carcinomas.  Two patients did not 
receive any chemotherapy due to elderly age and significant co-morbidities. 
Radiotherapy:  75/77 patients received external beam radiotherapy (50Gy) and intra-
cavity brachytherapy as described in the methods.  One patient, (stage IVA) underwent 
pelvic radiotherapy following hysterectomy: external beam radiation to the pelvis (45Gy 
in 25 fractions over 5 weeks/10MV photons) and vault brachytherapy (13Gy in 2 
fractions/HDR/0.5cm from surface of applicator), whilst another, (stage IVB) had 
consolidative pelvic radiotherapy 40.0Gy in 5 fractions over 3 weeks after 6 cycles of 
Cisplatin and Topotecan for advanced disease. 
Surgery: Fifteen (15) women underwent laparoscopic para-aortic node dissection as part 
of staging.  There was only one major peri-operative complication; bowel injury due to a 
peri-operative complication with subsequent laparotomy with resection of perforated 
sigmoid and hartmann’s colostomy, this patient went on to suffer severe late toxicity 
requiring a right hemi-colectomy.  Only 3 women had surgery (total abdominal 
hysterectomy and bilateral salingo-oophorectomy - TAH/BSO) prior to (chemo)-
radiation; 2 of these were incidental diagnoses on pathology.  
 
Treatment – Endometrial Cancer 
Chemotherapy: 27/75 (36%) received 5/6 cycles of Carboplatin and Paclitaxel 
chemotherapy prior to radiation treatment. 
Radiotherapy: All patients received external beam radiotherapy, as described in methods. 
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Surgery: Forty-three (43) patients underwent a total abdominal hysterectomy and bilateral 
salpingo-oophorectomy (TAH/BSO) while 32 patients had a laparoscopic procedure 
(TLH/BSO).  One patient was an incidental pathological diagnosis on a vaginal 
hysterectomy specimen (done for prolapse).  Surgical staging also involved pelvic and/ or 
para-aortic lymphadenectomy in 14 patients.  Five (5) had an omentectomy as part of 
staging to exclude metastatic disease. 
 
Presenting Signs and Symptoms of Bowel Injury after Treatment 
 
We identified 14 common ‘new’ bowel symptoms/signs reported and recorded by 
oncologists at follow-up; patients usually had multiple symptoms (Table 2.2).  Patients 
who reported symptoms affecting quality of life were referred to gastroenterologists; 90% 
(69/77) cervical cancer patients, and 83% (62/75) of the endometrial cancer patients.  
Median time to presentation with bowel symptoms after completion of radiotherapy (or 
chemo-radiation) was 8 months (1 month – 9 years) in the cervical cancer group and 10 
months (1 month – 5 years) in women treated for endometrial cancer.   
Figure 1.1 shows the interval time to presentation (in oncology outpatient clinic or 
emergency department with acute bowel obstruction) from completion of radiotherapy.  
There was no statistical difference in interval from completion of radiotherapy to 
presentation between cancer types. 
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Patient Group   
Cervical Cancer (n=77) Endometrial Cancer (n=73) ALL 
(n=152) 
 n % of total n % of total n (%) 
Abdominal Pain 38 49.4 34 45.3 72 (47.4) 
Bloating 22 28.6 23 30.7 45 (29.6) 
Nausea 12 15.6 7 9.3 19 (12.5) 
Vomiting 12 15.6 5 6.7 17 (11.2) 
SABOa 19 24.7 9 12.0 28 (18.4) 
ABOb 6 7.8 2 2.7 8   (5.3) 
Diarrhoea 47 61.0 36 48.0 83 (54.6) 
BO<4/day 51 66.2 49 65.3 100 (65.8) 
BO>4/day 26 33.8 20 26.7 46 (30.3) 
Urgency 62 80.5 62 82.7 124 (81.6) 
Faecal Incontinence/leaking 26 33.8 16 21.3 42 (27.6) 
Flatulence 12 15.6 12 16.0 24 (15.8) 
PR bleed 28 26.4 28 37.3 56 (36.8) 
PR mucus 7 9.1 6 8.0 13 (8.6) 
SAQOL 32 41.6 28 37.3 60 (39.5) 
 
Table 2.2. Reported signs and symptoms of radiation-induced bowel injury. Patients presented with 
multiple symptoms, with defeacation urgency being the most common presenting symptom. BO= number 
of times ‘bowels opened’ (frequency); SAQOL = patients reporting symptoms ‘affecting their quality of 
life’; SABOa   - symptoms of intermittent sub-acute bowel obstruction; ABOb- symptoms of acute bowel 
obstruction presenting as an emergency. 
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Figure 2.1.  Interval to Presentation with symptoms of radiation-induced bowel injury. 
 
Defecation urgency was the most common reported (and documented) symptom in 
124/152 (81.6%) of women.  Diarrhoea was reported in 54.6% (83/152) of women; 
30.3% of women reported increased frequency with bowels frequency over 4 times a day 
(range 5 - 10).  Twenty-eight women (18.4% of entire cohort) presented with, or reported 
symptoms and signs of intermittent sub-acute bowel obstruction (SABO) at oncology 
follow-up.  Six (6) women in cervical cancer group, and 2 in endometrial cancer group 
presented to emergency department with symptoms and signs of acute bowel obstruction 
(ABO).  Forty-two (27.6%) women reported faecal incontinence or admitted to leaking 
on questioning at gastroenterology assessment, whilst 36.8 % (n=56) of women in the 
entire group reported rectal bleeding after radiotherapy.   
 
2.3.2 Factor Analysis – Three Factor Solution 
 
Principal components analysis (PCA) was first used to assess the suitability of data for 
factor analysis. Inspection of the correlation matrix revealed the presence of many 
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coefficients 0.300 and above. The Kaiser-Meyer-Olkin value was 0.659, exceeding the 
recommended value of 0.600 (Kaiser 1974), and Bartlett’s Test of Sphericity reached 
statistical significance (Bartlett 1954), supporting the factorability of the correlation 
matrix.  PCA (Armstrong and Soelberg, 1968) revealed the presence of three 
components, with Eigen values exceeding 1, explaining 24.1%, 15.1%, and 13.3%. An 
inspection of the scree plot revealed a clear break after the third component. Using 
Cattell’s (1966) scree test, we split the ‘symptom clusters’ to three components. This was 
further supported by the results of parallel analysis, which showed only three 
components, with Eigen values exceeding the corresponding criterion values for a 
randomly generated data matrix of the same size (14 variables × 152 respondents). The 
three-component solution explained a total of 52.5% of the variance. To aid in the 
interpretation of these, three components Oblimin Rotation was performed. Factor 
loadings are shown in Table 2.3.  The 3-factor solution demonstrated minimal cross 
loadings.  All 14 items (symptoms and signs) were retained and all except for ‘PR 
mucus” (n=13 women recorded this variable), had loadings >0.3. 
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Pattern Matrix Structure Matrix Communalities Symptoms/Signs 
Component Component  
 1 2 3 1 2 3  
Nausea 0.889   0.893   0.799 
Vomitting 0.869   0.874   0.767 
SABO 0.817   0.825   0.701 
ABO 0.547   0.548   0.352 
BO>4d  0.915   0.895  0.794 
BO<4d  -
0.847 
0.333  -
0.808 
 0.849 
Diarrhoea  0.545   0.562  0.34 
FI  0.507   0.543 0.308 0.401 
Bloating 0.365  0.695 0.354  0.689 0.608 
Flat   0.589   0.591 0.373 
Abdo pain 0.517  0.546 0.508  0.537 0.555 
Urgency  0.367 0.46 -
0.341 
0.427 0.486 0.479 
PRB -
0.303 
 -0.339   -0.338 0.205 
PR mucus   0.339   0.336 0.124 
Table 2.3. Factor Analysis; Component loadings for presenting symptoms of bowel injury.   
ABO: Acute bowel obstruction; FI: Faecal Incontinence; PRB: Per-rectal bleeding; PR mucus: per-rectal 
mucus; SABO: Sub-acute bowel obstruction.  Oblimin rotation generates both a pattern matrix and a 
structure matrix.  The structure matrix is simply the factor loading matrix as in orthogonal rotation, 
representing the variance in a measured variable explained by a factor on both a unique and common 
contributions basis.  The pattern matrix, in contrast, contains coefficients that represent unique 
contributions of each variable/item within the structure (similar to correlation coefficient).  For Oblimin 
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rotation, the researcher looks at both the structure and pattern coefficients when attributing an item to a 
factor.  A factor loading of over 0.3 in absolute value is considered to indicate which item/variable belongs 
to a factor; in any event factor loadings must be interpreted in light of theory, not on arbitrary cut-off levels.  
Loadings which indicate which variables where assigned to each component are highlighted in bold.  The 
variance – the sum of the squared factor loadings for each item/variable (row).  The communality measures 
the percent of variance in a given item/variable explained by all the factors jointly and is used as the 
reliability of the indicator. 
 
Component 1 suggest ‘Obstructive’ Symptoms, because it maintains high loading in 
symptoms suggestive of (radiotherapy-induced) bowel stricture/obstruction (nausea, 
abdominal pain, vomiting, signs and symptoms of intermittent sub-acute bowel 
obstruction (SABO), and acute bowel obstruction (ABO)). Component 2 – ‘Enteropathy’ 
Symptoms (diarrhoea, loose stools and increased bowel frequency, and faecal 
incontinence) suggests symptoms of small bowel dysfunction, while component 3 is more 
pathgnomonic, (though not definitive) of ‘Colitis-Proctitis/Proctopathy’ Symptoms 
(bloating, flatulence, abdominal pain, faecal urgency, per-rectal bleeding (PRB), and per-
rectal mucus (PR mucus)).  Factor scores were computed and used in subsequent 
analyses. The purpose of this type of analysis and ‘clustering’ presenting symptoms was 
to try to identify, within our cohort of women, associations and possible predictors of, 
disease course and severity, site of bowel injury and underlying patho-physiological 
processes. 
 
 
2.3.3 Predictors of Severity and Chronicity of Bowel Problems 
 
Patients were followed up until symptoms resolved or until their last 
oncology/gastroenterology follow-up prior to the end of data collection in December 
2012.  Information on status of bowel symptoms (and disease/general health) was 
obtained from documentation at these consultations. Table 2.4 shows a summary of 
documented status at last follow up.    
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Cervical Endometrial ALL  
n n n % 
Alive and well, Bowel 
symptoms resolved 
21 21 42 27.6 
Alive with Disease 
Progression 
3 2 5 3.3 
Alive, ongoing Bowel 
symptoms 
  
 Mild, managed with 
Imodium/Diet 
25 38 63 41.4 
 Moderate, awaiting 
further 
investigations 
4 1 5 3.3 
 Severe, symptoms 
affecting QoL 
19 2 21 13.8 
Deceased   16 10.6 
 Dead, recurrent 
disease 
3 9 12  
 Dead, secondary to 
enteritis 
complications 
1 0 1  
 Dead, other causes 1 2 3  
Table 2.4. Patient Status at last follow-up 
 
At the time of analysis, 42/152 (27.6%) of women were alive, disease-free with 
resolution of bowel symptoms.  Five patients (3.3%) were alive with disease progression, 
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without clear documentation of follow-up of late bowel toxicity symptoms. 63/152 
(41.1%) of all patients were disease-free with ongoing mild symptoms managed by 
oncologists and/or discharged from gastroenterology follow-up.  Majority of these 
patients had mild urgency, and frequency with loose stools, with bowel motions on 
average twice a day.  Most patients reported stable symptoms not affecting quality of life 
and some required anti-motility drugs (Imodium) intermittently with dietary manipulation 
to control symptoms.  Five women (3.3%) had ongoing moderate symptoms, with 
significant diarrhoea, frequency and urgency and were undergoing further investigations.   
Twenty-one patients (21) – 13.8% of patients still had ongoing severe symptoms 
affecting their quality of life, some even after surgical intervention.  Only 2 of these 
patients had been treated for endometrial cancer whilst 19 had received concurrent 
chemo-radiation for a cervical primary cancer.  Median follow-up time (from 
presentation with symptoms of radiation-induced bowel injury) was 89 months for the 
patients who had resolution of their symptoms at last follow-up; 37.75 months for 
patients with mild manageable symptoms; 50.5 months for the 5 patients with ongoing 
moderate symptoms (mostly urgency and diarrhoea); and 34.5 months for patients with 
ongoing severe symptoms of radiation-induced bowel injury at last follow-up.  There was 
no statistical significant difference when comparing follow-up time and status (resolution 
or degree of severity) at last follow-up.   
Figure 2.2 shows the follow-up time from presentation with bowel symptoms.  We found 
a significant difference between cancer types (log rank χ2 = 8.065, p=0.005) suggesting 
women with endometrial cancer were more likely to have less severe, but more chronic 
symptoms. 
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Figure 2.2. Follow-up of patients with bowel symptoms. 
 
In univariable ordinal logistic regression analysis (Table 2.5), significant predictors of 
increasing severity of symptoms (from presentation to bowel status at last follow-up) 
were age, cancer type (cervical cancer; concurrent chemo-radiation), bowel injury 
requiring surgical intervention, and symptom cluster/factor 3 i.e. patients presenting with 
predominantly bloating, flatulence, abdominal pain, faecal urgency, per-rectal bleeding 
(PRB), and per-rectal mucus (PR mucus).  
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Variable OR (95 % CI) p value 
Age 0.96 (0.94-0.98) 0.001 
Cancer Type  
[Endometrial vs Cervical] 
0.49 (0.26-0.93) 0.028 
History of Diabetes/Hypertension 1.57 (0.64-3.96) 0.312 
History of previous IBS/Diverticular Disease 1.52 (0.53-4.31) 0.436 
Smoking History 0.32 (0.17-0.77) 0.008 
Stage of Disease (Cervix) 0.76 (0.42-1.36) 0.356 
Stage of Disease (Endo) 0.78 (0.45-1.36) 0.388 
NACT pre-Chemoradiation (Cervix) 1.58 (0.41-2.50) 0.976 
Extended Field RT (Pelvic Side Wall Boost/PA 
Strip) (Cervix) 
0.37 (0.14-0.96) 0.041 
Laparoscopic vs Open Hysterectomy (Endo) 0.59 (0.21-1.65) 0.311 
Chemo vs no Chemo (Endo) 0.95 (0.34-2.63) 0.921 
P/PA Node Dissection (Endo) 2.13 (0.58-7.75) 0.255 
P/PA Node Dissection (Cervix) 0.67 (0.24-1.85) 0.442 
Surgical Treatment (No vs Yes) 0.22 (0.08-0.55) 0.001 
‘Symptom Cluster’ at presentation  
 Factor 1 1.18 (0.86-1.63) 0.302 
 Factor 2 1.10 (0.80-1.51) 0.548 
 Factor 3 1.36 (1.00-1.86) 0.053 
Table 2.5.  Univariate (unadjusted) ordinal regression analysis showing predictors of RIBI severity in 
our cohort. NACT – Neo-adjuvant chemotherapy, P/PA – Pelvic/Para-Aortic Lymph Node Dissection. 
 
In multivariate ordinal regression analysis (Table 2.6), younger age (OR: 0.97, 95% CI: 
0.94-1.0, p=0.05), smoking history (OR: 0.42, 95% CI: 0.18-0.98, p=0.044), surgical 
intervention (OR: 0.23, 95% CI: 0.08-0.62, p=0.005) and initial presentation with 
  68 
‘symptom cluster’/factor 3 (OR: 1.51, 95% CI: 1.08-2.11, p=0.017) were independent 
predictors of severity of bowel symptoms, after correcting for cancer type. 
 
 
 95% Confidence Interval   
OR Lower  Upper p value 
Age 0.97 0.94 1.00 0.050 
Smoking 0.42 0.18 0.98 0.044 
‘Symptom Cluster’/Factor 3 1.51 1.08 2.11 0.017 
Cancer type  
(Cervical vs Endometrial) 
1.21 0.55 2.63 0.637 
SURGERY 
 (No vs Yes) 
0.23 0.09 0.65 0.005 
Table 2.6.  Multivariate (adjusted) ordinal regression analysis showing predictors of severe RIBI. OR – 
Odds Ratio. 
 
2.3.4 Investigations and non-surgical Therapeutic Interventions for Chronic 
Radiation Enteritis/Proctitis in our cohort 
 
Initial assessment of patients presenting with bowel symptoms after pelvic radiation was 
by the oncologists.  Patients who typically had mild stable symptoms of radiation enteritis 
(diarrhoea alternating with loose stool, faecal urgency and increase number of motions 
per day (BO<4) were usually monitored with dietary manipulation advice, and anti-
diarrhoeal agents Imodium and/or Codeine Phosphate prescribed.  Patients were offered 
referral to gastroenterologists if they had symptoms that were affecting their quality of 
life or if symptoms worsened.  Patients who presented with rectal bleeding, urgency with 
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faecal incontinence or any combination of symptoms which the patient deemed ‘affecting 
quality of life’ were immediately referred to a gastroenterologist. 
Routine bloods tests to exclude anaemia and vitamin B12 deficiency were done for all 
patients presenting to gastroenterology.  The most common investigation was a 
colonoscopy (and biopsy of any abnormal areas); 73/152 (48%) women underwent a 
colonoscopy whilst 22 women (14.5%) had a flexible sigmoidoscopy.  Forty (40/73) of 
these patients had clear endoscopic evidence of distal colitis/proctosigmoiditis, and or 
telangiectasia/angioma attributed to radiation changes to bowel mucosa, and documented 
on endoscopy findings. 
Radiological imaging remains part of the work-up in these women; either an MRI to 
exclude disease recurrence as a cause for symptoms or a CT scan, usually if bowel 
obstruction was suspected.  Radiological imaging was useful in supporting diagnoses by 
demonstrating dilated and /or thickened small or large bowel loops and radiation –related 
strictures, as well as bladder wall and rectal thickening and oedema. Endo-anal 
ultrasound scans and ano-rectal physiology testing were performed to exclude sphincter 
defects in women who presented with incontinence/leaking.  From 2010, a small 
proportion of patients had a SeCHAT scan to exclude bile acid malabsorption as a 
potential cause for ongoing diarrhoea, whilst 14 women required a hydrogen breath test 
to exclude small bowel bacterial overgrowth.   
We analysed investigations relating to the 3 presenting symptom clusters/factors derived 
from factor analysis.  There was a significant difference p<0.05 in the proportion of 
patients presenting with symptom cluster/factor 1 (obstructive) who went on to have an 
MRI/CT compared to those who scored higher for factors 2 and 3.  Patients who had an 
endo-anal ultrasound and ano-rectal physiology as part of work-up for presenting 
symptoms of bowel toxicity were more likely to have scored for factor 2 compared with 
factor 1/3; (p<0.001).  There was no significant difference between the 3 symptom 
clusters/factors for patients who underwent flexible sigmoidoscopy or colonoscopy. 
The use of anti-motility/anti-diarrhoeal drugs was the most common initial intervention 
in most patients – 62.5% o all patients needed Imodium either regularly or as required for 
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a period.  Only 10 patients had documented evidence of requiring Codeine phosphate as 
well as Imodium to control diarrhoea/frequency of motions.  The trial of interventions 
varied over time and clinician, and was individualised based on symptoms and patients 
investigation results.  Before 2005, some patients received trials of steroid treatments; 
predsol enema, predfoam and hydrocortisone suppositories.   
Other treatments used of the treatment period in this study included: mebeverine (n=3), 
activated charcoal (n=2), asacol suppositories (1), Colesevalam and Cholestyramine 
when bile acid malabsorption was suspected (n=6), trial of antibiotics when small bowel 
bacterial overgrowth was diagnosed (n=5), biofeedback to manage faecal incontinence 
(n=5), and hyperbaric oxygen therapy under a clinical trial (HOTII Trial) (n=3).  Thirty-
two (32) patients in total (16 each in both cancer groups) required Argon Beam 
Coagulation (APC) therapy and colonoscopy to manage rectal bleeding; 8 of these 
patients required multiple procedures to control bleeding.  Four (4) women were treated 
for transfusion- dependent rectal bleeding, with repeat blood transfusions and argon beam 
coagulation. 
 
2.3.5 Surgical Management of Radiation Induced Bowel Injury 
 
Table 2.7 illustrates the type of surgical treatment received by the women in our cohort 
who suffered severe late toxicity.  Twenty (20/152; 13.2%) required surgical intervention 
to manage severe late radiation-induced toxicity.  Four (4) women required  (ongoing) 
home parenteral nutrition (TPN) after surgery to maintain nutrition, whilst 7 women still 
had ongoing symptoms affecting their quality of life, even after surgical resection/bypass.  
One patient was treated with repeated sigmoid dilatation (2006) for symptoms of 
intermittent sub-acute bowel obstruction with subsequent resolution of symptoms. 
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Cervical 
Cancer 
Endometrial 
Cancer 
 
Surgical Procedure 
n n 
Small Bowel Resection + Adhesiolysis 7 2 
 Primary Anastamosis 2 2 
 Ileostomy 1 0 
 Reversal of Ileostomy 4 0 
Ileocaecal Resection 2 1 
Right Hemicolectomy  4 2 
 Primary Anastamosis 2 1 
 Colostomy Formation 2 1 
End Colostomy Formation (Bypass) 3 0 
Adhesiolysis only* 1 0 
Sigmoid Stricture Dilatation 1 0 
Table 2.7. Surgical Management of Radiation-induced Bowel Injury *Previous small bowel resection 
and re-obstruction 
 
On univariate analysis, only cancer type (cervix) was associated with an increased risk of 
requiring surgery.  There was no significant association found with tumour stage, 
smoking, past history of irritable bowel syndrome (IBS), divertucular disease, past 
history of diabetes or hypertension, the use neo-adjuvant chemotherapy, extended field 
radiation with pelvic side wall +/- a para-aortic boost.  
In endometrial cancer patients, type of primary surgery received; open vs laparoscopic, or 
whether patients received adjuvant chemotherapy prior to radiation or not were also not 
found to be significant predictors of severe late toxicity in our cohort.  Although smoking 
was not found to be a statistically significant predictor of severe late toxicity requiring 
surgery, of 6 women reported heavy smoking on diagnosis >20/day; 5/6 of these women 
required surgical resection of radiation- damaged bowel whilst the one remaining patient 
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had ongoing severe symptoms of enteritis and required surgery to repair a radiation-
induced femoral occlusion.   
 
2.3.6 Other non-bowel radiation-induced toxicity in cohort (Table 2.9) 
 
Cervical Cancer Endometrial Cancer  
n  n  
Radiation Cystitis 9*  3  
Colo-Vaginal Fistula 1  0  
Recto-Vaginal Fistula 2  0  
Vesico-Vaginal Fistula 2  0  
Radiation-induced Ureteric Stenosis 2  0  
Radiation-induced Femoral Occlusion 1  0  
Avascular Necrosis Femoral Head 1  1  
Radiation-induced Osteonecrosis 1  0  
Radiation-induced Vaginal Necrosis 1  0  
Vaginal Stenosis 1  0  
Total 21  4  
Table 2.9. Non-bowel related toxicity in our cohort 
 
2.4 Conclusions and Discussion 
 
The aim of this study was to describe and analyse the nature of presenting symptoms of 
bowel injury thought to be directly related to radiation treatment in our cohort of women 
and to determine associations with severity and chronicity of symptoms. Data was 
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clinician-reported and collected retrospectively from patient notes.  It is important to 
acknowledge not only that the reported number of cases and the proportion of women 
who seek help are only a fraction of true prevalence (Gami et al, 2003; Andreyev et al, 
2005), but also that this still, underestimates the actual frequency of pathologic changes 
and ‘bowel injury’, given some women may be asymptomatic and symptoms do not 
always correlate with disease activity directly related to radiation changes.   
Studies (Khalid et al, 2006; Olopade et al, 2005) using patient-reported symptom tools; 
validated/modified questionnaires have shown this method of collecting toxicity data to 
be more sensitive in characterising symptoms than clinician-based reporting without 
toxicity scores/questionnaires.  Yet others (West and Davidson, 2009) acknowledge, that 
outside of the clinical trial setting these questionnaires/scoring tools (especially the 
CTCAEv3), are impractical in the clinical setting.  Barraclough et al, (2012), in a 
prospective analysis of patient-reported late toxicity in gynaecological cancers (73% 
cervix), had 126/226 (56%) patients withdraw from their study, with 60 patients 
discontinuing completion of questionnaires at various points throughout the study.   
We appreciate that it is always difficult to make concrete conclusions from 
retrospectively collected data, yet this summary of our centre’s experience gives some 
insight into current practice and highlights the significant proportion of women who 
suffer symptoms affecting their quality of life persisting with varying severity and 
chronicity.  What is clear is that patients present with ‘clusters’ of symptoms and this 
data, and if collected prospectively and systematically at oncology follow-up, over time 
points, may well provide further evidence of the clinical course and predictors of severity 
of bowel symptoms. 
 We demonstrated the nature of symptoms reported and recorded in our cohort and found 
faecal urgency to be the most common reported (and documented) symptom, in keeping 
with the literature (Gami et al, 2003; Denham et al; 1999, Andreyev et al, 2010; Putta and 
Andreyev, 2005).  Multivariate analysis in our study showed that younger age, treatment 
for cervical cancer and presenting with the multiple symptom ‘cluster’ that included; 
bloating, flatulence, abdominal pain, faecal urgency, rectal bleeding and rectal mucus 
were associated with more severe ongoing symptoms at follow-up (median 34.5 months).   
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Capp et al (2009) have best defined symptom clusters for rectal toxicity in men treated 
for prostate cancer with data obtained through modified self-assessed questionnaires, and 
follow-up at 1, 2, and 3 years after radiotherapy.  This study highlights the flaws within 
the CTC (common toxicity criteria) grading scale, especially in identifying rectal injury.  
The clusters identified (made up of only 8 individual components/symptoms, at different 
time points, and as we have done, showing faecal urgency to be at the ‘core’ of all 
symptom clusters.  What remains unclear is how the various symptom clusters identified 
related to underlying radiation-induced patho-physiological processes. 
Barraclough et al (2012) in their study, use factor analysis to identify the most important 
questions likely to account for inter-patient variability in subjective toxicity using a 
disease site-specific questionnaire developed from the LENT-SOMA scales which was 
used to score patient data.  Both studies highlight the need for a better guide for clinicians 
in assessing patients at initial presentation (and prior to radiotherapy).  It is our belief that 
more data available to test the reproducibility of the symptom cluster approach and the 
degree of severity of each symptom may well help to better identify the type and site of 
the underlying radiation-induced bowel injury pathological processes and thus guide 
management. 
I demonstrated a prevalence of around 13% of women in our cohort with severe late 
bowel injury requiring surgical intervention, highlighting the associated morbidity and 
the need for further research to try to identify these patients at risk and offer early 
interventions.   I recognise a number of limitations in our study.  All data collected was 
performed entirely by me to ensure consistency of record reviews.  All relevant 
correspondence, letters, investigations and results related to each patient were reviewed. 
Patients with incomplete or no follow-up documentation were excluded (n=22).   
Collecting clinician-reported data retrospectively relies on documentation of different 
clinicians with varying views of symptoms, experience dealing with patients’ bowel 
toxicity, and assessment which all may be influenced by the patients’ clinical situation.  It 
is impossible to correct for under-reporting and lack of documentation especially for 
those symptoms that may have been deemed ‘less serious’ by clinicians.  There is also the 
question of whether bowel toxicity is more likely to be reported and recorded in 
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‘healthier’ survivors.  Patients with disease recurrence and progression are less likely to 
report symptoms which may be related to radiation-induced bowel injury as they are no 
longer focused on symptoms of toxicity, but rather worrying about symptoms related to 
their cancer progression. 
As this was a retrospective study, there was no data identifying women’s bowel function 
prior to radiotherapy, however a thorough past medical history, including any reported 
abnormal bowel symptoms were routinely obtained from each patient at our centre prior 
to treatment and recorded on a ‘front sheet’.  All symptoms reported at initial 
presentation, referral to gastroenterology and on first consultation with gastroenterology 
were recorded.  Analysis of clinical features did not take into account the grading/severity 
of each symptom – for example the degree of urgency in combination with other 
symptoms in a ‘cluster’ might indeed represent different underlying patho-physiological 
processes for two different patients.   
Prospective studies are urgently needed to better understand the natural history of 
radiation-induced bowel injury to guide the development of objective biomarkers of 
toxicity, and a standard in assessing degree of toxicity.  This study also highlights the 
important role of all clinicians; oncologists, gynaecologists and referral to 
gastroenterologists in the follow-up and management of treatment related morbidity.  
 
 
 
  76 
 
Chapter Three  A Clinical Score to Predict Severity and Progression of 
Radiation-induced Bowel Injury (RIBI)? A potential means to 
improve reporting of symptoms after Pelvic Radiotherapy in 
Cervical and Endometrial Cancers. 
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Chapter Three A Clinical Score to Predict Severity and Progression of RIBI? 
 
3.1 Measurement Tools in Clinical Oncology: Background and Introduction 
 
The identification of patients at risk of significant gastrointestinal toxicity after radiation 
treatment for gynaecological cancers in clinical practice remains inadequate. The overall 
morbidity attributed to radiation-induced bowel injury (RIBI) remains unknown as 
studies measuring delayed toxicity after treatment for cervical and endometrial cancers 
are mostly incomparable.  A universal, acceptable scoring tool that is practical in the 
clinical setting is essential.  In the context of increasing survivors, the pressures of 
follow-up consultation times, the collection of reliable toxicity data must be improved.  
Historically, the Radiation Therapy Oncology Group and the European Organization for 
Research and Treatment of Cancer (RTOG/EORTC) scale (Cox et al, 1995) was used to 
measure toxicity in clinical trials.  The Late Effects on Normal Tissues – Subjective, 
Objective, Management and Analytic (LENT-SOMA) scale, the first to include both 
clinician (objective) and patient (subjective) scoring of toxicity is known to be difficult to 
use and requires a time-consuming structured interview with patients; Routledge et al 
(2003) report 89% compliance).    
The Inflammatory Bowel Disease Questionnaire  - Bowel Subset (IBDQ-B) and Vaizey 
Incontinence questionnaires  (which incorporates important questions missing from the 
IBDQ_B; urgency, incontinence), when compared to LENT-SOMA has been shown to 
be more reliable in collecting bowel toxicity data (Olopade et al, 2005).  The authors 
suggest this to be a more sensitive indicator of late effects than the LENTSOMA (Khalid 
et al, 2006).  Others report the IBDQ-B in the trial setting as a reliable measure 
(Davidson et al, 2003; Wedlake et al, 2010) 
The Franco-Italian Glossary first described by Chassagne et al (1993) and validated for 
use in cervical cancer (Sinistrero et al, 1993), has shown correlation with scores obtained 
using the LENT SOMA system (Davidson et al, 2003).  The National Cancer Institute’s 
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Common Toxicity Criteria (CTCAE version 3.0) published in 2003 (Trotti et al, 2003), 
and revised in 2010 (CTCAEv4.03) remains the current standard for used for monitoring 
(acute) toxicity in clinical trials.  Other institution based tools such as the Royal Marsden 
Hospital scale has been shown to be useful in clinical trials in prostate cancer (Dearnaley 
et al, 2007). 
West and Davidson (2009) reviewed the use of measurement tools for reporting 
gastrointestinal toxicity and highlighted the need for a scoring system both patient- and 
clinician-reported data that can be implemented in clinical practice.  Most oncologists 
refer less than 50% of patients they see, with most referring less than 10%.  Henson et al, 
(2012) sent a questionnaire to 314 clinical oncologists in the UK who treat pelvic 
malignancies.  With a 61% response rate, the authors found most oncologists (76%) 
screen for bowel dysfunction after pelvic radiotherapy through history taking rather than 
using formal tools, and concluded that symptoms were poorly recognized, with 
inadequate service provision for diagnosing and managing patients with radiation –
induced bowel injury and  ‘pelvic radiation disease’.   
It is clear that current available tools are not being utilized in the clinical setting.  A 
number of women with ‘mild –moderate’ disease will go on to have more significant 
delayed symptoms when they well might have benefitted from earlier referral.  Bentzen et 
al (2007) document the challenges in recording, analyzing and reporting toxicity data and 
highlight that late effects may persist or even progress in severity affecting long-term 
quality of life and potentially compromise survival benefit.   
In this chapter, I will attempt to create a scoring tool using revisited data from chapter 1.  
It remains to be shown in prospective studies whether the questionnaire approach is 
relevant in context of diagnostic pathways and helping to identify the specific patho-
physiology of the bowel injury.  I propose collecting and analyzing data based on the 
‘cluster’ of symptoms patients present with. 
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3.2 Materials and Methods  
 
Study Cohort 
I revisited data obtained from my retrospective study as described in chapter 2.  Clinical 
features at presentation with radiation-induced bowel injury (RIBI) after treatment for 
cervical and endometrial cancer was available from our retrospective cohort (Kuku et al, 
2013).  This included the 152 women diagnosed with mild to severe RIBI between 
February 2003 and June 2010 within the North London Cancer Network (UCLH).  
Clinician-reported toxicity data was obtained from records was utilized for this analysis.  
All patients were identified as presenting with new bowel symptoms 3 months after 
completion of radiotherapy.   
Cervical cancer patients received concurrent weekly Cisplatin along with primary 
radiotherapy (50.4Gy in 28 fractions over 5.5 weeks using 8-15mV photons) and 
intracavity brachytherapy using an ovid system (15Gy in 2 fractions/HDR/point A).  
When used, extended fields; 45Gy in 25 fractions over 5 weeks and a further 5.04Gy in 3 
fractions delivered to the pelvic side wall (n=27).  Endometrial Cancer patients received 
45Gy in 25 fractions with an additional 12Gy in 2 fractions to the vaginal vault. When 
adjuvant treatment was given, patients received 6 cycles of Carboplatin AUC 5 and 
Paclitaxel 175mgmin-2 every 3 weeks. 
 
Exploratory and Confirmatory Factor Analysis 
The cohort was randomly divided into two subsamples to create a ‘Test set’ and 
‘Validation set’.  We performed an exploratory factor analysis (EFA) of the 14 items 
(symptoms/signs) on the first subsample (test set) to prove the validity of the 3-
(factor/cluster) structure.  The EFA was then applied to the second subsample (validation 
set) to determine whether the proposed clustering structure from the first subsample was 
maintained.  Patient demographics for the two subsets are shown in Table 3.1; there were 
no statistical differences between the two groups. 
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Variable EFA  
‘Test Set’ (n=75) 
CFA  
‘Validation’ Set  
(n= 77) 
 N % N % 
Cancer Type     
Cervical 44 58.7 33 42.9 
Endometrial 31 41.3 44 57.1 
Smoker     
No 53 70.7 51 66.2 
Yes 17 22.7 20 26.0 
Ex-Smoker 5 6.6 6 7.8 
Stage     
Stage I 18 24.0 25 32.5 
Stage II 41 54.7 33 42.9 
Stage III 11 14.7 17 22.1 
Stage IV 5 6.6 2 2.6 
Histology     
SCC 32 42.7 25 32.5 
Adenocarcinoma 35 46.7 42 54.5 
Other 8 10.6 10 13.0 
Previous Bowel History*     
No 67 89.3 69 89.6 
Yes 8 10.7 8 10.4 
Diabetes or Hypertension     
No 63 84.0 64 83.1 
Yes 12 16.0 13 16.9 
Chemotherapy     
No 50 66.7 46 59.7 
Yes 25 33.3 31 40.3 
Table 3.1. Patients Demographics.  There were no statistical differences between the groups for any of 
the variables (Chi-squared test). 
Following confirmation of the stability of the clustering using confirmatory factor 
analysis (CFA), I used factor loadings from each item (symptom/sign) to create score 
points to represent the weighting of each item within a factor/cluster.  To measure and 
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compare the predictive accuracy of the model in the test and validation sets, we generated 
‘receiver operating characteristics’ (ROC) curves and compared their C-statistics (AUC).  
A template for a final proposed RIBI-Clinical Score was generated using factor loading 
score points. SPSS version 21 - IBM was used for all statistical analyses. 
 
3.3 Results 
 
3.3.1 Statistical Analysis 
 
Validation  
The EFA suggested a 3 factor solution – 1st factor – 4 items, 2nd factor – 4 items, 3rd 
factor – 5 items, although results suggested that ‘PR Mucus’ should be dropped 
(Communality 0.06) and loading values lowest (0.06 – 0.179).  This was not surprising, 
given the small number of patients in this cohort who were documented to have presented 
with this symptom (8.6% of all patients only). 
 
Subsample 1: Exploratory factor analysis 
This first subset included 75 women (mean age = 57.3, range 22-85]. Other demographic 
information is shown in Table 3.1 above.  The 14 items of the RIBI score were subjected 
to principal components analysis (PCA) and revealed the presence of three components, 
with Eigen values exceeding 1, explaining 23.9%, 18.1%, and 14.1% of the variance 
respectively. An inspection of the scree plot revealed a clear break after the third 
component. Using Cattell’s (1966) scree test, it was decided to retain three components 
for further investigation.  The three-component solution explained a total of 56.1% of the 
variance. Factor loadings for all three components are shown in Table 3.2. To aid in the 
interpretation of the three components, Oblimin Rotation was performed.   
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 Pattern Matrix Structure Matrix Communalities 
 Component Component  
 1 2 3 1 2 3  
NAUSEA 0.932 -0.056 0.084 0.927 -0.004 0.057 0.868 
VOMITTING 0.932 -0.056 0.084 0.927 -0.004 0.057 0.868 
SABO 0.755 0.021 0.249 0.75 0.07 0.23 0.625 
ABO 0.64 0.02 -0.056 0.642 0.051 -0.072 0.416 
BO>4D 0.016 0.904 -0.11 0.066 0.9 -0.075 0.78 
BO<4D -0.233 -0.812 0.242 -0.281 -0.815 0.217 0.823 
INCONTINENCE -0.225 0.649 0.021 -0.192 0.638 0.053 0.458 
DIARRHOEA 0.029 0.596 0.203 0.054 0.605 0.225 0.408 
BLOATING 0.187 -0.014 0.749 0.166 0.025 0.743 0.588 
ABDOPAIN 0.361 -0.019 0.683 0.341 0.026 0.672 0.582 
PRB -0.179 -0.192 -0.581 -0.173 -0.223 -0.584 0.413 
URGENCY -0.41 0.436 0.507 -0.401 0.435 0.535 0.626 
FLATULENCE -0.263 -0.168 0.487 -0.284 -0.162 0.487 0.339 
PRMUCUS -0.153 -0.06 0.179 -0.161 -0.061 0.18 0.06 
Table 3.2. EFA from 14 items. Factor analysis used to split the items (signs/symptoms) into 3 
‘clusters’/components comprising groups of symptoms patients presented with. 
 
As described in chapter 1, the factor analysis again divided the items into 3 clusters.   
Component/Factor 1 suggested ‘obstructive’ symptoms, because it maintains high 
loading in symptoms suggestive of (radiotherapy-induced) bowel stricture/obstruction 
(nausea, vomiting, sub-acute bowel obstruction and acute bowel obstruction). 
Component 2 – diarrhoea and increased bowel frequency < 4 x daily or >4 x daily and 
faecal incontinence) could suggest symptoms of small bowel dysfunction, whereas 
component 3 is more pathgnomonic, (though not definitive) of ‘colitis-
proctitis/proctopathy’ symptoms (bloating, flatulence, abdominal pain, faecal urgency, 
per-rectal bleeding, and per-rectal mucus).  
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Subsample 2: Confirmatory Factor Analysis 
 
The second subset consisted of 77 women (mean age = 56.8, range 28-80) and was used 
to re-test the factor structure of the items. Confirmatory factor analysis was used in order 
to test whether the proposed structure of the RIBI symptom clustering remained stable in 
another sample.  Common model fit-measures were used: the ratio of the model’s chi-
square with the degrees of freedom (χ2/df), Comparative Fit Index (CFI), (Bentler, 1990), 
and the Root Mean Square Error of Approximation (RMSEA) (Steiger, 1990). The path 
diagram for the CFA model, illustrating the individual factor loadings for each item to 
those in the EFA is shown in Figure 3.1.   
 
 
 
Fig 3.1. CFA. Factor Loadings comparable to EFA. The factor loadings (next to the boxes with 
symptom labels are compared to factor loadings from table 3.2) are a measure of the match of the clustering 
analysis to the test set. 
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Assessing the fit indices of the CFA these were acceptable with regards to comparative fit 
indices, the parsimony adjusted measure RMSEA and the standardized χ2 (χ2/df) (Table 
3.3).  I observed that in most cases the factors loadings of the CFA (sign and magnitude) 
were similar with those with from the EFA. That indicates satisfactory stability of the 
clustering of symptoms. 
 
Model Fit indices Recommended Value Results 
χ2/df ≤ 3.0 1.190  
CFI ≥ 0.9 0.966 
RMSEA (90% CI) ≤ 0.08 0.050  
Table 3.3. Fit indices of the CFA for Cognitive Affective Factors 
(χ2/df); the ratio of the model’s chi-square with the degrees of freedom, (CFI); Comparative Fit Index, 
(RMSEA); Root Mean Square Error of Approximation 
 
3.3.2 Developing a scoring system taking into account factor loadings/symptom 
clusters 
 
The validity of the 3-factor model confirmed, I the utilized factor loadings from the total 
sample size of 152 patients as described in chapter 1.  Factor loadings for each item 
within a cluster were multiplied by 2 to obtain a whole number nearest to 1, with the 
closest integer used as a simple score ‘point’ (-1 to 2) (Table 3.4).  
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Symptom Factor loadings Points 
 F1 F2 F3  
Nausea 0.889     2 
Vomiting 0.869     2 
SABO 0.817     2 
ABO 0.547     1 
BO>4d   0.915   2 
BO<4d   −0.847  -2 
Diarrhoea   0.545   1 
FI   0.507   1 
Bloating   0.695 1 
Flatulence   0.589 1 
Abdo pain   0.546 1 
Urgency   0.460 1 
PRB   −0.339 -1 
PR mucus     0.339 1 
Table 3.4. Score Points using Factor Loadings 
 
Four scores were generated for each patient: a score for each factor/cluster, and a total 
score. This takes into account the weighting of all 14 signs/symptoms each patient 
presented with, multiplied by the ‘loading’ or ‘weighting’ within each factor /cluster.   
ROC analysis was performed to compare the diagnostic accuracy of each factor/cluster 
score between resolved/mild disease and moderate to severe disease. Figure 3.2 
demonstrates the ROC curves generated to test and compare the predictive accuracy of 
the scoring model for the entire data set.   
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Figure 3.2. ROC analysis comparing the diagnostic accuracy of each symptom cluster/factor score; 
resolved or mild ongoing bowel symptoms cf ongoing moderate to severe disease. Results are shown in 
Table 3.5 below. 
 
The calculated AUC values for the scores in the 3 factors (clusters) and the total score are 
shown in Table 3.5 with confidence intervals.   
The total score and score for F2 (Factor/Cluster 2) had the highest diagnostic accuracy; 
AUC 0.697 (95% CI 0.593 to 0.802) and AUC 0.636 (95% CI 0.535 to 0.738) 
respectively. All were moderately satisfactory (AUC >0.600).  The various cut-off scores 
with their sensitivity and specificity are shown in Table 3.6.   
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Area Under the Curve 
Asymptotic 95% 
Confidence Interval 
Test Result 
Variable(s) 
Area Std. Errora Asymptotic 
Sig.b 
Lower 
Bound 
Upper 
Bound 
Score_F1 .622 .066 .054 .492 .751 
Score_F2 .636 .052 .031 .535 .738 
Score_F3 .624 .056 .050 .515 .733 
Total_Score .697 .053 .002 .593 .802 
The test result variable(s): Score_F1, Score_F2, Score_F3, Total_Score has at least one tie between the 
positive actual state group and the negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Table 3.5. ROC Analysis for scores for each Symptom Cluster/Factor (F1,F2,F3) 
 
 
 
 
 
 
 
 
  88 
Test Result Variable(s) Positive if Greater Than 
or Equal To 
Sensitivity Specificity 
Score_F1 -1 100 0 
 0.5 38.5 85.5 
 1.5 38.5 86.4 
 2.5 26.9 89.1 
 3.5 23.1 90 
 4.5 23.1 93.6 
 5.5 19.2 93.6 
 6.5 7.7 98.2 
 8 0 100 
Score_F2 -3 100 0 
 -1.5 96.2 35.5 
 -0.5 57.7 60 
 1 26.9 70.9 
 2.5 26.9 76.4 
 3.5 19.2 88.2 
 5 0 100 
Score_F3 -2 100 0 
 -0.5 100 8.2 
 0.5 88.5 30 
 1.5 61.5 57.3 
 2.5 38.5 77.3 
 3.5 3.8 91.8 
 4.5 0 98.2 
 6 0 100 
Total_Score -4 100 0 
 -2.5 100 5.5 
 -1.5 100 11.8 
 -0.5 96.2 23.6 
 0.5 88.5 39.1 
 1.5 76.9 50.9 
 2.5 73.1 58.2 
 3.5 53.8 68.2 
 4.5 38.5 77.3 
 5.5 38.5 87.3 
 6.5 26.9 90.9 
 7.5 19.2 93.6 
 8.5 7.7 98.2 
 9.5 3.8 98.2 
 11 0 99.1 
 13 0 100 
Table 3.6. Cut off scores of ROC analysis with respective sensitivity and specificity 
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For this cohort, a total score cut-off of 5.5 confers a sensitivity of 38.5% and specificity 
of 87.3%.  As a predictive screening tool, ensuring a low number of false negatives, 
rather than false positives would be more useful when collecting toxicity data.  Increasing 
the study numbers when validating this tool on a prospective cohort would improve both 
sensitivity and specificity.  
 
3.3.3 Creating a Radiation- Induced Bowel Injury Score (RIBI) Score 
 
I created a 14-item score based on the above analysis. This ideally would also include 
weighting for the degree (grade) of each symptom based on frequency of experiencing 
these symptoms. The score developed (Template shown as Table 3.7) is a multiple point 
score that can potentially be modified further to incorporate other variables.  
It is important that any score takes into account the degree to which symptoms affect a 
patient’s quality of life.  While recognizing that mild-moderate urgency may affect two 
different patients in different ways, some degree of uniformity can be achieved by 
eliciting symptom frequency, i.e. how often a symptom occurs – daily, weekly, monthly 
etc. 
Each symptom cluster score would highlight the predominant ‘cluster’, with the total 
score taking into account all signs/symptoms.  The multiplying integers represent the 
relative weighting within the cluster (note bowel frequency <4 has a factor scor of (-2), 
whilst bowel frequency >4/day has a factor score of (+2). 
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Grade/ 
Severity 
0 1 2 3 4 
      
Factor 
Score 
Total 
Nausea      2  
Vomiting      2  
SABO*      2  
ABO**      1  
        
BO>4      2  
BO<4      -2  
Diarrhoea      1  
     1  Faecal 
Incontinence        
Bloating      1  
Flatulence      1  
Abdo pain      1  
Urgency      1  
PRB      -1  
PR Mucus      1  
        
Total Score   
 
Table 3.7. ‘RIBI’ Score Template: Radiation Induced Bowel Injury after Pelvic Radiotherapy; UCLH 
Departments of Oncology, Gastroenterology & Nutrition.  Validation required on a prospective cohort with 
grades of severity for each item.  For grading of each item; 0 : none, not experienced, 1: occasional (rarely), 
2: intermittent (i.e. once/twice monthly), 3: persistent i.e. weekly and 4: refractory (i.e. daily) 
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3.4 Conclusion and Discussion 
 
It is well recognized (Henson et al, 2012) that the use of the available formal tools to 
report toxicity data by oncologists and service-provision in the UK for patients presenting 
with symptoms of radiation-induced bowel injury, or ’pelvic radiation disease’ is poor.  
Few studies have addressed this issue although several research groups in the UK are 
currently conducting studies.  
This experimental study aimed to design a tool that might help predict patients in need of 
early referral to gastroenterologist, whilst giving diagnostic clues that may well prevent 
expensive (and invasive) tests in all patients.  Capp et al (2009) first describe this 
clustering process in men treated for prostate cancer.  Urgency was found to be at the 
‘core’ of many symptom clusters (made up of 8 items only), with ‘bleeding’ identified as 
a ‘peripheral’ symptom.  This research group suggests that the ‘position’ of symptoms in 
the cluster may be related to the path-physiological process.   They also highlight the 
shortcomings in the CTCAEv3.0 in failing to define rectal injury especially as it is well 
documented that faecal urgency is the most common and troubling symptom affecting 
men and women after radiation (Andreyev 2007).  
Prediction and early recognition of patients with RIBI could improve the quality of life in 
these women if managed appropriately.  Multivariate ordinal regression analysis in 
chapter 1 suggested that patients presenting with symptom factor/cluster 3; (bloating, 
flatulence, abdominal pain, faecal urgency, per-rectal bleeding, and per-rectal mucus) 
were more likely to suffer severe, more progressive and chronic disease.   I applied ROC 
analysis to evaluate the validity of our predictive scoring model and showed AUC>0.600 
for each factor score and the total cores.  This study is limited as it uses data collected 
retrospectively from a relatively small number of patients (n=152).  The model needs to 
be tested prospectively on a larger cohort of patients from multiple centers to provide 
further data to substantiate its applicability, and validate the score.  The development of a 
simple RIBI Score Online Calculator to collect data at different time points during 
oncology follow-up that may provide a platform for prospective data collection which 
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could improve individual patient care but also provide a simple, accessible tool in 
planning future clinical trials.    
In conclusion I propose a clinical score validated in our cohort of patients that may be 
used to predict severity and progression of symptoms of radiation-induced bowel injury 
(RIBI).  The score enhances prediction of severity by taking into account the weighting 
of each symptom within a cluster of presenting complaints and may help identify those 
patients needed early referral to a gastroenterologist and early intervention to prevent 
progression of the ‘disease’ process.  The score is potentially easy to use in the clinical 
setting and could also be used as a data collection tool at sequential points during follow-
up after radiotherapy for use in prospective studies to improve further research into the 
patho-physiology of radiation-induced bowel injury. 
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Part II  Biomarkers in Clinical Oncology 
 
Chapter Four Cell-cycle Markers in Cervical Cancer – utility as a predictive 
and prognostic marker of (chemo)-radiosensitivity and tumour 
response? 
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Chapter Four Cell-cycle Markers in Cervical Cancer – utility as a predictive 
and prognostic marker of (chemo)-radiosensitivity and tumour 
response? 
 
4.1 Replicating Licensing Factors and The Cell-Cycle 
 
The dysregulation of mechanisms that control cellular proliferation, differentiation and 
apoptosis has long been recognised as the mechanism by which cancer cells acquire 
growth advantage over non-cancerous cells.  The DNA replication-licensing pathway 
consists of a complex of initiator proteins, which bind and open the DNA at origins.     
Replication licensing factors (RLFs) ORC, Cdc6, Cdt1, and Mcm2-7, during late mitosis 
and in the rest phase before DNA synthesis (G1) (Figure 4.1), assemble into pre-
replicative complexes, which render replication origins ‘licensed’ for DNA synthesis.   
During DNA synthesis (S phase), Cdc7 kinase and cyclin-dependent kinases induce a 
conformational change in the pre-replicative complex, resulting in recruitment of 
additional initiator proteins that collectively promote DNA unwinding and recruitment of 
DNA polymerases (Bell et al 2002; Eward et al 2004). 
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Figure 4.1. The cell-cycle.  G1 and G2 shown as rest-phases between DNA synthesis (S) and mitosis (M).  
Cells leave the cell-cycle at G0. 
 
 
4.1.1 MCM Proteins 
 
The Mcm (minichromosome maintenance) proteins (Mcm2-7), constituents of a DNA 
replicative helicase, are expressed throughout the cell cycle (G1-S-G2-M) but are tightly 
downregulated during exit into out-of-cycle (G0) or differentiated states (Stoeber et al 
2001; Barkley et al, 2007; Williams and Stoeber, 2007).  The expression levels of Mcm 
proteins therefore reflect the proliferative capacity of a cell and they thus have been 
shown to be useful for cancer detection and prognosis in many tumour types (Williams 
and Stoeber, 2007; Baldwin et al, 2003). Williams et al, (1998) have also showed the 
potential use of Mcm5 in detecting low and high-grade dysplastic lesions in abnormal 
cervical smears. 
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4.2. Ki67 (Clone MIB-1) 
 
The cell-cycle antigen Ki67 (clone MIB-1) is a cellular marker of proliferation present 
during all active phases of the cell-cycle (G1-S-G2-M) but absent from resting cells (G0).  
The precise function of Ki67 is uncertain, however the combination of its tight cell-cycle 
phase regulation and a short half-life have established the protein as a robust marker for 
proliferating cells (Yerushalmi et al, 2012). 
 
4.3 Geminin 
 
During S-G2-M phases, the presence of the licensing repressor protein Geminin prevents 
inappropriate reinitiation events at origins that have already been activated, through its 
interaction with Cdt1, resulting in a block to Mcm2-7 loading to chromatin (Hook et al, 
2007).   Geminin, therefore is used as a biomarker of S-G2-M progression.    
 
4.4 Use of Cell-cycle markers in Clinical Oncology 
 
Expression profiles of Mcm, together with Ki67 and Geminin measure cell cycle kinetics 
and allows cells in out-of-cycle states to be distinguished from those residing in cycle and 
can assign cells to G1 and S-G2-M phase.  (Kulkarni AA et al, 2007; Loddo et al, 2009).  
The Mcm2/Ki67 ratio defines the proportion of cells that are licensed to proliferate, i.e. 
Mcm2-7 also identifies non-cycling cells with proliferative potential; the higher the 
Mcm2/Ki67 ratio, the greater the proportion of cells that reside in a licensed non-cycling 
state. (Williams and Stoeber, 2007; Kulkarni et al, 2007; Loddo et al, 2009; Dudderidge 
et al, 2005).  Ki67, since present throughout the cell cycle in proliferating cells, together 
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with Geminin can be used to determine the rate of cell-cycle progression - the 
Geminin/Ki67 ratio may be used as an indictor of relative length of G1 phase.  
Multiparameter analysis of these DNA replications licensing factors (RLFs) - Mcm2-7, 
Ki67 and Geminin, readily detectable by immunohistochemistry in surgical tumour 
biopsies have been linked to tumour cell cycle state and clinical outcome in penile 
squamous cell carcinoma (Kayes et al, 2009).  In this study, analysis of RLF expression 
showed accelerated cell-cycle progression was significantly associated with high grade 
tumour, increased tumour size, depth of invasion and shorter overall survival time, 
suggesting that RLF analysis may be used as prognostic and predictive biomarkers.  In 
this chapter, I sought to study the cell cycle kinetics in a cohort of cervical cancers and 
identify any potential correlation between protein expression levels of these RLFs with 
tumour differentiation, stage of disease at presentation, and response to chemo-radiation. 
 
4.5 Materials and Methods 
 
4.5.1 Study Cohort. 
 
All patients were part of a multicenter single arm phase II study (Cervix II) (McCormack 
et al, 2013) of weekly neoadjuvant carboplatin and paclitaxel chemotherapy followed by 
standard radical chemo-radiation with cisplatin for locally advanced cervical cancer. 
Patients received dose-dense carboplatin (AUC2) and paclitaxel (80mg/m2) weekly for 6 
cycles followed by chemo-radiotherapy with 40mg/m2 of weekly cisplatin.  Radiation 
(with concomitant cisplatin) to the whole pelvis was given to a total dose of 50.4Gy in 28 
fractions over 5.5 weeks using 8-15 mV photons.  Intra-cavity brachytherapy was given 
following completion of external beam radiation; patients received a total dose of 15Gy 
in 2 fractions.   Between June 2005 and October 2008, 46 patients diagnosed with 
squamous, adeno-squamous or adenocarcinoma of the cervix, FIGO stage IB2 – IVA 
were recruited to take part in the study. As part of the eligibility criteria patients had to be 
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age over 18, considered suitable for radical chemo-radiation, and fit for treatment.  All 
patients had a pre-treatment biopsy during staging examination under anaesthesia (EUA).  
Patients who had histologically positive para-aortic lymph nodes were also included in 
the study.   
 
The majority of patients were treated within the North London Cancer Network and 
biopsy specimens were reviewed by a specialist gynae-oncology pathologist at diagnosis.  
Formalin-fixed paraffin wax-embedded tissue was retrieved from the archives of the 
Department of Pathology (UCL Hospitals, London, UK) for 35 patients within the trial.  
Normal cervix tissue was obtained from patients following colposcopic assessment and 
biopsies.  Clinical information was extracted from hospital medical records and the trials 
database.  Ethics approval was obtained from the local research ethics committee from 
the joint University College London/University College London Hospitals Committees 
on Ethics of Human Research.  Histologic grade and stage of the primary tumour were 
recorded.  Tumour grade was defined using Broders’ classification: well differentiated 
(grade 1), moderately differentiated (grade 2), and poorly differentiated (grade 3).  
Follow-up data was obtained for 35 patients with available cervical tumour tissue 
samples for immunohistochemistry.  Table 4.1 shows the clinicopathologic 
characteristics of patients.  The median age of all patients at time of diagnosis was 42 
(range 27 – 71).  Fifty-seven percent (57%) of the tumours were moderately 
differentiated (grade 2).  Majority (80%) were of squamous cell histology.  
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 Frequency (%) 
Age (years)  
Median (Range) 42 (23 – 71) 
Grade  
1 1 
2 20 (57%) 
3 14 
Tumour Stage  
1B2 3 
IIB 23 (66%) 
IIIA 1 
IIIB 6 
IVA 2 
Histology  
Squamous Cell 28 (80%) 
Adenocarcinoma 6 
Adeno-squamous 1 
Median follow-up (months) 37.7  
Median (range) (3.4 – 73.9) 
Table 4.1. Patient Characteristics and Cancer Demographics 
 
4.5.2 Antibodies. 
 
Rabbit polyclonal antibody against human geminin were previously generated and 
validated at the UCL laboratory (Eward et al, 2004; Wharton et al, 2009).  Ki67 
monoclonal antibody (Mab) (clone MIB-1) was obtained from DAKO (Glostrup, 
Denmark) and Mcm2 monoclonal antibody (clone 46) from BD Transduction 
Laboratories (Lexington, KY, USA).  The specificity of Ki67 and Mcm2 monocloncal 
antibodies were previously been confirmed in previous studies (Loddo et al, 2009; 
Kulkarni et al, 2007; Dudderidge et al, 2005). 
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4.5.3 Immunohistochemistry 
 
Consecutive serial sections were cut from each paraffin-embedded tissue block 
representative of the tumour.  Three-micrometer sections were cut onto Superfrost Plus 
slides (Leica Microsystems), dewaxed in Xylene, and rehydrated through graded alcohol 
to water.  For antigen retrieval, slides were pressure cooked in 0.1ml citrate buffer (ph 
6.0) at 103kPa for 2.5min.  Tissue sections were immunostained using the Bond Polymer 
Define Detection Kit and Bond Polymer Define Detection kit and Bond-X automated 
system (Leica) according to the manufacturer’s instructions.   
Primary antibodies were applied at the following dilutions: Ki67 (MIB-1) (1:70), Mcm2 
(1:2000) and Geminin (1:1000).  Coverslips were applied using Pertex mounting medium 
(Cellpath).  Incubation without the primary antibody was used as a negative control and 
tonsil epithelium was used as positive control. 
 
4.5.4 Protein expression profile analysis  
 
Protein expression levels were expressed as a labelling index (LI), as previously 
described (Dudderidge et al, 2005; Shetty et al, 2007; Kulkarni et al, 2007).  Slides were 
evaluated at x100 magnification to view the advancing edge of the tumour and select 
areas with the most densely stained tumour cells starting from the edge to the centre of 
the tumour.  Three to five areas were image captured at x400 magnification with a 
charge-coupled device camera and AnalySIS image analysis software (SIS).   
Images were then printed for quantitative analysis, which was undertaken before I 
became aware of clinicopathologic and outcome (all slides were blinded by using 
laboratory numbers).  Both positive and negative cells in the field were counted, 
excluding stromal and inflammatory cells.  A minimum of 500 cells was counted for each 
case.  The LI was calculated using the formula: LI = number of positive cells/total 
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number of cells x 100.  Reassessment of 20 randomly selected cases by an independent 
assessor  (Ian Proctor, Pathologist & laboratory Supervisor) showed concordance in all 
cases. 
 
4.5.5 Statistical analysis 
 
Biomarkers labelling indices were summarised using median and interquartile ranges. 
Mann-Whitney test was used to compare relationship between biomarker expression and 
tumour differentiation, stage of disease and type of primary tumour. Disease-free and 
overall survivals (DFS and OS) were measured from the date of study registration until 
relapse, death from any cause, or the date last seen alive.  Events for DFS included 
recurrence or death from any cause.  
All survival endpoints were measured from the date of registration, and patients who did 
not have the event of interest were censored at the date of last follow up. Kaplan-Meier 
curves and Cox regression analyses were performed. Analyses performed using STATA 
12 and all p-values are two-sided.  All factors were assessed separately for association 
with biomarker expression.  All tests were two-sided and a statistical significance level of 
p<0.05 was used. 
 
4.6 Results 
 
4.6.1 Cell-cycle marker expression in normal and malignant cervical epithelium 
 
Protein expression profiles for Mcm2, Ki67, and Geminin were determined in both 
benign and malignant lesions of the cervix using previously characterised monospecific 
antibodies against Mcm5 protein and Ki67 (MIB-1).  In contrast to dysplastic and 
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malignant epithelium, all 13 control cases of normal squamous epithelium only showed 
protein expression restricted to the basal and suprabasal cells as previously described 
(Williams et al, 1998; Kayes et al, 2009); median Mcm2; 65.1% (range 34% – 98.4%) 
and median Ki67 (MIB-1); 11.6% (range 9%- 44.1%.   
Geminin expression in normal cells were low; median 6.1% (range 0 – 10.2%) (Table 
4.2).  Cells in the superficial layers with well-differentiated phenotype showed a low 
level of Mcm expression (0-2%).   
 
 
Figure 4.2. Photo-micrographs of paraffin wax-embedded tissue sections of representative normal 
squamous epithelium (n=13), squamous cell carcinoma-in-situ (n=28), and cervical adenocarcinoma (n=7), 
immunohistochemistry stained with antibodies to Ki67, Mcm2, and geminin. Magnification X200 
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4.6.2 Cell-cycle state and tumour differentiation, stage and survival. 
Protein expression profiles for Mcm2, Ki67 and Geminin were determined in the 35 
cervical tumours.  No significant relationship was found between biomarker expression 
and clinicopathologic variables.  Expression levels of Mcm2, Ki67 and Geminin were not 
associated with tumour grade (G1/2 vs G3), stage or overall survival.  Median Mcm2 
expression for G1/2: 92.2%, interquartile range (86.0 – 92.0) and G3: 89.2% (84.6 - 97.2) 
respectively.  Median Ki67 was lower, G1/2: 76.8% (59.0 – 86.0) and G3: 77.3% (65.8 - 
83.6) than Mcm2 expression, but with both biomarkers extending over a broad range.  
Table 4.2 summarises the statistical analysis of the relationship between marker 
expression and clinicopathological variables.   
Median Geminin expression was lower for all cases: G1/2 (29.1%) and G3 (37%); 
geminin is only present during S-G2-M and represents a lower growth fraction (Eward et 
al, 2004).  There was a trend towards a higher Mcm2/Ki67 ratio in squamous cell 
compared to adenocarcinoma (1.3 vs 1.0, p=0.06), but this was not statistically 
significant.  The Mcm2/Ki67 ratio reflects the proportion of non-proliferating cells that 
are licensed for DNA replication and we would expect this to increase with increasing 
grade to reflect a shift in the proportion of cells licensed to proliferate from well 
differentiated to poorly differentiated tumours.  There was no association with 
Geminin/Ki67 ratio and tumour differentiation as shown in epithelial ovarian cancer 
(Kulkarni et al, 2007; Loddo et al, 2009).  This ratio indicates the relative length of G1 
phase and the rate of cell-cycle progression.  
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 Mcm2 Ki67 Geminin Mcm2/Ki67 Geminin/Ki67 
Normal Cervix (n=13) 65.1 (38.9 70.6) 11.6 (10.0 –26.4) 6.3 (2.9 – 7.7) 3.40 (2.60 -4.63) 0.35 (0.13 – 0.55) 
Cervical Cancer (n=35) 90 77 32 1.19 0.45 
      
Grade      
1/2 (n=21) 92 (86-98)* 77 (59-86) 29 (23-38) 1.19 (1.05-1.51) 0.45 (0.32-0.57) 
3   (n=14) 89 (85-97) 77 (66-84) 37 (27-43) 1.19 (1.08-1.41) 0.48 (0.37-0.55) 
p-value**  0.50 0.50 0.14 0.80 0.48 
      
Stage      
IB2/IIB (n=26) 91 (70-98)* 77 (56-86) 32 (26-39) 1.19 (1.05-1.51) 0.46 (0.37-0.57) 
IIIA/IIIB/IVA (n=9) 88 (86-98) 78 (66-84) 36 (23-40) 1.24 (1.07-1.48) 0.43 (0.33-0.50) 
p-value**  0.97 0.68 0.85 0.85 0.63 
      
Histology      
SCC (n=28) 92 (86-97.8)* 76 (60-83) 32 (25-40) 1.25 (1.08-1.49) 0.49 (0.36-0.58) 
Adenocarcinoma 
(n=7) 
90 (51-98) 82 (46-89) 37 (25-39) 1.02 (0.85-1.19) 0.45 (0.32-0.46) 
p-value** 0.43 0.43 0.93 0.06 0.38 
      
 
Table 4.2. Relationship between biomarker expression and clinicopathologic variables. Labelling 
index (expressed as percentage) used, *Median (interquartile range), ** Mann-Whitney test. 
 
There was no evidence of an association between cell-cycle phase specific markers and 
stage (IB2/IIB vs IIIA/IIIB/IVA), grade or survival (disease-free and overall survival).  
Figure 4.3 shows the LIs for all markers by tumour grade.  There were no differences 
found for percentage expression and proliferation markers between well differentiated 
and moderately differentiated tumour and poorly differentiated (high grade) tumours. 
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Figure 4.3. Distribution of biomarkers by tumour grade; median and interquatile ranges (boxed), and 
range for Mcm2, Ki67 and Geminin.  There is no statistical difference shown between the groups G1/2 
(n=21) and G3 (n=14) 
 
At the time of analysis (survival data collected until December 2012 as part of a clinical 
trial (McCormack et al, 2013), 11 patients had relapsed and died.  One patient died of a 
non-cancer related cause (cerebral haemorrhage).  Median follow-up period was 37.7 
months (range 3.4 - 73.9).  Cox regression analysis was used to calculate survival time.  
11(31%) of patients had died at the time of analysis.  There was no association found 
between disease-free (DFS) and overall survival (OS) and expression of Mcm2, Ki67 and 
geminin on univariate analysis.   
Kaplan-Meier curves were generated to show DFS and OS by grade (Figures 4.4a and b).   
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Fig 4.4a. Disease-Free Survival (DFS) by Tumour Grade 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4b. Overall Survival (OS) by Tumour Grade 
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There was poorer survival (DFS and OS) in patients with G3 tumours but this was not 
statistically significant; DFS (G3 vs G1/2); HR 1.45 (95% CI: 0.44-4.75), p=0.44), OS; 
HR 1.51 (95% CI: 0.46-4.95, p=0.45).   
 
4.6.3 Radiation toxicity – Incidence in this cohort 
 
The recorded incidence of radiation induced bowel injury in this cohort was 20% (7/35).  
Three (3) out of these 7 women had significant symptoms requiring investigations.  There 
was no difference found for labelling indices for all of the cell-cycle markers in these 7 
women compared to women who did not experience or present with symptoms of 
radiation-induced bowel injury.   
Sub-analysis in the small numbers did not show a difference in survival between these 
two groups and thus I was unable to support the hypothesis of the potential of cell-cycle 
phase specific markers as a marker of (chemo)-radiosensitivity, with an associated 
increased risk of normal tissue injury. 
 
4.7 Conclusions 
 
In this pilot study, I assessed the utility of Mcm2, Ki67 and Geminin as biomarkers in 
cervical cancer.  In contrast to studies in other cancers, cell cycle phase specific markers 
do not predict disease grade or stage and were not predictors of disease progression and 
overall survival.  In our small sample size of 35 tumours, the expression of each cell 
cycle biomarker was very high in all cases.  All the cases of squamous cell carcinoma of 
the cervix (n=28) and all but one of the adenocarcinomas (n=7) in this study displayed an 
aggressive ‘actively cycling’ phenotype with high Mcm2, Ki67, and geminin expression.   
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Univariate analysis did not show an association between RLF expression and survival.  
There was no statistical difference in both disease-free (DFS) and overall survival (OS) 
between grade1/2 and high-grade disease.  There appeared to be no association with 
expression of markers between low and high grade, with differentiated (G1/2) tumours 
expressing similar high levels of RLFs as poorly differentiated tumours (G3).  We 
recognize our study is limited due to small numbers however our results raise the 
question of whether degree of tumour differentiation is an unreliable prognostic marker in 
cervical cancer, unlike in other epithelial tumours (e.g. ovary).  The most likely 
explanation for this would be the viral aetiology of this disease.  HPV E6 and E7 
oncogenes have a wide range of cellular targets, most notably the degradation of p53 
tumour suppressor protein by E6 and the abrogation of pRB tumour suppressor function 
by E7.  Chronic expression of E6 and E7 are understood to lead to the acquisition of 
genomic instability and proliferative capacity. 
Gradual down-regulation of Mcm2-7 occurs as cells mature and adopt a fully 
differentiated functional phenotype. There is evidence to show increasing mcm 
expression from low to high-grade dysplastic (Williams et al, 1998).  The arrested 
differentiation that characterises cancer, particularly in high-grade tumours, is associated 
with failure to down-regulate the replication initiation proteins. In contrast to normal 
cervical epithelium the expression levels of Mcm2, Ki67 and geminin expression as 
expected, are indicative of a hyper-proliferative state. 
The mechanisms involved in radiation-induced injury to the bowel and the responses that 
occur after radiation following normal tissue injury suggest that following mucosal 
damage, tissue with normal repair capacity may well behave as if in a hyper-proliferative 
state in response to crypt cell death.  This lead me to further questions on the possible 
role of cell-cycle markers in defining the proliferative state and thus repair capacity of 
bowel mucosal crypt cells following radiotherapy.  
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Part III  Can Cell-Cycle Markers Predict Symptom Presentation and 
Severity Of Radiation-induced Bowel Injury (RIBI) after 
Treatment For Cervical And Endometrial Cancers? 
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Chapter Five Cell Cycle Phase Specific Markers as Predictive and Prognostic 
Markers In Radiation-induced Bowel Injury (RIBI) after 
Treatment For Cervical And Endometrial Cancers? 
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5.1 Introduction 
The prevalence of pelvic radiation disease and significant effect on the quality of life of 
survivors of cancer demands that future research must focus on understanding the 
physiological and pathological responses of the intestine to radiation injury.  It remains 
unclear why some women will develop symptoms of radiation-induced bowel injury 
(RIBI) and others do not.  It has also been difficult to predict which women will 
experience chronic mild to moderate symptoms that either resolve over time, or persist at 
a manageable level, and those as risk of severe symptoms affecting their quality of life, 
which often progress or remain unresolved even after surgical intervention.  As part of 
investigations for symptoms of RIBI, an endoscopic assessment and diagnostic biopsy of 
areas of abnormality or ‘inflammation’ has become part of the work-up for patients in 
centers that manage gastrointestinal symptoms after radiation therapy.  
It is imperative that future research studies focus on finding predictive methods to 
identify patients with a high risk of developing healthy tissue toxicity.  Ongoing 
molecular epidemiology research aimed at identifying genetic or epigenetic 
characteristics that confers a susceptibility to delayed radiation-induced bowel injury 
must become a priority (Hauer-Jensen et al, 2014). 
In this chapter I have attempted, using archived colonic biopsy samples from patients 
who underwent endoscopic assessment at symptom presentation, to investigate whether 
variations exist in the cell-cycle status of the proliferation compartment in colonic crypts, 
and to correlate the information obtained to variations in repair capacity of the 
proliferating cells in the intestinal villi, severity of symptoms of RIBI and other variables.   
 
5.1.1 Cell Organisation in the Colonic Crypt of the Intestinal Epithelium 
 
The bowel mucosa is a layer of rapidly self-renewing epithelial cells, responsible for 
absorption of nutrients and water but also acts as a protective barrier against pathogenic 
microbes.  The functional cells of the mucosal surface of the gastrointestinal epithelium 
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maintain haemostasis by mechanisms that regulate the shedding and replacement of 
functional cells in the intestinal villi. New functioning epithelial cells are produced from 
proliferating stem cells and their progeny.  These stem cells are found within millions of 
crypts spaced along the length of the gastrointestinal tract within the millions of villi. 
New cells are produced in the proliferative compartment of these crypts and each 
survives through out the lifetime of an animal by regulating the balance between 
programmed cell death (apoptosis) and renewal (Li et al, 1994).  The progenitor cells 
responsible for replacement and renewal are located in the crypt base (Potten et al, 1990).  
As daughter stems cells are produced from cell division, the cells move higher up along 
the crypt and divide, differentiate and mature, giving the differentiated middle 
compartment of the crypt.   
Experimental studies (Potten and Hendry 1983; Potten et al, 1990; Potten and Booth 
1997) have been able to determine the location or exact position of stems cells along the 
crypt-villus axis (Figure 5.1).  In the small intestine, the stem cells are thought to reside at 
positions 4-5 (four or five cells up from the crypt base).  In the normal colon, the stem 
cells are found at the crypt base (positions 1-2).  New functioning epithelial cells are 
produced from these proliferating stem cells and their progeny.   
 
 
 
 
 
Figure 5.1. Cell position in the crypt base and positional frequency of markers 
(titrated thymidine in this example) (LI%), recorded in intestinal crypts – (Potten 
and Booth, 1997).  Positive cells after staining can be counted in many sections to 
calculate the frequency of an event at each cellular level position.   
 
474 C. S. Potten and C. Booth
FIG. 2. A typical longitudinal section of a small intestinal
crypt from a mouse 4.5 hr after a dose of 1 Gy. Cells in mito-
sis can be seen (arrow: anaphase arrowhead: metaphase) and
several apoptotic fragments (large arrows). Both mitosis and
apoptosis involve chromatin condensation and occasionally
it is difficult to distinguish between the two processes. Hae-
matoxylin and eosin stained (!500).
in cross section). Later stages see the cell and nucleus frag-
mented and phagocytosed by neighbouring cells. This pro-
FIG. 1. The positional frequency of markers such as tritiated cess involves the expression of specific endonucleases that
thymidine (LI%), can easily be recorded in intestinal crypts. cleave the DNA into fragments of 200 base pair multiplesPositive cells can be seen in histological longitudinal crypt
in size, observed as a ladder when separated by electrophore-section (see Fig. 2), their position along the crypt axis noted
sis on a gel, or as larger DNA fragments (approximately 50(where cell position 1 is the crypt base) and, by counting
many sections, the frequency of that event at each cellular and 300 kb) in some situations. Thus, apoptotic cells can be
position can be calculated. Using such techniques it is possi- identified by their characteristic morphology, by techniques
ble to determine the effects of certain treatments on cells in that detect the fragmented DNA (both on tissue sectionsthe stem cell region.
or in gels), or by flow cytometry techniques that detect flu-
orescent fragments containing the condensed chromatin.
Apoptosis is often used by nature to remove unwantedhealthy cell, although it can occasionally be more difficult
to distinguish from mitotic cells. Apoptotic cells have a cells, often where loss of a single cell may serve to protect
or preserve a population. In the normal small intestine, ashrunken cytoplasm, although the organelles are intact, and
the nuclear chromatin is condensed around the nuclear low level of apoptosis (known as spontaneous apoptosis) can
be seen—it has been estimated that only one apoptotic cellmembrane (commonly appearing to form a crescent shape
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The entire intestinal epithelium is replaced every 2-3 days in mice and every 3-5 days in 
humans.  This requires tight regulation of cell production, differentiation, migration and 
turnover.  Malfunctions in the cell turnover regulation have been linked to inflammatory 
bowel disease, formation of adenomas and eventually malignant tumours (van der Wath 
et al, 2013).   
The mechanisms controlling this regulation and the self-renewal machinery by cell 
division and differentiation to replenish lost functional cells and repair tissue following 
injury are not completely well understood.  There is evidence that suggests this tightly 
controlled mechanism includes some asymmetric chromosome segregation in stem cells 
and the re-activation of dormant stems cells following injury (Wilson et al, 2008).  Crypt 
cells have the ability to detect induced damage and either ignore, repair or delete cells 
from the system by apoptosis (Potten and Booth, 1997). 
Labelling index studies (de Rodriguez et al 1979; Potten et al, 1982) have provided 
information about the details on distribution of proliferative cells along the length of the 
colonic crypt.  Labelling index (LI) in the crypt is a measure of mitotic activity along the 
crypt and is defined as the number of cells in the S phase of the cell-cycle at the vertical 
position divided by the total number of cells in that position.  These studies have shown a 
distinct ordering of proliferative cells at the base of the crypt (B) and mature 
differentiated cells at the superficial end (S) opening into the lumen.   
In recent years, Ki-67 immunostaining (Batlle et al, 2002; Hanna-Morris et al, 2008; 
Leedham et al, 2012) has been used as a marker of cell proliferation and has shown a 
distinct boundary between the proliferative cells and mature cells, with proliferative cells 
primarily occupying the lower third/ base (B) of the crypt.  Recent biological research 
focusing on finding markers for intestinal stem cells within the proliferative compartment 
of the crypt has provided more evidence to suggest the direct progeny of proliferative 
stem cells proliferate rapidly and migrate along the crypt wall towards the superficial 
third (Potten et al, 1990; Potten et al, 2009).   
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5.2 Effect of radiation on cell proliferation kinetics 
 
The balance against the probability of achieving local tumour control and the damage 
induced by radiation is dependent on the proliferation kinetics of dose-limiting normal 
epithelial tissue.  The rate of development of radiation damage is intimately linked to 
their cell population kinetics.  The interval between fractions in a therapeutic regime is 
generally thought to give time for repair of (reversible) damage, giving time for re-
population of ‘normal’ epithelial cells.  Studies developed to determine the response of 
normal tissues to fractionated radiation, have assumed that the target stem cells have 
similar radiation sensitivity throughout the regime (Morris et al, 1996).   
 
5.2.1 Radiation sensitivity and the cell cycle 
 
The variation in observed radio-sensitivity of cells in different phases of the cell cycle 
was first published in the 60s (Terasima et al 1963; Sinclair et al 1966).  Cells in mitosis 
(M) and late G2 phases of the cell cycle are most sensitive to radiation, whilst cells in late 
S phase are most resistant.  Cells in early S phase and G1 would usually demonstrate 
intermediate radiosensitivity (Withers, 1975).  One of the first effects of ionizing 
radiation on a proliferative cell population is the induction of a delay in cell cycle 
progression.  This delay is temporary and arrests the progression of the cell cycle through 
G1, S or G2 (Maity et al, 1994) and invariably induces an accumulation of cells at G1/S 
and G2/M interphases resulting in a synchronized progression of cells into the first post-
irradiation cell division.   
The duration of the mitotic delay is directly related to the radiation dose and the cell 
doubling time of the proliferation compartment within the epithelial tissue.  The doubling 
time is defined as the time taken for the renewal of all the epithelial cells in the 
proliferative compartment. Due to the presence of non-proliferative cells in the 
proliferative compartment, the doubling time is invariably longer than the cell cycle time.  
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Fig 5.2. A typical longitudinal section from a small intestinal crypt from a mouse 4.5hr after 1 Gy 
dose of radiation. (Potten and Booth 1997).  Cells in the mitosis can be seen (arrow: anaphase, 
arrowhead: metaphase).  Both mitosis and apopotosis involve chromatin condensation and can be difficult 
to distinguish.  Haemoatoxylin and eosin stained (x500) 
 
Mitotic delay in the intestinal epithelium depends on the position of cells in the crypt.  A 
single dose of 1Gy results in a delay in cell cycle progression which approximates to 13% 
of the doubling time, at cell positions 1-5 at the base of the crypt and falls to ~8% of the 
doubling time at cell position 6 and upwards (Leschert 1967; Chwalinski and Potten 
1986; Potten 1990). 
After exposure to 1Gy of irradiation, there is a progressive dose-dependent decline in 
crypt cellularity, demonstrated in mice small intestine that leads to denudation of the 
surface mucosa within days after irradiation (Potten 1981,1990; Potten et al 1975, 1990).  
Cells in the epithelium continue to proliferate during the initial recovery from radiation 
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exposure, however some cells degenerate and undergo apoptosis and necrosis.  Over the 
course of fractionated radiation, the number of cells that degenerate increases, with no 
clear evidence that this is dose-dependent (Devik, 1971).  Repopulation after irradiation 
is determined by the cell population characteristics and kinetics of the normal non-
irradiated epithelium.   
In rapidly proliferating epithelium of the gastrointestinal tract, this occurs shortly after 
irradiation.  The time of onset of this repopulation of cells lengthen during a course as the 
turnover of cells in the basal layer of the crypts increases progressively.  The recovery of 
these cells from the mitotic delay with an increase in cells undergoing mitosis, 
demonstrated by an increase in cell labeling indices to ‘normal’ control levels, marks the 
beginning of repopulation.  Figure 5.2 demonstrates the staining of crypt basal cells after 
radiation exposure.  In the acute phase of recovery, the timing of repopulation appears to 
be determined by radiation dose, the overall recovery of cells and subsequent repair of 
tissue injury appears to be related to other intrinsic factors, as inter-patient variability in 
tissue repair would suggest.  It is recognized that cells exhibit a variability in radio-
sensitivity with respect to their position in the cell cycle at the time of exposure to 
radiation, suggesting some normal tissue cells’ proliferation kinetics are unaltered by 
exposure to radiation (Morris GM, 1993).  The evidence from experimental studies 
investigating the variations in radio-sensitivity and the effects of radiation exposure on 
cell cycle progression suggests that variations exist in this initial tissue injury response 
(Gilbert et al, 1965).   
 
5.2.2 Radiation and Cell-cycle dynamics in the Gastrointestinal Tract 
 
It is widely accepted that radiation predominantly kills rapidly proliferating cells such as 
progenitor cells in the intestinal crypts, which leads to insufficient replacement of the 
villus epithelium (Potten, 1977).   It remains unclear how the responses to radiation in the 
acute phase and the repair capacity of individual patients is related to the proliferation 
status at the end of a course of radiotherapy.  
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Whilst some patients present with chronic symptoms associated with the TGF-B 
mediated fibrosis in strictures and new vessel formation and telangiectasia, others will 
present with symptoms of chronic insufficiency of the functional cells of intestinal 
mucosa resulting from loss of stem cells, incomplete healing and ischaemia (Figure 5.3). 
 
 
Figure 5.3. Mechanisms of radiation-induced bowel injury (Ferreira et al, 2014).  Several mechanisms 
act concurrently to provoke gastrointestinal symptoms after radiation. 
 
5.3 Radiation-Induced Bowel Injury as a model of Inflammatory Bowel Disease 
(IBD) 
 
Animal models describing the pathology and patho-physiology of Inflammatory Bowel 
Disease (IBD) have confirmed in patients models, the identical patho-physiology in RIBI 
(Hauer-Jensen et al, 2014).  Whilst in inflammatory bowel disease, the ‘toxic’ agent, or 
‘insult’ has yet to be clearly identified, dose-response animal models in radiation make it 
possible to continue to investigate relationships between radiation exposure and normal 
tissue responses (Hauer-Jensen et al, 1988), however it remains difficult to extrapolate 
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formation, which, at the high concentrations elicited by 
pathogens, are microbicidal. They also lead to chemotaxis 
and upregulate proinfl ammatory pathways. By eliciting 
small increases in reactive oxygen species through 
formylated peptide receptor activation, commensal 
microorganisms in the gut enhance antioxidant capacity, 
cytoprotection, and epithelial restoration.27 By eliciting 
such responses, the commensal microbiota is counter-
acting the eﬀ ects of radiation. However, by promoting an 
oxidative burst, potential pathogens might be responsible 
for enhancing the radiation response, leading to further 
deleterious eﬀ ects on the normal gut.
The human gut microbial genome, collectively known 
as the intestinal microbiome, is enriched with metabolic 
genes involved in the degradation and processing of diet-
derived substrates, producing energy sources used by 
both the host and the symbiont. The microbiota also 
produces vitamins and aminoacids.10,12
A dysbiotic milieu may change the metabolism of the 
host and provoke increased infl ammation. Dysbiosis 
aﬀ ects the metabolism of short-chain fatty acids, which 
are known to have immunomodulatory properties and 
play a part in radiation-induced bowel toxicity.28,29 
Moreover, microbial imbalances contribute to carcino-
genesis in the colon through chronic infl ammation, 
immune evasion or suppression, and modi fi  cation of the 
metabolism of carcinogenic substances.30
Microbiota and radiation-induced bowel toxicity
Pelvic radiation disease is defi ned as transient or longer 
term problems that arise in healthy tissues as a result of 
radiotherapy to a tumour of pelvic origin. Its symptoms 
range from mild to very severe.31 Radiation enteropathy, 
one of the syndromes of pelvic radiation disease, aﬀ ects 
the intestine (fi gure 2), and has been arbitrarily divided 
into acute (until 90 days after last treatment) and late 
enteropathy (occurring thereafter). Acute changes in the 
gastrointestinal tract are mediated by the cytotoxic eﬀ ect of 
radiation to the rapidly proliferating epithelium; these 
changes are amplifi ed by infl ammation. Both the cytotoxic 
eﬀ ect to the proliferating epithelium and the infl ammation 
determine increases in free radicals, damaging the DNA, 
and producing functional eﬀ ects.32 Eosinophilic crypt 
abscesses are the most characteristic change seen acutely 
with radiotherapy.4 Activation of the coagulation system 
leads to ischaemia and further necrosis.33 Increased 
formation of thrombin, a serine protease, is important in 
promoting thrombus formation and platelet activation, but 
also in regulating infl ammation by enhancing epithelial 
permeability and recruiting neutrophils and monocytes.33 
This mechanism can lead to ulceration, which exposes 
the underlying tissues to bacteria, changes the host–
microbial interaction, and increases infl ammation as the 
immune system struggles to contain bacterial trans-
location. The ulcer might then progress to fi brosis, a 
process initially driven by a TGFβ1-mediated phenotypic 
switch, which turns fi broblasts into collagen 
matrix-producing myofi broblasts. However, ulceration is 
not necessary for a fi brotic process to occur, as micro-
vascular lesions and infl ammation are suﬃ  cient to 
initiate fi brosis, which progresses independently of 
infl ammation.34 Furthermore, intestinal tissues with a 
delayed radiat on response can become n crotic, eliciting
a sustained infl ammatory response.35
Radiation toxicity has been viewed as a result of the 
cytotoxic eﬀ ects on target cells, defi ning tissues as either 
early or late reacting according to their radiosensitivity, 
repair capacity, proliferation rate, and tissue organisation. 
Although radiation kills cells by direct or indirect eﬀ ects 
on the DNA,22 toxicity is also mediated by other 
mechanisms: indirect eﬀ ects (eg, infl ammation or 
bystander eﬀ ects); and functional eﬀ ects (eg, modifi cation 
of gene expression).3 In addition to the repetitive and 
cumulative nature of damage to normal tissue induced by 
fractionated radiotherapy, a non-healing acute response 
might progress into a lat  eﬀ ct. The fr quency or severity 
of these responses, termed consequential eﬀ ects, are 
aﬀ ected by the exte t of the acut  chang s in the same 
tissue, including their grade or duration.35
Dysbiosis might play a part in radiation enteropathy. 
The gut fl ora is heterogeneous, and diﬀ erent micro-
organisms have various radiosensitivities. Further more, 
commensal microorganisms are in close inter action with 
an environment that substantially changes during pelvic 
radiotherapy. Therefore, not only is dysbiosis likely to 
develop, but it might also contribute to toxicity.
Preclinical studies
In the 1960s, irradiated germ-free mice were shown to 
develop fewer gastrointestinal symptoms, leading to 
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Figure 2: Mechanisms of radiation-induced gastrointestinal symptoms
Several mechanisms act concurrently to provoke radiotherapy-induced gastrointestinal symptoms, both in the 
acute and late settings.
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results from animal models to the understanding of radio-sensitivity, repair capacity, and 
inter-patient variation in responses to treatments.  
Research into IBD is overwhelmingly more prevalent that studies related to RIBI.  The 
prevalence of pelvic radiation disease remains higher and continues to rises.  There are no 
reliable markers currently in widespread use in clinical practice that give an indication of 
disease activity and degree of mucosal inflammation in the bowel to enable monitoring of 
IBD disease activity.  In an experimental study using sections from colonic biopsy and 
resection specimens of 48 patients with IBD, Davies et al, (2003) investigated 5 patients 
inactive/quiescent Crohn’s disease (CD), 13 with active CD, 19 with inactive/quiescent 
Ulcerative Colitis (UC), 11 with active UC, and 15 normal controls.  Sections were 
immunostained with antibodies to Mcmc2 and Ki-67.  Labelling index (LI) was 
determined by calculating the percentage of immunopositive epithelial nuclei for the 
entire glands, and for gland thirds (superficial, middle and basal).  Mcm2 LI was 
increased in the superficial third in active vs inactive/quiescent UC and Crohn’s. The 
Mcm2 Li was significantly greater than Ki67 in active IBD both in entire glands and in 
gland thirds.  Mcm2 LI for entire glands were significantly higher in UC (all cases) 
compared to CD.  This study showed an increase in cell cycle entry as indicated by 
expression of Mcm2 (and to a lesser extent Ki67) in the superficial third of colonic 
glands in active disease compared to inactive disease. Figure 5.4 shows staining in 
normal and IBD colon from the study.   
This increased expression in superficial third of the glands suggests an on-going 
subclinical microscopic chronic inflammation in the epithelial cells at the 
mucosal/luminal interface and raised interesting questions about the role of cell-cycle 
markers adding immunohistochemical support to the histopathological diagnostic features 
which to this day, fail to identify patients at increased risk of ongoing inflammation and 
carcinogenesis.  Cell-cycle entry of epithelial cells in the middle and superficial thirds of 
glands in active IBD has been shown to be consistent with the local release of pro-
inflammatory cytokines in active inflammation, together with a direct response to injury 
of epithelial cells (Rhodes and Campbell, 2002). 
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Figure 5.4. Immunostains showing Mcm2 and Ki67 staining in normal colon, active and inactive IBD 
(Davies et al 2003). (A) Mcm2 and (B) Ki67 expression in normal colon.  Both proteins are confined to the 
basal third of the glands, with Mcm2 being expressed more frequently than Ki67. ((C) quiescent CD, (D) 
active CD, (E) quiescent UC and (F) active UC. Cells expressing Mcm2 are present in the superficial third 
of the glands in regions of active inflammation, but are absent from this location in inactive/quiescent 
disease 
 
Other studies (Bortoluzzi et al, 1995; Gloria et al, 1996) have investigated proliferative 
activity in colonic mucosa in IBD patients as a marker of ongoing inflammation. 
  
 
 
or Ki-67 LI for entire glands nor for the superficial third
of glands.
Active IBD
In active UC and active CD, the Mcm2 LI was
significantly greater than the Ki-67 LI for entire glands
(P < 0.0001 for each) and for the superficial third of
glands (active UC, P ¼ 0.001; active CD, P ¼ 0.0002).
For this reason, subsequent comparisons between active
IBD and inactive ⁄ quiescent IBD or ormal colon were
restricted to analysis of the Mcm2 LIs.
There was a significant increase in Mcm2 LI for the
superficial third of the glands in active UC compared to
inactive ⁄ quiescent UC (P < 0.0001); in active UC
compared to normal colon (P < 0.0001); in active CD
Figure 2 (A,B) Immunoperoxidase stains
showing (A) Mcm2 and (B) Ki-67 expre-
ssion in normal colon. Both proteins are
mainly confined to the basal third of the
glands, with Mcm2 being expressed more
frequently than Ki-67. (C–F) Further
immunoperoxidase stains showing Mcm2
expression in (C) quiescent CD, (D) active
CD, (E) quiescent UC and (F) active UC.
Cells expressing Mcm2 are present in the
superficial third of the glands in regions of
active inflammation, but are absent from
this location in inactive ⁄ quiescent disease.
Minichromosome maintenance protein 2 and IBD R. J. Davies et al.
106 ! 2004 Blackwell Publishing Ltd. Colorectal Disease, 6, 103–110
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5.4 Cell-Cycle markers in the Intestinal Mucosa 
 
The use of cell-cycle markers in clinical oncology and multiparameter analysis of Mcm2, 
geminin and Ki-67 was described in Chapter 4.  In this section, I will attempt to describe 
their use in assessing proliferative status in colonic (rectal) crypts in normal and 
radiation-exposed samples. The loss of proliferative capacity and cell-cycle withdrawal 
following engagement of the somatic differentiation program is tightly coupled to down-
regulation of core constituents of the DNA replication licensing machinery, including the 
Mcm2-7 proteins.  This coupling between loss of proliferative capacity, cell cycle 
withdrawal, down-regulation of the Mcm2-7 helicase complex and differentiation has 
been observed in anal, bladder, cervical, oesophageal, oral, pancreatic, prostate and also 
colonic epithelia (Kayes et al, 2009) 
Hanna-Morris et al (2009) investigated the sensitivity of Mcm2 over Ki-67 as markers of 
mucosal crypt cell dynamics.  ‘Normal control’ archived samples were obtained from 
patients undergoing colorectal resection for benign conditions who had no history of 
colorectal cancer or inflammatory bowel disease.  Mcm2 staining suggested that 
significantly more normal control mucosal cells were proliferating in all crypt 
compartments than was demonstrated by Ki67 staining.  The difference was larger for the 
middle and superficial compartments (Figure 5.5). Minichromosome maintenance 
(MCM) proteins are demonstrated in early G1 phase when Ki-67 cannot be detected.  
They are essential for replication and hence loss of cell cycle control is associated with 
increased MCM protein expression.   In this study I will attempt to define the 
proliferation status of the radiation-exposed colonic crypt compartments in patients 
investigated for symptoms of RIBI and its clinical relevance. 
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Figure 5.5. Sections of macroscopically normal mucosa sampled 10cm proximal to colorectal 
adenocarcinoma immunostained for Ki-67 and Mcm2 (Hanna-Morris et al, 2009).  A higher 
proportion of nuclei in the superficial and middle compartments staining for Mcm2 expression is 
demonstrated (magnification X 250)  
 
5.5 Materials and Methods 
 
5.5.1 Study Cohort 
Sections of archival formalin-fixed, paraffin-embedded from 72 rectal biopsy samples 
were obtained from diagnostic biopsy specimens.  Normal colo-rectal tissue samples 
were used as controls (n=16), whilst 56 samples were from patients who presented at 
oncology follow-up with symptoms of radiation-induced bowel injury (RIBI) after 
treatment for cervical and endometrial cancer.  Patients were identified from the UCLH 
Oncology and Gastroenterology database.  Ethics approval was obtained from the local 
research ethics committee; University College London/University College London 
Hospitals Committees on Ethics of Human Research.  All samples were anonymised 
using Freezerworks in accordance with the UCL/UCLH Biobank.   
Clinical data was extracted from hospital records on patient and cancer demographics, 
oncology follow-up, type and dose of radiotherapy received, chemotherapy received, date 
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of presentation with bowel symptoms, nature of symptoms at presentation to oncologist 
and gastroenterologist, histological features reported from biopsy samples, and status of 
RIBI-related symptoms at last follow-up.  The normal colo-rectal samples were obtained 
from endoscopic biopsy samples from female patients without a diagnosis of cancer or 
inflammatory bowel disease who underwent investigations for unrelated symptoms and 
who had never received any radiation treatment.  As all sections were anonymised, 
clinical data was blinded until data analysis was performed. 
 
5.5.2 Antibodies. 
 
The primary antibodies used were mouse monocloncal Mcm2 antibody (clone 46) 
obtained from BD Transduction Laboratories (Lexington, KY, USA).  Ki-67 monoclonal 
antibody (Mab) (clone MIB-1) was obtained from DAKO (Glostrup, Denmark) Rabbit 
poloclonal antibody against human geminin were previously generated and validated at 
the UCL laboratory (Leica Biosystems, Cat No. NCL-L Geminin). 
 
5.5.3 Immunohistochemistry 
 
Sections were cut from each paraffin-embedded tissue block of colo-rectal tissue.   Three-
micrometer sections were cut onto Superfrost Plus slides (Leica Microsystems), dewaxed 
in xylene, and rehydrated through graded alcohol to water.  For antigen retrieval, slides 
were pressure cooked in 0.1ml citrate buffer (ph 6.0) at 103kPa for 2.5min.  Tissue 
sections were immunostained using the Bond Polymer Define Detection Kit and Bond 
Polymer Define Detection kit and Bond-X automated system (Leica) according to the 
manufacturer’s instructions.  Primary antibodies were applied at the following dilutions: 
Ki67 (MIB-1); 1:70, Mcm2; 1:2000 and geminin (1:200) and incubated for 49 minutes.  
Coverslips were applied using Pertex mounting medium (Cellpath).   
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All antibodies were diluted using Bond antibody diluent.  Antigen retrieval protocol as 
follows - Mcm2; 30mins ER1 (EDTA-based); ph 6.0 at 100degrees centigrade, Geminin; 
30 mins ER2 (EDTA-based), ph 9.0 at 100 degrees centigrade.  Endogenous peroxidase 
was blocked using 3-4% (v/v) hydrogen peroxide for 5 mins prior to the primary antibody 
application.  Haematoxylin applied for 2 mins to counterstain; both included as part of 
the Bond Polymer Refine Detection kit. For all tissues, incubation without the primary 
antibody was used as a negative control and tonsil epithelium was stained for marker 
expression as positive control. 
 
5.5.4 Quantification of staining results 
 
A quantitative value for the degree of expression of Mcm2, Ki-67 and Geminin was 
obtained by calculating a labeling index (LI) for each marker, representing the percentage 
of epithelial nuclei that were immunopositive.  Three to five crypts were assessed for 
each case for each marker.  LIs were calculated by counting both the iummunopositive 
cells in the entire glands and gland thirds and cells that did not stain for the markers.  The 
LI percentage was calculated as (number of positive cells/total number of cells x100. The 
gland thirds represented the superficial (S), middle (M) and basal (B) thirds and were 
defined by measuring the crypt length and dividing by three.  Figure 5.6 below 
demonstrates this in one of my stained slides.  For all sections the slides were counted 
individually by myself and confirmed by 2 research assistants also blinded to clinical data 
(SD, CI).  Median and mean LIs were determined for entire crypts and for superficial, 
middle and basal compartments. 
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Figure 5.6 Hamatoxylin and eosin stained section of normal colon, demonstrating the division of a 
colonic crypt into superficial, middle and basal thirds for calculation of LIs  
 
5.5.5 Statistical Analysis 
 
Mcm2, Ki-67 and Geminin labeling indices (LIs) for entire glands and gland thirds were 
compared using Kruskal-Wallis test. Differences in LIs for Mcm2, Geminin and Ki-67 
groups were assessed using the Wilcoxon signed rank test. To compare normal colon and 
RIBI marker espression, Mann-Whitney test was used 
The aim of the study was to explore differences in both the proliferative compartment 
(basal third), and determine evidence of increased cell cycle entry in the superficial third 
of the glands in patients who had symptoms of severe disease.  I also sought to compare 
differences in in relation to findings on histopathological assessment.  Crypt cell 
dynamics where compared for the 3 previously defined presenting symptom ‘clusters’ 
using Mann-Whitney Test.  Pearson correlation and mean ranks were calculated to assess 
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for a relationship between crypt third marker expression and interval to presentation.  All 
analyses were carried out using SPSS version 21 - IBM (SPSS Inc., Chicago, USA). 
 
5.6 Results 
 
5.6.1 Cell-cycle marker expression in Normal colonic crypts (controls)  
Expression of Mcm2, Ki-67 and Geminin in normal colon was largely confined to the 
basal third of the glands as previously reported (Freeman et al, 1999; Davies et al, 2002).  
There was a statistically significant difference found when comparing expression of 
markers between gland thirds Mcm2, Ki-67 and Geminin (P<0.0001).  Mcm2 LI was 
significantly greater than the Ki-67 LI for entire glands and for the basal thirds 
(P<0.0001).  Table 5.1 shows the percentage LI for crypt compartments for all three 
markers stained, with evidence of a predominance of proliferating cells in the basal third.  
Figure 5.7 shows results demonstrated in box-and-whisker plots. 
  
Marker Crypt Thirds Median (Range)% p values 
Mcm2 Superficial 7.5 (0 – 44) 
 Middle  55.4 (4 – 85) 
 Basal 83.8 (51.7 – 91.5) 
Ki-67 (MIB-1) Superficial 5.1 (0 - 20) 
 Middle  34.3 (3.2 – 67.7) 
 Basal 66 (39 – 84) 
Geminin Superficial 0 (0 – 3) 
 Middle 8.6 (2.6 – 20.4) 
 Basal 21.1 (9.5 – 37) 
 
 
 
 
<0.0001* 
 
Table 5.1. Cell-cycle marker expression in normal colo-rectal controls.  Results confirm the prescence 
of cycling cells predominantly in the basal compartment, with high expression of Mcm2, Ki-67 and 
Geminin expression. 
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Figure 5.7. Box and Whisker plots demonstrating marker LIs for Normal Colon.   
 
5.6.2 Cell-cycle marker expression after radiotherapy in patients who presented 
with symptoms of RIBI  
 
In patients who presented with symptoms of radiation-induced bowel injury (RIBI), rectal 
biopsy samples at gastroenterology assessment were immunostained to assess expression 
of Mcm2, Ki-67 and Geminin. There was a statistically significant difference in cell-
cycle marker expression between all compartments (P<0.0001).  Expression of all 3 
markers was mainly confined to the basal third of the crypt.   
The median values and range of LI percentages are shown in Table 5.2.  Figure 5.8 
illustrates the results in a box-and whisker plot showing Li for all markers in the crypt 
thirds.  Although median Ki-67 was greater than Mcm2 in the group, this was not 
statistically significant (Wilcoxon test; p = 0.08). 
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 Marker Crypt Thirds Median (Range) 
p values 
Mcm2 Superficial 0.7 (0 -27.0) 
 Middle  5.0 (0-55.7) 
 Basal 18.3 (0-97.0) 
Ki-67 (MIB-1) Superficial 1.0 (0 – 33.5) 
 Middle  10.3 (0 – 76.0) 
 Basal 27.6 (0- 82.0) 
Geminin Superficial 0 (0-20.1) 
 Middle 6.2 (0- 31.0) 
 Basal 11.6 (0 – 41.2) 
   
 
 
 
 
<0.0001* 
 
 
Table 5.2 Cell-cycle marker expressions in colorectal mucosa of patients who presented with 
symptoms of RIBI.  LI for all markers was significantly greater in the basal third. 
 
 
 
Figure 5.8. Box and Whisker plots demonstrating LIs in patients who presented with symptoms of 
RIBI 
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5.6.3 Comparing Cell-cycle marker expression and proliferative states in normal 
colon and RIBI 
 
In patients who presented with symptoms of RIBI compared to normal colon, there was a 
statistically significant difference in Mcm2 LI and Ki-67 LI for entire crypts and all crypt 
thirds (p<0.0001), with a significantly lower expression of markers of proliferation in the 
basal third.  Geminin LI was significantly lower in RIBI samples compared to normal 
colon for the basal third (p=0.004) and for middle thirds (p=0.026) although median LIs 
were 6.2% and 8.6%.  Table 5.3 shows results of the comparison of RIBI samples 
compared to normal colon.  A box-and-whisker representation of all markers in both 
groups is shown in Figure 5.9.   Figure 5.10 shows nuclear staining in all compartments 
for cell-cycle markers investigated in both normal controls and in a sample from a patient 
who presented with symptoms of RIBI. 
 
Marker Crypt Thirds Normal Control 
Median (Range) 
RIBI 
Median (Range) 
 p- values * 
Mcm2 Superficial 7.5 (0 – 44.0) 0.7 (0 -27.0) <0.0001 
 Middle  55.4 (4 – 85.0) 5 (0-55.7) <0.0001 
 Basal 83.8 (51.7 – 91.5) 18.3 (0-97.0) <0.0001 
Ki-67 (MIB-1) Superficial 5.1 (0 – 20.0) 1 (0 – 33.5) 0.009 
 Middle  34.3 (3.2 – 67.7) 10.3 (0 – 76.0) <0.0001 
 Basal 66 (39 – 84.0) 27.6 (0- 82.0) <0.0001 
Geminin Superficial 0 (0 – 3) 0 (0-20.1) 0.401 
 Middle 8.6 (2.6 – 20.4) 6.2 (0- 31.0) 0.026 
 Basal 21.1 (9.5 – 37.0) 11.6 (0 – 41.2) 0.004 
     
 
Table 5.3.  Mcm2 and Ki-67 LIs in entire crypt and all crypt thirds were significantly lower in RIBI 
samples compared to normal control.  Median LI for Geminin for both groups was 0%.  Geminin LI was 
significantly lower post-radiation in patients presenting with RIBI. * Mann-Whitney Test 
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(A) (B) 
 
 
Figure 5.9. Box and Whisker plots 
comparing normal colon controls and RIBI 
marker expression in (A) Mcm2 (B) Ki-67 
(C) Geminin 
 
 
 
 
(C) 
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Figure 5.10. Sections of (A) normal mucosa and (B) bowel mucosa from patient with symptoms of 
radiation-induced bowel injury (RIBI) (magnification X 200).  Immunostaining demonstrated 
predominantly in the lower thirds of the crypts.  This patient presented at 6 months after completion of 
radiotherapy with diarrhoea, increased frequency, urgency and mild urge incontinence.  Endoscopic 
findings reported mild oedema and congestion from the anal verge to descending colon with some 
telangiectasia.  Biopsy findings were normal.  The patient still had ongoing mild sympotoms at the time of 
analysis despite intervention.  
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5.6.4 Relationship between Cell-cycle marker expression and interval to 
presentation with RIBI 
The median interval from completion of radiotherapy to presentation was 8 months 
(range 4 – 50).  Samples were taken at gastroenterology assessment at the time of 
presentation with symptoms of RIBI.   Pearson correlation showed a statistically 
significant correlation between Mcm2 expression in the superficial (p=0.008) and middle 
(0.005) thirds only. There was a trend towards significance for Mcm2 expression in the 
basal third of the crypts (p=0.084).  The longer the interval to presentation, the higher the 
frequency of Mcm2 expression.  This difference was not found for ki-67 expression. 
Table 5.4 shows correlation coefficients for marker LIs for gland thirds. 
 
MIB 
 
MCM GEM  
S M B S M B S M B 
INTERVAL TO 
PRESENTATION* 
0.14 0.188 0.074 .436 .462 0.292 0 0.117 0.044 
Table 5.4. Correlation between marker expression and interval to presentation in patients presenting 
with RIBI.  Values represent the pearson correlation coefficient for each marker for all crypt thirds.  
Statistical significance was found for Mcm2 only; superficial and middle thirds. 
  
5.6.5 Relationship between Cell-cycle marker expression and severity of symptoms 
of RIBI 
 
There was no statistical difference found for Mcm2, Ki-67 and Geminin Lis for crypt 
thirds in patients who had complete resolution of symptoms compared to those with 
ongoing mild/moderate symptoms, and those with severe symptoms of RIBI at the time 
of analysis.  Table 5.5 below shows results.  Figure 5.11 shows marker expression in 
crypt thirds for each marker for status of RIBI symptoms  
 
  132 
  RIBI – Mean Ranks for marker LIs  
  Symptoms 
Resolved 
Mild/Moderate Severe p-value* 
Mcm2 S 18.16 18.13 17.43 0.260 
 M 19.00 18.13 15.50 0.675 
 B 17.50 19.58 16.43 0.896 
Ki-67 (MIB-1) S 16.62 22.47 22.93 0.986 
 M 19.03 22.00 18.07 0.752 
 B 19.41 19.83 21.79 0.783 
Geminin S 23.88 17.07 16.86 0.126 
 M 20.59 20.60 17.29 0.785 
 B 20.38 22.37 14.00 0.272 
      
 
Table 5.5 Table showing Mean Rank scores for marker LI showing no relationship to  RIBI 
symptoms status at last follow-up.  Mann-Whitney test (non-parametric) for (n=39 with missing data).  
There was no statistical difference found for crypt thirds, although not statistically significant, the mean 
rank scores were lower in the basal third/proliferative compartment for patients with ongoing severe 
symptoms of radiation-induced bowel injury at time of analysis. 
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Figure 5.11(A) 
 
 
 
 
 
 
(C) 
 
 
 
 
 
(B) 
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Figure 5.11. Box and Whisker plot showing marker expression in patients presenting with RIBI by 
severity of symptoms (A) Ki-67 (MIB)  (B) Mcm2 (C) Geminin.  Patients with resolved symptoms 
(None); n=17.  Mild/moderate – mild symptoms not affecting quality of life; n=14, managed with dietary 
manipulation and/or Imodium/codeine; moderate symptoms requiring further investigations; n=1.  Severe 
symptoms requiring surgery and/or TPN even after surgical intervention; n=7. 
 
5.6.6 Relationship between Cell-cycle marker expression and presenting symptom 
cluster  
 
Factor analysis in chapter 2 was used to define 3 presenting symptom factors or 
‘clusters’. There was a statistically significant difference in expression of both Mcm2 (p= 
0.022) and Ki-67 (MIB) (p=0.032) for the basal third for patients presenting with 
symptom cluster/factor score 2 (diarrhoea, loose stools and increased bowel frequency – 
bowels open (BO) >4times/day) and faecal incontinence) only.  No statistically 
significant correlation was found for factor scores for presenting symptoms cluster and 
crypt marker expression for Geminin.  Table 5.6 shows Pearson correlation coefficients 
for crypt thirds for all markers in the 3 symptom clusters. 
 
 MIB_S MIB_M MIB_B MCM_S MCM_M MCM_B GEM_S GEM_M GEM_B 
Factor 1  -0.046 0.072 0.124 -0.058 -0.199 -0.236 -0.084 -0.165 -0.032 
Factor 2  0.049 0.111 0.352 0.191 0.248 0.348 -0.235 -0.144 -0.071 
Factor 3  -0.013 0.074 0.134 0.122 0.012 -0.024 -0.074 -0.186 -0.032 
Table 5.6. Correlations of Factor Analysis (Symptom Presentation Cluster) Scores with Crypt third 
Marker Expression.  Values represent the Pearson Correlation coefficients between factor scores and 
expression of markers.  Increased Ki67 (MIB) and MCM expression was found in the basal zone with 
increased scoring for factor/cluster 2 only. Factor/Cluster 1- nausea, vomiting, symptoms and signs of acute 
or subacute bowel obstruction; Factor/Cluster 2- increased bowel frequency, loose stool, diarrhoea, faecal 
incontinence; Factor/Cluster 3 - bloating, flatulence, abdominal pain, urgency, rectal bleeding and per-
rectal mucus 
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5.6.7 Relationship between Cell-cycle marker expression and histopathological 
findings on biopsy 
 
Histological findings on biopsy in patients presenting with symptoms of RIBI ranged 
from normal to mild non-specific inflammatory changes, and varying degrees of colitis 
and crypt architecture distruption as reported on histopathological reports.  Of all patients 
with endoscopic and biopsies at presentation with symptoms of RIBI to 
gastroenterologists, 15/41(36%) had evidence of pathological changes suggestive of 
radiation changes while 26 of the samples where reported as normal.  There was no 
significant difference in cell-cycle marker expression for crypt thirds between the normal 
and pathological groups.  Mean rank values and p values are shown in Table 5.7. 
 
     
  Normal Histology Radiation changes* p-value 
Mcm2 S 26.41 24.93 0.747 
 M 26.80 23.89 0.533 
 B 27.26 22.68 0.326 
Ki-67 (MIB-1) S 27.94 30.03 0.666 
 M 27.83 30.33 0.611 
 B 27.55 31.10 0.471 
Geminin S 31.48 22.07 0.041 
 M 29.73 2697 0.580 
 B 28.70 29.83 0.821 
 
Table 5.7.  Comparison of cell-cycle marker expression with normal vs pathological findings of 
radiation changes on histology  (Radiation changes; Mild to Significant colitis with crypt architecture 
distortion and/or mild fibrosis of lamina propria) (*Mean Rank Values for marker expression) 
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5.7 Conclusions and Discussion 
To my knowledge, this is the first description of the expression of cell-cycle phase 
specific markers in colo-rectal tissue samples taken from patients with symptoms of 
radiation-induced bowel injury (RIBI). The expression of cell-cycle states using 
immunohistochemistry in radiation-induced bowel injury (RIBI) has not been previously 
investigated.  Hanna-Morris et al (2009) report an increased sensitivity of Mcm2 over Ki-
67 as markers of colonic mucosal crypt cell-cycle dynamics in active inflammatory bowel 
disease.   
I demonstrate decreased expression of cell-cycle markers Mcm2, Ki67 (MIB-1) and 
Geminin in colonic crypts exposed to pelvic radiation after treatment for cervical and 
endometrial cancers.  Compared to normal colon, the colonic crypts in women presenting 
with bowel symptoms after pelvic radiation showed decreased cell cycle entry 
suggesting a reduced capacity of cells in the basal/proliferative compartment.  Exposure 
of normal bowel mucosa to radiation is associated with variable cellular responses; it is 
presumed that injury to the rapidly dividing and extremely radio-sensitive mucosal crypt 
cells is predominantly responsible for acute radiation toxicity whilst chronic radiation 
toxicity is caused by injury to the less mitotically active and less radiosensitive intestinal 
cells (Bismar and Sinicrope, 2002). 
 The observed reduction in expression of Mcm2, Ki67 and Geminin in the basal 
(proliferation) compartment in RIBI samples compared to normal controls were not 
found to be significant when comparing marker expression with severity of symptoms.  I 
appreciate the limitations of this explorative study, given the small sample size and the 
retrospectively collection of clinical data.  I found a statistically significant correlation 
between Mcm2 expression in the superficial and middle compartments and the interval to 
presentation (median; 8 months).  This seems to suggest that the longer the interval from 
the insult (radiation), the higher the percentage of increased cell-cycle entry in the 
superficial and middle compartments without a significant increase in proliferation in the 
basal compartment, suggesting limited evidence of improving repair capacity in the basal 
compartment with time from radiation.   
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In chapter 2 I used factor analysis to divide 14 items - symptoms (and signs) into 3 
presenting symptom ‘clusters’.  In this cohort study, patients who presented with 
presenting symptom cluster/factor 3 (bloating, flatulence, abdominal pain, urgency, 
rectal bleeding and per-rectal mucus) were more likely to have severe symptoms of RIBI 
compared to cluster/factor 2 (diarrhoea, loose stools and increased frequency and faecal 
incontinence) or cluster/factor 1 (nausea, vomiting, symptoms/signs suggestive of acute or 
sub-acute bowel obstruction).  When looking for associations between cell-cycle marker 
expression and presenting symptom cluster in the present study, I found a statistically 
significant correlation between marker expression and symptom cluster/factor 2 only.  
Patients who scored highest for this cluster of symptoms were more likely to have higher 
marker expression in the proliferative (basal) compartment of crypts, suggesting a higher 
proportion of actively proliferating cells compare to cluster 3, and thus suggesting that 
patients scoring higher for cluster 2 were more likely to improve over time.  
 In summary, we have demonstrated decreased Mcm2, Ki67 and Geminin expression in 
the basal third (proliferative compartment) of colonic crypts in patients who had 
endoscopic biopsies taken during investigation for symptoms of RIBI.  Though no 
definite conclusions can be drawn, our results also suggest a relationship between 
symptom cluster presentation and proliferation (and repair capacity) that needs to be 
further investigated. 
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Chapter Six Summary Discussion 
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Chapter Six Summary Discussion 
 
6.1 Summary of Hypotheses 
 
A national survey of consultant gastroenterologists in the UK (Henson et al, 2012), 
confirmed that the reporting of toxicity data amongst UK clinicians is poor, and mostly 
done by history taking.  This is still true and outside of clinical trials, retrospective 
reviews provide unstructured clinician-reported information.  In this work, I initially set 
out to explore the incidence and nature of presentation of radiation-induced bowel injury 
in women treated for Cervical and Endometrial cancer in a London cancer centre in a 
retrospective study.  
Following this, I then set out to develop a model for a scoring tool as a proposed way of 
improving the reporting of new bowel symptoms after radiation treatment.  The specific 
patho-physiology of the radiation-induced bowel injury is not always identified during 
routine investigations.  An effective scoring system may well have the potential to aid in 
the diagnosis of the underlying patho-physiology and guide clinical management. 
In search of surrogate markers of radiation toxicity, I applied (to our knowledge, for the 
first time in cervical cancer) the use of cell-cycle markers using immuno-staining 
techniques to explore the potential of Mcm2, Ki67 and Geminin as markers of (chemo)-
radio-sensitivity.  It can be assumed that a marker of radio-sensitivity and tumour 
response might have a bearing on radiation toxicity, if we are to presume that both 
sensitivity to tumour and normal healthy tissue is related. 
The immuno-histochemical methods used to analyse cervical tumour samples were then 
utilised to stain for the same cell-cycle markers in colonic crypt cells in women treated 
with radiation and who subsequently presented with symptoms of radiation-induced 
bowel injury (RIBI).  Rectal samples from women investigated with endoscopy and 
biopsy were stained with Mcm2, Ki67 and Geminin, multi-parameter analysis of these 
markers serves as a marker of proliferative status.  I conclude with an explorative 
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analysis of the link between the proliferation status of the bowel mucosa exposed to 
radiation with the symptom cluster at presentation, severity of symptoms at follow-up, 
and other secondary endpoints. 
 
 
6.2 Summary of Results  
 
6.2.1 Retrospective-Prospective Cohort 
 
A review of records of 541 women treated within the North London Cancer Network 
between 2003 and 2010 with radiotherapy (with or without chemotherapy) for cervical 
and endometrial cancer identified 152 (28%) women who reported significant new bowel 
symptoms after pelvic radiation.  As all women presented with multiple symptoms, we 
analysed the presenting clinical features in this cohort of 152 women and therefore by 
‘clustering’ of 14 reported symptoms and signs documented into 3 clusters, we were able 
to analyse the data in a more practical context.   Median follow-up for all patients was 60 
months from end of radiotherapy to last oncology follow-up.  Univariate analysis showed 
increasing age, smoking, extended field radiation and cervical cancer (cf endometrial 
cancer) treatment, as well as the need for surgical intervention to be significant predictors 
of ongoing disease at last follow-up.  In multivariate analysis, the only significant 
predictors of severity of bowel symptoms after radiation were; age, cervical cancer and 
patients presenting with symptom ‘cluster 3’- (bloating, flatulence, rectal bleeding and 
per-rectal mucus).   
Fifteen women (19%) in the cervical cancer group had RIBI requiring surgical 
intervention compared with 5 (6.7%) in the endometrial cancer group.  Although no 
differences were found in multivariate analysis for severity of symptoms with the 
addition of chemotherapy or extended field boosts, our results suggest in keeping with the 
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literature, that the treatment of cervical cancer (no prior hysterectomy, concomitant 
chemo-radiation with weekly Cisplatin and 50.4Gy over 5.5weeks plus intracavity 
brachytherapy; 15Gy in 2 fractions) confers greater risk to normal healthy bowel than in 
endometrial cancer treatment (pre-radiation hysterectomy, followed by adjuvant 
radiotherapy - 45Gy over 4 weeks; patients who receive chemotherapy (FIGO stage 
III/IV ) usually receive 6 cycles of Carboplatin and Paclitaxel prior to radiation). 
This retrospective-prospective study (patients who completed radiation after 2010 were 
followed prospectively) revealed the prevalence and features of pelvic radiation disease 
(28%) in our cohort, with over 10% of patients suffering severe symptoms requiring 
surgical resection of injured bowel and strictures.  Factor analysis in this study enabled an 
analytical approach to presenting features of bowel injury.  Data was collected from 
patient records and although clinician-reported, highlights the need for patient-reported 
toxicity tools, practical for use in the clinical setting.  
 
6.2.2 Proposed Model for RIBI Scoring Tool 
 
Whilst recognising that data collected from records at follow-up consultations regarding 
toxicity is clinician – reported and unstructured, I sought to create a model for a scoring 
tool using available data from our cohort.  Research studies that require long-term follow-
up of patients after treatment are difficult to conduct, as patients do not always continue 
long-term follow-up within the cancer centre were treatment was received.    Andreyev et 
al, (2013) in the ORBIT trial showed algorithm-based care using a patient- reported 
structured questionnaire (IBDQ-B), in the clinical trial setting could be administered by a 
nurse.   
Given the increasing pressure on services both in terms of time allocated to clinics and 
the feasibility of collecting toxicity data with patient-reported questionnaires, which 
usually have to be completed before consultation, I proposed in this chapter, a template 
for a scoring tool.  The ideal scoring tool is easy to use, patient and clinician reported, 
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and easily reproducible.  Collection of toxicity data should enable identification of the 
specific sites and nature of bowel injury and analysis of long-term follow-up data should 
enable greater insight into the patho-physiology of radiation-induced bowel injury. 
Data from our cohort study of 152 women was re-visited. Median follow-up time was 60 
months.  The scoring model was developed by dividing the cohort into 2 sub-sets; a ‘test’ 
set (n =75) which was validated on a ‘confirmatory’ set (n=77).  Factor analysis used re-
used to ‘cluster’ 14 presenting symptoms and signs into the 3 groups as defined in 
chapter 1.  Predictive accuracy of the score (for severity of symptoms) was compared by 
the area under the receiver operating characteristics curve (ROC) for each ‘symptom 
cluster’ /’factor’ score as well as a total score for the three clusters.  
The score proposed (see template in chapter 3) should incorporate the weighting of each 
symptom/sign within each symptom cluster.  The factor loadings in the confirmatory set 
fell within 95% confidence intervals (CI) of those in the test set, indicating the stability of 
the model.  The area under the ROC curve for prediction of severity of symptoms with 
the total score was AUC 0.697 (95% CI 0.593 to 0.802) suggesting reliability of the 
model. 
The RIBI-score model is potentially simple and practical for use by nurses and doctors.  
This score will require validation in a long-term prospective multi-center study, to prove 
its reliability for use in the clinical setting.   
 
6.2.3 Cell-Cycle Markers – Use and Application in Clinical Oncology 
 
Multi-parameter analysis of cell-cycle markers has shown a strong relationship between 
cell-cycle progression and tumour grade, stage and clinical outcome in penile (Kayes et 
al, 2009), breast (Loddo et al, 2009), and ovarian (Kulkarni AA et al, 2007) cancers.  We 
sought to link expression of cell-cycle phase specific markers in cervical cancer to 
tumour to clinical outcome, to investigate their potential roles as markers of chemo-radio-
sensitivity.  Pre-treatment biopsy specimens were obtained for 35 patients with cervical 
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cancer (stage IB2-IVA) and 12 normal cervix control cases.  Each patient had received 
neo-adjuvant chemotherapy prior to conventional concomitant (chemo)-radiation, as part 
of a phase II trial conducted at the North London Cancer Network.   
Immuno-histochemical staining was performed using a panel of cell-cycle phase markers; 
Replication Licensing Factors; Mcm2 and Geminin, and the standard proliferation marker 
Ki67 (clone MIB-1).  The expression of each marker was high in all cases of squamous 
cell carcinoma (SCC) regardless of stage or grade of disease.  Our results showed that all 
cases displayed an aggressive, so-called  ‘ actively-cycling phenotype’.  Univariate 
analysis showed no correlation with level of expression and clinical outcome, 
unsurprising given the high level of expression of markers in all cases.  All the cases of 
squamous cell carcinomas (n=28) and all one of the adenocarcinomas (n=7) displayed an 
actively cycling phenotype.   
Seven out of the 35 (20%) women experienced significant symptoms of radiation-
induced bowel injury (RIBI), with no difference in marker expression or clinical outcome 
(disease-free survival).  Of the 20% (7/35) of patients in this cohort who reported 
symptoms of RIBI, 3/7 of them had required endoscopic examination with rectal 
biopsies.  There were no differences in cell-cycle expression (or survival) found between 
these patients and who did not report any symptoms suggestive of RIBI.  Of course, 
conclusions cannot be drawn from such a small sample.  The potential however, for 
markers of proliferation as a surrogate marker for both (chemo)-radiosensitivity and the 
risk of normal tissue sensitivity warrants further exploration. 
 
6.2.4 Use of cell-cycle markers to define colo-rectal crypt cellularity after radiation 
treatment and relevance to symptomatology and severity of RIBI. 
 
The patho-physiology of radiation-induced bowel injury (RIBI) is still not well 
understood.  It is unclear why some cancer survivors develop significant symptoms, and 
it is well accepted that symptoms of RIBI most likely arise as a result of multiple 
functional, structural and physiological deficiencies related to radiation injury. The aim 
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of this chapter was to investigate proliferation profiles in colonic crypts of women who 
presented with bowel symptoms after radiotherapy.  I sought to investigate any 
correlations between the proliferation status in the crypt compartments and presenting 
symptom 'cluster’, severity of symptoms and histological findings.  
 
Sections from colonic biopsy of 56 women investigated for symptoms of RIBI and 17 
controls were immunostained with antibodies to Mcm2, Ki67 (clone MIB-1) and 
Geminin. The percentage of immunopositive epithelial nuclei was determined by 
calculating a labeling index (LI) for mucosal crypt thirds.  I demonstrated reduced 
expression of all proliferation markers in samples from women with RIBI compared to 
normal controls (p<0.05). This analysis suggests decreased expression of Mcm2, Ki67 
and Geminin in the proliferative compartment (basal third) of colonic crypts in women 
presenting with symptoms of RIBI compared to normal controls; this is in contrast to 
increased cell cycle entry described in active inflammatory bowel disease (Davies et al, 
2003).   
 
The symptom cluster 2; (diarrhoea, increased bowel frequency, and faecal incontinence), 
was associated with the highest expression of Mcm2 and Ki67 in the basal third 
(proliferation compartment) of crypts.  In my analysis in chapter 2, I showed that scoring 
high for symptoms cluster 3 (bloating, flatulence, rectal bleeding and per-rectal mucus) 
was associated with the most severe symptoms of RIBI at follow-up.  It can be presumed 
although not concluded, that the finding of highest expression of proliferation markers in 
the basal third of colonic crypts in patients scoring highest for symptom cluster 2 
suggests a correlation between proliferation (and hence repair capacity) compared to 
patients who presented in symptom cluster 3 (and who were more likely to have severe 
symptoms).  These results may suggest some variation in proliferation in mucosal crypt 
cells depending on patho-physiology. 
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6.3 Conclusions and Implications for Cancer Survivors 
 
The prevalence of radiation-induced bowel toxicity remains higher than that of 
Inflammatory Bowel Disease (IBD) and continues to rise (Andreyev et al, 2012).  There 
is much evidence in the literature to suggest gastrointestinal toxicity remains a significant 
factor in the quality of life of survivors (Andreyev, 2007), yet research into understanding 
and reducing toxicity is limited.  
Evidence from animal models in IBD suggests similar patho-physiology in patients 
presenting with symptoms of RIBI (Hauer-Jensen et al, 2014).  Whilst in IBD, the ‘toxic’ 
agent, or ‘insult’ has yet to be clearly identified, dose-response animal models in 
radiation make it possible to investigate relationships normal tissue responses after 
radiation exposure (Hauer-Jensen et al, 1998).  It remains difficult to extrapolate results 
from animal models to the understanding of inter-patient variability in normal tissue 
responses to radiation.  In an experimental study using sections from colonic biopsy and 
resection specimens of 48 patients with IBD, Davies et al, (2003), described an increase 
in cell cycle entry as indicated by expression of Mcm2 (and to a lesser extent Ki-67) in 
the superficial third of colonic glands in active disease compared to inactive disease.   
Cell-cycle entry of epithelial cells in the middle and superficial thirds of glands in active 
IBD has been shown to be consistent with the local release of pro-inflammatory 
cytokines in active inflammation, together with a direct response to injury of epithelial 
cells (Rhodes and Campbell, 2002).  It is not yet clear whether the observed increase in 
proliferative activity in IBD is associated with epigenetic and kinetic changes or merely 
reflects hyper-proliferation associated with active inflammation.   
It is difficult given the small numbers in our study to know what conclusions can be 
drawn and whether it can be extrapolated that the observed decrease in proliferative 
activity may reflect a sustained loss of repair capacity of the crypt epithelium in patients 
with RIBI.  The site of injury is usually multiple in patients with RIBI (Andreyev, 2007) 
and sometimes difficult to identify.  The management of these patients can be challenging 
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and this study, I believe raises interesting questions that need to be evaluated in larger, 
prospective cohorts.  
 
6.4 Clinical Relevance and Future Work 
 
There is a wealth of knowledge to be gained from studies to investigate the patho-
physiology of RIBI and thus improve the management of these cancer survivors.  
Prospectively collected long-term data, using patient and clinician- reported tools is 
needed, as well as tissue samples from both primary tumour and from multiple sites of 
bowel from patients presenting with radiation-induced bowel injury.   
Following on from this work, the Gynaecological oncology team at University College 
London Hospital are developing a ‘Pelvic Radiation Disease’ working group to create 
structured pathways for managing these patients as well as collecting long-term data. 
The currently recruiting INTERLACE STUDY which is investigating the role of neo-
adjuvant treatment in patients with locally advanced cervical cancer will be used as a 
platform to collect prospective toxicity data as well as a bio-bank for both tumour and 
bowel tissue for women investigated for symptoms of radiation-induced bowel toxicity.  
This will be a reliable cohort to continue this work at UCLH – the group will be looking 
to validate the clinical score, whilst collecting data on presenting symptoms, and 
investigate cell-cycle markers on a larger scale. 
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Background: The number of women surviving cancer who live with symptoms of bowel toxicity affecting their quality of life
continues to rise. In this retrospective study, we sought to describe and analyse the presenting clinical features in our cohort, and
evaluate possible predictors of severity and chronicity in women with radiation-induced bowel injury after treatment for cervical
and endometrial cancers.
Methods: Review of records of 541 women treated within the North London Gynaecological Cancer Network between 2003 and
2010 with radiotherapy with or without chemotherapy for cervical and endometrial cancer identified 152 women who reported
significant new bowel symptoms after pelvic radiation.
Results: Factor analysis showed that the 14 most common and important presenting symptoms could be ‘clustered’ into 3 groups
with predictive significance for chronicity and severity of disease. Median follow-up for all patients was 60 months. Univariate
analysis showed increasing age, smoking, extended field radiation, cervical cancer treatment and the need for surgical
intervention to be significant predictors for severity of ongoing disease at last follow-up. On multivariate analysis, only age, cancer
type (cervix) and symptom combinations/‘cluster’ of (bloating, flatulence, urgency, rectal bleeding and per-rectal mucus) were
found to be significant predictors of disease severity. Fifteen (19%) women in the cervical cancer group had radiation-induced
bowel injury requiring surgical intervention compared with five (6.7%) in the endometrial cancer group.
Conclusion: Women with cervical cancer are younger and appear to suffer more severe symptoms of late bowel toxicity, whereas
women treated for endometrial cancer suffer milder more chronic disease. The impact of radiation-induced bowel injury and the
effect on cancer survivorship warrants further research into investigation of predictors of severe late toxicity. There is a need for
prospective trials to aid early diagnosis, while identifying the underlying patho-physiological process of the bowel injury.
The significant increase in cancer survival rates over the last few
decades have lead to more patients living with adverse effects of
cancer treatments, which greatly affect their quality of life. Around
one in ten of all women diagnosed with cancer in the UK will have a
gynaecological cancer. Although cervical cancer is the nineteenth
most common cancer in the UK accounting for about 2% of all new
cancers in women, endometrial (uterine) cancer remains the most
common gynaecological malignancy and fourth most common
cancer in women (Cancer Research UK, Cancer statistics, 2010).
Pelvic radiation, as adjuvant treatment with or without
chemotherapy in intermediate/high-risk endometrial cancer, and
used concurrently with chemotherapy for locally advanced cervical
cancer, remains a mainstay of multimodality treatment in
gynaecological cancers. The number of long-term survivors has
risen over the last few decades (Cancer Reseach UK, Cancer
Satistics, 2010). Multimodality treatment has been shown in
prospective randomised trials (Keys et al, 1999; Rose et al, 1999;
Peters et al, 2000; Vale et al, 2010) to improve loco-regional disease
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Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and 
Outcome in Cervical Carcinoma?  
 
Int J Gynecol Cancer. 2015 Jan 23. [Epub ahead of print] 
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Abstract 
AIMS: 
Multiparameter analysis of cell cycle markers has shown a strong relationship between cell cycle 
progression and tumor grade, stage, and clinical outcome in penile, renal, ovarian, and breast 
cancers. We sought to link expression of cell cycle phase-specific markers in cervical cancer to 
tumor grade, stage, and clinical outcome to investigate their potential use as prognostic and 
predictive markers. 
METHODS: 
Pretreatment biopsy material was obtained from 35 patients with cervical cancer (stage IB2-IVA) 
and 12 normal cervix control cases. Each patient was treated with neoadjuvant chemotherapy 
followed by chemoradiation. Immunohistochemical staining was performed using a panel of cell 
cycle phase markers: replication licensing factors: Mcm2 (minichromosome maintenance 2) and 
geminin, and the standard proliferation marker Ki67 (clone MIB-1). 
RESULTS: 
The expression levels of each cell cycle biomarker were very high in all cases of squamous cell 
carcinoma of the cervix regardless of grade or stage of disease. In our cohort, all cases displayed 
an aggressive, so-called actively cycling phenotype. Univariate analysis showed that none of the 
cell cycle biomarkers predicted grade, stage, or clinical outcome. 
CONCLUSIONS: 
Cell cycle phase-specific markers do not appear to predict disease grade, stage, or outcome in 
our sample of patients with cervical cancer. This is not surprising, given that the expression of 
each cell cycle biomarker was very high in all cases.  Indeed, all the cases of squamous cell 
carcinoma of the cervix (n = 28) and all but 1 of the adenocarcinomas (n = 7) in this study 
displayed an aggressive "actively cycling" phenotype. This predominance of actively cycling 
tumors is unusual and may reflect the viral etiology underlying the disease. These preliminary 
findings raise many interesting questions including the prognostic value of disease grade and 
markers of proliferation in cervical tumors as reliable prognostic indicators. Further work on a 
larger cohort of patients is warranted. 
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Abstract 
Background: The patho-physiology of Radiation-Induced Bowel Injury (RIBI) is still not well understood. 
It is unclear why some cancer survivors develop significant symptoms. The aim of this study was to 
investigate proliferation profiles in colonic crypts of women presenting with symptoms of chronic RIBI and 
determine correlations with presenting symptom 'cluster’, severity and histological findings.  
 
Methods: Sections from colonic biopsy of 56 women investigated for symptoms of RIBI and 17 controls 
were immunostained with antibodies to Mcm2, Ki67 (clone MIB-1) and Geminin. The percentage of 
immunopositive epithelial nuclei was determined by calculating a labelling index (LI) for mucosal crypt 
thirds. 
 
Results: Reduced expression of all proliferation markers was found in samples from RIBI compared to 
normal controls (p<0.05).  The symptom cluster of diarrhoea, increased frequency, and faecal incontinence 
was associated with the highest expression of Mcm2 and Ki67 in the basal third of crypts. 
 
Conclusions: Our analysis suggests decreased expression of Mcm2, Ki67 and Geminin in the proliferative 
compartment (basal third) of colonic crypts in women presenting with symptoms of RIBI compared to 
normal controls.  This is in contrast to increased cell cycle entry described in active inflammatory bowel 
disease. Our results also suggest some variation in proliferation in mucosal crypt cells depending on 
presenting symptom cluster that warrant further investigation. 
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